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GenerAL inTroduCTion
Pancreas transplantation is to date the only definitive treatment option for patients with 
type 1 diabetes mellitus (T1DM). For patients with metabolic dysregulation-induced end 
stage renal disease (ESRD) a simultaneous kidney and pancreas transplantation is an op-
tion, whereas for non-uremic patients suffering from hypoglycemic unawareness solitary 
pancreas transplantation is a feasible option.
In December 1966, at the University of Minnesota Hospital, Kelly and Lillehei, performed 
the first pancreas transplantation, combined with a kidney transplantation, to treat a ure-
mic, type I diabetic patient. The results of their series were published by another pancreas 
transplantation pioneer, David Sutherland, in a hallmark paper on pancreas transplanta-
tion in 2001.1 More recently, other larger single center studies that were published came 
from Wisconsin, USA2 and the first large European series was from Innsbruck.3 Multiple 
other large pancreas transplantation centers and (inter)national registries have published 
results as well and all show excellent outcomes in terms of survival.4-8 Table 1 represents an 
overview of their results.
Since the first transplantation, over 50.000 pancreas transplantations have been performed 
worldwide.9 Most of these transplantations were performed as a simultaneous pancreas 
kidney (SPK) transplantation, which is still the most commonly performed type of pancreas 
transplantation. The first pancreas transplantation in the Netherlands was performed at the 
Academic Hospital Leiden (currently Leiden University Medical Center) in 1984.10
Both the increased experience in dedicated pancreas transplantation centers and ongoing 
success have paved the way and pancreas transplantation became an accepted treatment for a 
broader range of suitable recipients. This phenomenon has frequently been described as ‘the 
transplant paradox’11: that by increasing the numbers of transplantation and thus increas-
ing experience and awareness, the indications and recipient selection become increasingly 
more liberal. This leads to waiting lists increasing even more, and without a similar increase 
in organs leads to organ shortage and increased waiting time. On the other hand, it appears 
that for many healthcare professionals pancreas transplantation is still a black box and many 
still think of it as an experimental procedure. Through increasing awareness, the number 
of suitable candidates and transplantations may increase. This may have partially been the 
aim of Smets et al. in a study in which all Dutch type 1 diabetic patients that started renal 
replacement therapy (RRT) in The Netherlands were included.12 Furthermore, this study 
was the first randomized trials that showed that, for patients suffering from (imminent) 
renal failure secondary to type 1 diabetes, a 50% reduction in long term mortality may be 
achieved by simultaneous pancreas kidney transplantation, as compared to kidney trans-
plantation alone. This was a vital addition to previous reports that predominantly focused 
on prolonged kidney graft survival and increased quality of life after simultaneous pancreas 
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kidney transplantation and even contradicted each other on the benefit of addition pancreas 
transplantation.13,14
A large part of this thesis was made possible by Eurotransplant. Eurotransplant manages 
the above mentioned waiting list; acts as a mediator between the donor and the recipient 
and plays a key role in the distribution of organs in 8 European countries (The Nether-
lands, Belgium, Luxembourg, Germany, Austria, Slovenia, Croatia, Hungary).15 In order 
to be able to perform this key task of allocation, Eurotransplant collects data on donors 
and recipients. In addition to allocation, Eurotransplant is continuously trying to improve 
allocation algorithms based on the latest medical, ethical and legal principles. In order to do 
so, Eurotransplant also collects data on outcome following transplantation. In this thesis, 
these Eurotransplant data, along with data derived from Leiden University Medical Center, 
will be analyzed.
Patients suffering from ESRD due to T1DM that are eligible for kidney transplantation 
are the prime candidates for SPK. In patients with ESRD, the benefits of a simultaneous 
pancreas kidney transplantation outweigh the burden of life-long immunosuppression and 
the surgical risks of the operation. The goal of pancreas transplantation, in the context of 
simultaneous pancreas transplantation is to achieve exogenous insulin independence. By 
achieving insulin independence, the benefits are rendering patients free from intensive 
blood glucose self-monitoring and insulin administration, protection of the kidney trans-
plant, as well as counteracting, stabilizing, and perhaps even reversing, the progression of 
other secondary complications such retinopathy and neuropathy.16,17 Patients with ESRD 
that already received a kidney transplant might be candidates for pancreas after kidney 
(PAK) transplantation, then also gaining the benefits SPK recipients have. In case of life-
threatening hypoglycemic unawareness, patients not suffering from ESRD might still be 
considered as candidates for pancreas transplantation alone (PTA) in case of brittle diabetes 
or failure to achieve euglycemia on intensive exogenous therapy.14,18 SPK may also be a 
suitable option for patients not yet suffering from ESRD, but who are expected to become 
RRT dependent in the nearby future: a so-called pre-emptive transplantation.6 To date, the 
selection of patients with type 2 diabetes mellitus for pancreas transplantation is controver-
sial and, although pancreas transplantation is performed for T2DM, this constitutes only 
a very small minority and is therefore, beyond the scope of this thesis.19 Some patients 
with maturity onset diabetes of the young (MODY) may, on the other hand, be suitable 
candidates for transplantation.20
In selected cases, islet of Langerhans transplantation is a feasible option, which may be 
performed to render the recipient insulin independent.21,22 However, in most cases, islet 
transplantation is performed to protect the recipient and the graft from the secondary 
complications of the underlying disease. Due to inferior graft survival rates (in terms of 
insulin independence) of islet transplantation, as compared to vascularized pancreas, vas-
cularized transplantation is still the preferred first step in beta-cell replacement therapy in 
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our hospital. Furthermore, the islet yield from one single donor is frequently not enough to 
render the recipient off exogenous insulin and islets of two or more donors are combined 
to get an adequate islet yield for one recipient. Islet after kidney transplantation may be a 
less surgically invasive and thus suitable option for patients that may not be fit for surgery 
or following multiple previously failed vascularized pancreas transplants to protect the 
kidney graft against secondary complications associated with diabetes, without rendering 
the patient insulin independent.23
Outcome following pancreas transplantation is excellent, with death censored graft sur-
vival rates around 80% after 5 years and patient survival rates around 90% after 5 years (table 
1). While improvements in immunosuppressive regimes have improved mid- to long term 
outcome by protecting the recipient and his/her graft from rejection, short term outcome is 
still limited by a high incidence of surgical complications. This early graft failure is usually 
well-defined, since most patients require immediate graft explantation and exogenous insu-
lin therapy. Defining longer term graft failure on the other hand is more difficult. Different 
definitions are being used around the world.
Failure may be defined as return to exogenous insulin therapy. Failure may also be de-
fined as poor glycemic control (for example based on ADA definition of T1DM) or even 
absent c-peptide. Clearly, using one definition would be preferable, as different definitions 
yield different results and different different suggestions for the best definition have been 
proposed.24,25
Table 1. Overview of results of large single center or national registry studies
Authors Center/Country Year
Patient survival
Pancreas graft 
survival
Definition of pancreas graft 
failure
1 year 5 years 1 year 5 years
Sutherland et al. Minneapolis, 
Minnesota, USA
2001 92% 88% 79% 73% Non-death censored insulin 
independence
Thai et al. Pittsburgh, USA 2004 100% 94% Not-stated
Sollinger et al. Madison, 
Wisconsin, USA
2009 97% 89% 88% 76% Not-stated
Ollinger at al. Innsbruck, Austria 2011 98% 94% 88% 82% Insulin independence
Muthusamy et al United Kingdom 2012 95-96% 87-88% Death censored insulin 
independence
Walter et al. Bochum, Germany 2014 96% 91% 80% 73% Not-stated
Kopp et al. Leiden, The 
Netherlands
2015 96% 87% 84% 76% OPTN defined
Kopp et al. Eurotransplant 
region
2016 94% 91%* 84% 79%* Death censored, center 
reported
* 3-year survival
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The most feared complication is graft thrombosis. Because its etiology is still not fully 
understood, there is still no consensus on how to deal with this ‘Achilles heel’ of pancreas 
transplantation.26 Not only the change from high blood flow in the donor to low blood flow 
in the recipient, ischemia reperfusion injury and procurement related tissue damage with 
subsequent leakage of lytic enzymes27, but also the change from uremic to non-uremic re-
cipients are thought to play a role. Center specific protocols concerning surgical technique, 
immunosuppression, inotropic support may also play a role. Several strategies have been 
undertaken to deal with this complication, including tailor made high dose anticoagulants 
using thromboelastography (TEG)28, strict radiological follow up29,30 and different operating 
techniques.4,31 In case of complete thrombosis, donor pancreatectomy is usually required. 
Some studies report on graft salvage, either by endovascular or surgical interventions.32,34 
In case of partial thrombosis, which is considered to be ‘normal’ due to the changes in 
vascularization (especially by ligation of the splenic vein) by some physicians, grafts may 
be preserved by treating the patients with intravenous heparin and oral anticoagulants.35
In general, outcome following transplantation depends on several factors and might 
best be described as the following equation: donor + procurement + recipient + center and 
experience = outcome. Next to those 4 factors, yet unknown or unidentified factors, play a 
role. This thesis contains data that might further fill in the equation, by elaborating on most 
individual factors and measuring their association with outcome.
outline of this thesis
Chapter 2 of this thesis provides an overview of 30 years of pancreas transplantation at the 
LUMC. Pancreas graft survival is defined by multiple factors in this chapter.
Currently, there is a worldwide debate on how pancreas graft failure should be defined. 
Whether death censored or uncensored and whether this should be reinstitution of exog-
enous insulin therapy, the use of oral anti hyperglycemic agents, absent c-peptide, return 
of diabetes mellitus, yet remains unclear and without consensus. In general, graft failure in 
this thesis was defined as death censored and return to exogenous insulin therapy, unless 
defined otherwise in specific chapters.
Next to valid definition of outcome, valid measures to evaluate which factors enter 
the equation are just as important. Chapters 3 and 4 of this thesis elaborate on tools to 
measure pancreas donor quality, which are an important factor in the equation. In 2008, 
a Eurotransplant derived tool, called the Preprocurement Pancreas Allocation Suitability 
Score (P-PASS) was introduced.36 This was the first tool to describe pancreas donor quality 
in an evidence-based model. In 2010, Axelrod introduced the Pancreas Donor Risk Index 
(PDRI).37 In chapter 3, we aimed to validate the UNOS based PDRI in our center, since  in 
liver transplantation had previously shown that differences in populations exist. This would 
be the first step in the possible implementation of the PDRI. Chapter 4 elaborates on the 
use of different risk indices in organ allocation policies. After investigating risk indices in 
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our own center (chapter 3), we evaluated both existing risk indices (P-PASS and PDRI) in a 
large Eurotransplant donor database for their ability to predict allocation outcome. In this 
study, factors unknown at time of allocation, were set to reference.
In chapter 5, using a similar Eurotransplant database, supplemented with outcome data, 
the center effect is investigated as a part of the equation. Using a large Eurotransplant data-
base, the relationship between center volume and outcome was demonstrated.
Chapter 6 elaborates on one of the major concerns following pancreas transplantation: 
pancreas graft thrombosis.38 This feared complication has frequently been described as the 
‘Achilles heel’ of pancreas transplantation. In this chapter, we aimed to investigate a less fre-
quently reported problem: partial graft thrombosis and its clinical implications. In chapter 
7, another risk factor is investigated. In order to keep up with organ shortage, transplant 
professionals are increasingly forced to accept grafts from extended criteria donors, such 
as grafts from donation after circulatory death (DCD) donors. In this chapter, the Leiden 
University Medical Center experience with DCD pancreas transplantation is described.
Chapter 8 summarizes and discusses all results and conclusions described in this thesis. 
Chapter 9 is a general discussion and chapter 10 contains future perspectives in the field 
of pancreas transplantation and in particular the clinical research field. Chapter 11 is the 
Dutch summary of this thesis and contains explanations for people less experienced in the 
medical field.
Since the first pancreas transplantation in 1966, the procedure has gone from an experi-
mental surgical treatment to the, to date, single definitive treatment for T1DM. Multiple fac-
tors have to be considered when determining and interpreting outcome following pancreas 
transplantation, amongst them the factors studied in this thesis. Even though the experi-
ence around the world is steadily increasing, the way to fully understand all physiological, 
pathophysiological and clinical aspects of this highly complex procedure is still long and the 
equation remains yet to be completed.
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AbsTrACT
introduction: An overview of 30 years of pancreas transplantation at a high-volume center. 
Analysis of patient survival– and graft survival–associated risk factors.
Methods: All pancreas transplantations performed in our center from January 1, 1984, till 
December 31, 2012, were evaluated. Covariates influencing pancreas graft survival were 
analyzed using both univariate and multivariate analysis and Kaplan-Meier analysis.
results: In the study period, 349 pancreas transplantations were performed. With the in-
troduction of modern induction therapy in 1999, 5-year patient survival improved to 92.0% 
(p = 0.003). Five-year pancreas graft survival improved to 80.3% (p = 0.026). Pancreas graft 
survival was influenced by left or right donor kidney, transplant type, local origin of pro-
curement team, pancreas cold ischemia time, recipient cerebrovascular disease. Pancreas 
donor risk index increased to 1.39 over the years and pancreas donor risk index 1.24 or 
higher is a risk factor for graft survival (p = 0.007).
Conclusions: This study has shown excellent results in patient and pancreas graft survival 
after 30 years of pancreas transplantation in a high-volume center. Different donor, trans-
plant, and recipient related risk factors influence pancreas graft survival. Even with higher 
risk pancreas donors, good results can be achieved.
Thirty years of pancreas transplantation at Leiden University Medical Center 23
Simultaneous pancreas and kidney (SPK) transplantation is currently the first choice of 
treatment for patients with type 1 diabetes mellitus (T1DM) and related end-stage renal dis-
ease. Pancreas transplant alone (PTA) transplantation can be performed in case of T1DM 
with preserved kidney function in case of hypoglycemic unawareness.1 The first pancreas 
transplantation in the Netherlands was performed at the Leiden University Medical Center 
(LUMC) in 1984.2 Over the past 30 years, LUMC has become one of the largest pancreas 
transplantation centers within the Eurotransplant region.3
In the current literature, there are several publications reporting on long-term results 
after pancreas transplantation. The first large series were described by Sutherland et al4 in 
2001. More recently, Sollinger et al5 also reported on 22 years of follow-up of 1000 pancreas 
transplantations in Wisconsin, followed by more recent reports describing risk factors and 
long-term experiences.6-9 The largest European series is from Innsbruck, Austria, reporting 
on results of 509 consecutive pancreas transplantations with long-term follow-up.10 How-
ever, when comparing results from different trans- plant centers, it appears that no standard 
definition of pancreas graft survival is being used, making adequate comparison difficult. In 
2008, the Pancreas Transplant Committee (PTC) of the Organ Procurement Transplanta-
tion Network (OPTN) pled for 1 definition of pancreas graft function and failure, pointing 
out the importance of a unified definition, which should be used worldwide.11 In most stud-
ies, several donor-, transplant-, and recipient- related risk factors are believed to influence 
outcome after transplantation. The pancreas donor risk index (PDRI) was constructed by 
Axelrod and allowed for structural assessment of donor quality and prediction of 1-year 
graft survival after pancreas transplantation.8
Furthermore, center volume may also play a role in the outcome. In 2004, Mandal has 
shown that low volume pancreas transplantation centers (<10 transplantation/year) have 
poorer outcome in graft survival compared to medium (10–20 transplantations/year) or 
high (>21 transplantations/ year) volume centers.12
The objective of this study is to describe the results, measured in patient and pancreas 
graft survivals, of 30 years of pancreas transplantation in recipients with T1DM and possible 
related complications at the LUMC and to analyze donor-, transplant-, and recipient-related 
risk factors influencing pancreas graft survival. Also, we hope to show that with relatively 
lower quality donors, indicated by high PDRI, we are able to achieve good outcome in our 
high-volume center.
MeTHods
This study is a retrospective database analysis of all consecutive pancreas transplantations 
performed at the LUMC, from the first pancreas transplantation on May 14, 1984, till De-
cember 31, 2012. For all 349 transplantations, follow-up was collected until October 31, 2013.
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data Collection
All donor, transplant (Table 1), and recipient (Table 2) characteristics were systematically 
registered. Follow-up data were recorded to analyze outcome after pancreas transplanta-
tion, including; Hba1c levels, insulin use, c-peptide, fasting plasma glucose, patient death 
date and cause, failure date, failure cause, number of treated rejection episodes, date of 
transplantectomy, date last patient contact.
Table 1. Donor and transplant factors and their influence in univariate analyses on pancreas graft survival
donor factor n (%) Pa X2
Age category 0.006 12.391
<30b 134 (38)
30-39 78 (22)
40-50 128 (37)
>50 9 (3)
Sex 0.48 0.507
Male 171 (49)
Female 178 (51)
Cause of death 0.37 3.143
Trauma 129 (37)
CVA 199 (57)
Anoxia 9 (3)
Other 12 (3)
Diabetes Mellitus 0 (0) n/a
Hypertension (yes) 26 (7) 0.11 2.559
Malignancy (yes) 1 (0.3) 0.589 0.292
Drug use (yes) 8 (2) 0.51 0.426
Alcohol use (yes) 7 (2) 0.08 2.984
HCVAb pos 0 (0) n/a
HBcAb pos 2 (1) 0.342 2.143
CMV IgM/IgG pos 130 (37) 0.76 0.092
Cardiac arrest (yes)b 40 (12) 0.019 5.508
Hypotensive period (yes)c 123 (35) 0.56 0.342
Use of vasopressors (yes) 277 (79) 0.52 0.405
DCDD (yes) 6 (2) 0.86 0.031
  Median (range) P d  
Age, y 36 (10-57) 0.006
BMI 23 (14-35) 0.81
Serum sodium (mmol/L) 144 (123-175) 0.58
Serum creatinine (umol/L) 70 (25-190) 0.3
Serum lipase (U/L) 20 (7-332) 0.61
ICU stay (days) 2 (1-33) 0.058
Serum amylase (U/L) 80 (7-1756) 0.029
ICU stay (days) 2 (1-33) 0.058
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Postoperative Care
From March 1999, patients received any form of modern induction therapy, either inter-
leukin (IL)-II receptor antagonist or antithymocyte globulin (ATG). Currently, first started 
in December 2007, induction therapy consists of administration of anti-CD52 monoclonal 
antibody (alemtuzumab). Before 1999, patients received either anti-CD3 antibody (OKT3) 
or no induction therapy. As maintenance therapy, recipients are currently administered 
combination therapy, consisting of tacrolimus and mycophenolate mofetil. Until 1996, 
recipients received cyclosporine, azathioprine, and prednisone. From that time, until 2002, 
when cyclosporine was replaced with tacrolimus, patients received mycophenolate mofetil 
Table 1. (continued)
Transplant factor n (%) Pa X2
Allocation 0.66 0.837
Local 48 (14)
Regional 234 (67)
Extra-regional 67 (19)
Procurement team <0.001 17.441
Local b 60 (17)
Non-local 240 (69)
Unknown 49 (14)
Transplantation type <0.001 15.355
SPK b 325 (93)
PAK 21 (6)
PTA 3 (1)
Donor kidney <0.001 32.951
No kidney 24 (7)
Left b 276 (79)
Right 49 (14)
Perfusion fluid <0.001 27.999
UW b 312 (89)
HTK 25 (7)
Other 12 (3)  
  Median (range) P d  
Cold ischemia time (h) 12 (3-20) 0.005
PDRI 1.24 (0.68-2.31) 0.25
P-PASS 16 (9-22) 0.74  
a Univariate Kaplan-Meier analysis (Log Rank Mantel-Cox)
b Favorable factor in univariate analysis
c Defined as: systolic pressure < 80 mmHg, for at least 10 minutes.
d Univariate Cox-regression analysis
n/a not applicable; HTK, histidine-tryptophan-ketoglutarate; ICU, intensive care unit; IgG, immunoglobulin 
G; IgM, immunoglobulin M.
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Table 2. Recipient factors and their influence in univariate analyses on pancreas graft survival
recipient factor n (%) Pa X2
Age category 0.59 1.915
<40 156 (45)
40-49 142 (41)
50-59 49 (14)
≥60 2 (0.6)
Sex 0.42 0.652
Male 210 (60)
Female 139 (40)
Type of dialysis 0.835 0.361
No dialysis (pre-emptive transplant) 144 (41)
Haemodialysis 93 (27)
Peritoneal dialysis 112 (32)
Repeated transplantation 0.4 0.715
First transplant 330 (95)
Re-transplant 19 (5)
Thrombo-embolic event 4 (1) 0.253 1.307
Cerebrovascular disease 21 (6) 0.011 6.418
Coronary artery disease 54 (16) 0.591 0.289
CABG 11 (3) 0.557 0.345
PTCA 23 (7) 0.382 0.763
CMV mismatch 0.121 2.41
No mismatch (D-/R-) 269 (77)
D+/R- 72 (21)
Unknown 8 (2)
Modern induction therapy 0.026 4.939
Yesb 237 (68)
No 112 (32)
Primary drainage 0.55 0.367
Bowel 91 (26)
Bladder 256 (73)
Unknown 2 (1)  
  Median (range) Pc  
Age 42 (23-64) 0.99
BMI 24 (17-33) 0.2
Time on waiting list 1.1 (0-10) 0.32
Time since DM I (years) 27 (12-48) 0.51
Time since first dialysis treatment (years) 0.69 (0-8) 0.3
Total HLA mismatches 4 (0-6) 0.86  
a Univariate Kaplan-Meier analysis (Log Rank Mantel-Cox)
b Favorable factor in univariate analysis
c Univariate Cox-regression analysis
Thirty years of pancreas transplantation at Leiden University Medical Center 27
instead of azathioprine. Starting in 2008, routine administration of prednisone was ceased. 
Patients currently receive low dose (2850 IE) low molecular weight heparin in a twice-daily 
regime as graft thrombosis prophylaxis. This regime was started in 2008. Before that, regular 
antithrombotic therapy consisted of the same dose, administered once daily. On discovery 
of partial graft thrombosis, patients are prescribed vitamin K antagonists for a duration of 
at least 3 months. Routine computed tomography imaging is per- formed between the 4th 
and 7th day after transplantation, depending on renal (graft) function.
Analysis
Outcome was characterized by patient survival and graft survival. Patient death with a function-
ing graft was not considered as graft failure (death-censored graft survival). Endocrine pancre-
atic function was subdivided in grades A to E, using HbA1c and use of insulin as markers for 
pancreatic graft function. In this study and in particular, when performing univariate analysis, 
the OPTN definition of graft failure was used as a guideline, in which allograft function classi-
fied as grade A and B were considered as functioning grafts, and grafts with grades C, D, and E 
were considered as failed allografts. According to this definition, persistent HbA1c greater than 
6.3% and/or insulin was classified as grade C (insulin use less than 50% of pretransplant dose) 
or grade D (insulin use more than 50% of pretransplant dose), and persistent HbA1c 7.0% or 
higher was classified as grade E. Standard OGTT was not performed in analyzing graft func-
tion, for this was not required for classification of graft failure using the OPTN PTC definition. 
Graft thrombosis was defined as the presence of intravascular thrombus, proven after removal 
of the pancreas graft in case of complete thrombosis and, in case of partial thrombosis, presence 
of partial intravascular thrombus. Technical failure (TF) consists of pancreas graft thrombosis, 
infections, graft pancreatitis, leakage, and bleeding.13 Early graft failure was defined as graft 
failure within 90 days after transplantation.7 To compare groups based on outcome, we used 
the start of modern immunosuppressive induction therapy (ATG/IL-II receptor antagonist/
alemtuzumab) in March 1999 as a dividing point in the analysis of graft survival. The start of 
immunosuppressive therapy as induction therapy was a landmark in transplantation medicine, 
with marked improvement of long-term results in pancreas transplantation.
statistical Analysis
For statistical survival analysis, Kaplan-Meier and Cox regression models were performed 
using SPSS version 20.0. Significant factors in univariate analysis will be entered into a 
multivariate model. Other factors will be added to the model using stepwise forward selec-
tion. A p-value less than 0.05 was considered significant for factors in both univariate and 
multivariate analyses.
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resuLTs
Donor and transplant characteristics are shown in Table 1. In the study period, a total of 349 
consecutive pancreas transplantations were performed at the LUMC, of which 325 (93.1%) 
were simultaneous pancreas kidney, 21 (6.0%) were pancreas after kidney, and 3 (0.9%) were 
PTA. Mean follow-up was 8.0 years (0–24.2 years). Recipient characteristics are shown in 
Table 2. Primary indication for transplantation was T1DM (99.7%) with (96.8%) or without 
(2.9%) renal complications. In total, 19 retransplantations (5.4%) were performed, all were 
included in the analysis.
In univariate analysis, death-censored pancreas graft survival was influenced by the 
following donor- and transplantation-related risk factors: donor age (p = 0.006), donor 
alcohol use (p = 0.08), serum amylase (p = 0.029), origin of procurement team (p < 0.001), 
transplantation type (p < 0.001), donor kidney side (p < 0.001), perfusion fluid (p < 0.001), 
and cold ischemia time (p = 0.005). Donor cardiac arrest had a protective effect on pancreas 
graft survival (p = 0.019), not on kidney graft survival (p = 0.823). Retransplantation was 
found not to be a significant covariate for pancreas graft survival in univariate analysis (p = 
0.40). Recipient-related risk factors influencing pancreas graft survival were: cerebrovascu-
lar disease (p = 0.011) and induction therapy (p = 0.026). Results of the univariate analyses 
of death-censored OPTN-defined graft survival of all donor, transplant, and recipient fac-
tors are also reported in Tables 1 and 2.
In 256 (73%) patients, bladder drainage was initial drainage method. Of these patients, 
171 (66.7%) were converted to enteric drainage. Median (25th–75th percentile) interval 
between transplantation and conversion was 339 (173–772) days. Recipients who were 
bladder drained and not converted to bowel drainage had significantly worse pancreas graft 
survival (p < 0.001)
Overall patient survival at 1, 5, and 10 years was 95.7%, 86.9%, and 74.6%, respectively. 
One-, 5-, and 10-year overall pancreas graft survival was: 83.6%, 76.4%, and 70.8%, re-
spectively, using the OPTN definition. Death-censored pancreas graft survival was 85.1%, 
78.2%, and 72.8% at 1, 5 and 10 years in the SPK subgroup. For pancreas after kidney, this 
was 66.0% and 55.0%, longest follow-up before pancreas graft failure was 8.9 years. Longest 
death-censored graft survival was 3.2 years for PTA grafts, with 1-year graft survival at 
33.0%.
When pancreas graft failure occurred (n = 99), in the majority of cases, this was caused 
by graft thrombosis (35.4%) or rejection (20.2%). Other causes of graft failure were atrophy 
or exhaustion of the graft (6.1%), infection (5.1%), and bleeding (4.0%). Early pancreas 
graft failure due to TF occurred in 33 cases, 29 of which were due to graft thrombosis. From 
January 1, 2001, 43 cases of partial graft thrombosis occurred in 213 patients (20.2%). From 
January 1, 2008, the incidence of graft failure due to complete thrombosis was 9.3%.
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Kidney graft survival at 1, 5, and 10 years was 91.6%, 87.9%, and 81.6%. Kidney graft 
survival was significantly better when left kidney was donated, compared to when right 
kidney was donated: 94.4% versus 75.7% at 1-year follow-up (p < 0.001). Main reasons for 
right kidney graft loss were rejection (33.3%) or patient death (33.3%). Right kidney graft 
loss due to thrombosis occurred in 1 case.
Clinical outcome in different Periods of induction Therapy
Long-term results of the transplantations performed in the LUMC are shown in Figure 1, 
divided by transplant period (using the start of modern induction therapy in March 1999 as 
a dividing point). Two hundred thirty-seven (67.9%) recipients received modern induction 
therapy. Recipients in the induction therapy group were older (p < 0.001), had higher body 
mass index (p = 0.004), had been on the waiting list longer (p < 0.001), and had longer 
duration of diabetes mellitus (p < 0.001). They received pancreas grafts from higher body 
mass index donors (p = 0.025) and higher Pancreas Preprocurement Allocation Suitability 
Score donors (p < 0.001). Donors also had higher creatinine levels (p = 0.013), had had less 
hypotensive periods (p = 0.003), but had had more cardiac arrests (p = 0.001). They received 
more regionally allocated grafts (p = 0.001), but less local and extraregional allocated grafts 
(p = 0.001) Also, they received more grafts procured by the local team (p < 0.001). In the 
modern era, more pancreas grafts were transplanted without kidney, but less with right 
kidney (p < 0.001). Additionally, 20 (8.4%) were PAK in the modern era versus 1 (0.9%) 
in the historic group (p = 0.022). All recipients in the historic group were bladder drained, 
whereas 91 (38.4%) in the modern group were primarily enteric drained (p < 0.001).
Patient survival (Figure 1a) at 1-year, 5-year, and 10-year follow-up was, respectively, 
93.8%, 78.4%, and 65.7% for the historic group and 96.6%, 92.0%, and 80.9% for modern 
induction therapy group and was significantly better in the more recent period (p = 0.003). 
Death-censored pancreas graft survival (Figure 1b) at 1, 5, and 10 years was 73.0%, 68.2%, 
and 65.0%, respectively, in the historic group, and 88.5%, 80.3%, and 72.3%, respectively, 
in the modern induction therapy group. These results were also significantly better in the 
modern era (p = 0.026).
Different regimes of induction therapy led to following 1-year, 5-year, and 10-year pan-
creas graft survival rates: 75.6, 69.5%, and 66.8% without induction therapy; 68.0%, 64.0%, 
and 64.0% for OKT3; 89.1%, 83.5%, and 77.4% for IL-II receptor antagonists; 85.1%, 78.2%, 
and 67.1% for ATG; and 91.2% for alemtuzumab. Long-term follow-up (5 years and 10 
years) of alemtuzumab induction therapy is not yet available.
In the first 6 months after transplantation, kidney biopsy-proven acute rejection in SPK 
transplantation recipients occurred in 85.9% of recipients without induction therapy (n = 
91), 82.6% with OKT3 (n = 25), 52.8% with IL-II receptor antagonists (n = 37), 42.6% with 
ATG (n = 108), and 11.4% with alemtuzumab (n = 81) (p < 0.001). Data on induction therapy 
were missing for 6 patients; 1 patient received both IL-II receptor antagonist and ATG.
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No induction therapy
Induction therapy
No induction therapy
Induction therapy
figure 1a. Kaplan Meier survival curves of patient survival divided by use of induction therapy (p=0,003)
figure 1b. Kaplan Meier survival curves of OPTN defined death censored graft survival divided by use of 
induction therapy (p=0,026)
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Multivariate Analysis
Stratified by induction therapy, in a multivariate Cox-regression analysis, significant factors 
from univariate analysis were entered. Other factors were entered, and the model was fitted 
using forward selection. Significant factors of this multivariate analysis were: donor left 
versus right kidney: hazards ratio (HR), 3.18 (95% confidence interval [95% CI], 1.49–6.76, 
p = 0.003); SPK versus PAK/PTA: HR, 3.68 (95% CI, 1.65–8.19; p = 0.001); local origin 
of procurement center: HR, 2.72 (95% CI, 1.11–6.68, p = 0.029); pancreas cold ischemia 
time: HR, 0.9 (95% CI, 0.81–0.99; p = 0.033); recipient cerebrovascular disease: HR, 3.52 
(1.41–8.78, p = 0.002) for OPTN-defined death-censored pancreas graft survival (Table 3). 
Primary enteric or bladder drainage was borderline associated with pancreas graft survival 
in favor of bladder drainage: HR, 3.81 (p = 0.051).
donor Quality and Graft survival
Median PDRI was 1.24. Quality of donors decreased since the start of the transplant pro-
gram, indicated by an increase of median PDRI. The PDRI was calculated for each period: 
1984 to 1991: PDRI, 1.14 (0.68–2.20); 1992 to 1998: PDRI, 1.20 (0.73–2.01); 1999 to 2005: 
PDRI, 1.25 (0.72–2.31); 2006 to 2012: PDRI, 1.39 (0.70–2.21). The PDRI of 5 recipients 
could not be calculated. The PDRI was not associated with pancreas graft survival in uni-
variate analysis, when analyzed as a continuous variable (p = 0.25). However, PRDI 1.24 
or higher donor grafts had significant poorer outcome compared to PDRI less than 1.24: 
71.2% versus 83.8% graft survival at 5 years follow-up (p = 0.007). Starting in 2011, so far, 6 
Table 3. Multivariate analysisa of risk factors influencing pancreas graft survival
factor Hr 95% Ci P
Donor kidney side
Left kidney ref.
Right kidney 3.18 1.49 – 6.76 0.003
No kidneyb n/a n/a
Transplant type
SPK ref.
PTA/PAK 3.68 1.65 - 8.19 0.001
Procurement center
Local ref.
Non-local 2.72 1.11 - 6.68 0.029
Pancreas cold ischemia time 0.90 0.81 – 0.99 0.033
Recipient cerebrovascular disease
No ref.
Yes 3.52 1.41 - 8.78 0.007
a Forward selection stepwise multivariate analysis using OPTN definition for graft survival
b Unable to calculate HR due to stratum effect
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recipients were transplanted using grafts from donation after circulatory determination of 
death (DCDD) donors.14 With these numbers, DCDD did not influence graft survival (p= 
0.86).
disCussion
This article is an overview of 30 years of pancreas transplantation at our center.
Results, measured in patient and pancreas graft survival as defined by the OPTN, have 
improved over the last decade. As shown in this study, survival, especially 1-year graft 
survival, has significantly improved since the introduction of modern regimes of pre-
transplantation induction therapy. Improvement in surgical technique and maintenance 
immunosuppression therapy, however, may also have contributed to improved outcome. 
Furthermore, clinical experience with pancreas transplantation has improved throughout 
the center over the course of these 30 years. Incidence of kidney biopsy-proven acute rejec-
tion has also declined with introduction of modern induction therapy.
Several limitations apply to the study. It concerns single-center results, albeit from one of 
the larger pancreas transplantation centers in Europe. Because of the retrospective nature of 
our study, some selected data are incomplete. Because routine follow-up in our center does 
not include measurement of plasma C-peptide, values were only used for the determination 
of graft failure when present.
We have shown satisfying results in concordance with other large transplant centers and 
databases: Ollinger et al10 report a 94.3% patient survival and 81.5% pancreas graft survival 
(exogenous insulin dependent) at 5-year follow up in the last decade in Innsbruck, Austria. 
The largest series of pancreas transplantations described, is from Minnesota and reports 
1-year patient survival rates between 93.8% and 96.2% and 1-year death censored pancreas 
graft survival between 78.6% and 80.7% for local or imported allografts between 1998 and 
2008 (p > 0.05).6 Vinkers reported 1-year graft survival of 82% for recipients of P-PASS less 
than 17 donor allografts and 64% for recipients of P-PASS of 17 or higher donor allografts 
in a Eurotransplant cohort. Muthusamy et al15 compared DBD donors to DCDD donors in 
the United Kingdom and reported 88% versus 87% (p = 0.9) 1-year pancreas graft survival, 
defined as insulin administration dependency. Discussion still remains about the value of 
predictive models. We have shown that median PDRI is not associated with pancreas graft 
survival in this series. The authors believe that the increase of PDRI over time, together 
with simultaneous increase of pancreas graft survival over time, is responsible for this 
absent relationship. The continuous increase in PDRI over the years has not led to inferior 
outcome. On the contrary, outcome is still improving, whereas, from 2006 till 2012, median 
donor PDRI was 1.39, equally to a United Network for Organ Sharing donation after cardiac 
determination of death donor.8
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In 2012, Leiden University Medical Center was the second largest whole organ pancreas 
transplantation center in the Eurotransplant region.16 Combining both findings might im-
plicate that high-volume transplant centers might be able to compensate for inferior donor 
quality and that, currently, PDRI might not yet be reliable enough to predict outcome in the 
European cohort. As we have shown earlier, liver donor quality, measured in DRI, is inferior 
in the European region, as compared to the United States.17 Additional studies from own 
center show a relationship between pancreas graft survival and PDRI, when using median 
PDRI (1.24) as a cutoff value in multivariate analysis (unpublished data).
Multivariate analyses revealed left or right donor kidney, transplant type, local origin of 
procurement center, pancreas cold ischemia time, and recipient cerebrovascular disease as 
individual determents of OPTN-defined death-censored pancreas graft survival. Interest-
ingly, primary bladder drainage was borderline favorable for graft survival after multivariate 
analysis, even with nonconverted patients, which have inferior outcome, included in this 
group. This result is similar to results found by Finger et al7 when composing a risk model 
for predicting TF. The authors feel that the 2-step approach, initial bladder drainage fol-
lowed by conversion to enteric drainage, is a suitable and feasible drainage method for 
high-risk recipients, for example, with repeated peritonitis or high-risk donors or grafts.18,19 
However, risks of repeated surgery will have to be measured against graft survival benefit, as 
was stated earlier by Sollinger et al5 who reported no difference in outcome for both tech-
niques. Even though the use of UW as perfusion fluid was a protective factor in univariate 
analysis, this effect did not remain significant after multivariate analysis. It has previously 
been shown that the use of histidine-tryptophan-ketoglutarate bears an increased risk of 
graft failure in pancreas transplantation.20 The lack of relationship in this series might be 
due to the large amount of transplantations that were conducted using UW solution as 
perfusate. The use of DCDD pancreas did not influence graft survival in this series, and is, 
as we have shown earlier, a feasible option to expand the donor pool.14 After multivariate 
analysis, donor cardiac arrest was no longer a protective factor for pancreas graft survival. 
Also, donor cardiac arrest did not influence kidney graft survival. The authors believe that, 
in this study, the effect could be explained by small sample size, even though reports are 
published where ischemic preconditioning might have a beneficial effect on outcome.21 
Pancreas graft thrombosis is still an important complication after pancreas transplantation, 
even with modern regimes of anticoagulation therapy.
All pancreas transplantations (SPK, PTA, and PAK) were analyzed together. It was pre-
viously shown that pooled results provide useful data for reporting on program-specific 
outcome.22 Results might even be better in patient and graft survivals if only SPK trans-
plantations were analyzed because it is known that both other categories are associated with 
poorer outcome.10
In our opinion, preemptive SPK transplantation is a feasible option in recipients suffer-
ing from preterminal renal disease. This is indicated by the high number of preemptive 
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transplantations that was carried out at our center. Even though it did not influence graft 
survival, preventing recipients from becoming dialysis-dependent, provides improved 
quality of life in the pretransplantation phase. Interestingly, next to studies demonstrating 
superior outcome in kidney graft survival, depending on donation of left or right kidney,23 
this study demonstrates that a donated left or right kidney significantly influences pancreas 
graft survival. This could be explained, however, by the large difference in 1-year kidney 
graft survival of left and right donated kidneys. Early kidney graft loss results in a pancreas-
alone state, probably with comparable results as initial PTA transplantations. Right renal 
vein length and possible fragility might bear an increased thrombosis risk; however, in this 
study, this does not appear to be the reason for inferior kidney graft survival of the right 
kidney. The authors do not have an explanation for high rejection rates with donated right 
kidneys.
Pancreas graft survival in this study was death censored and measured using the OPTN 
PTC definition as guideline, where death with functioning graft was not considered graft 
failure. Using this definition allows for objective measurement of graft failure, using HbA1c, 
fasting plasma glucose, and casual plasma glucose, rather than measuring graft failure using 
restart of insulin therapy definition, for this, is, in our opinion, a more subjective way and 
also, predominantly, physician dependent.
When using the restart of any exogenous insulin after the directly postoperative period 
as a measure for pancreas graft survival or graft failure, results are different. Insulin-defined 
graft survival is different than OPTN-defined graft survival, with a difference of almost 6% 
at 10-year follow-up. Comparing both definitions of graft survival and (re)initiating, the 
discussion on the definition of graft survival will be subject of further studies. Without a 
general consensus on the definition of graft survival, future studies comparing graft survival 
in different cohorts would be difficult. Future studies will also have to be evaluated for their 
definitions of pancreas graft survival.
Even though center size was not investigated in this study per se, this study still shows 
that in a large center, a good result can be achieved without the use of perfect donor grafts. 
It is our opinion that future studies will have to point out the value of center size on the 
outcome after transplantation, not only in the field of pancreas transplantation. This opin-
ion was recently shared by Nijboer et al.24 Also, this study has shown better result with 
grafts procured by the local team. This might be because our center performs pancreas 
transplantation itself, and this may lead to higher quality of the transplanted graft and thus 
improved graft survival.25 In this perspective, the authors believe that early graft failure 
should be included in graft survival analysis, especially in pancreas transplantation because 
surgical complications are still an important risk factor in pancreas transplantation.
In conclusion, long-term patient and pancreas graft survival in this cohort was excellent 
and at least equal to results in other large centers. However, the exact nature and interpreta-
tion of the findings are highly dependent on which definition for pancreas graft success or 
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failure is used. Higher volume transplant centers might be able to achieve the same outcome 
in graft survival with higher-risk donors.
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introduction: In 2008, the preprocurement pancreas suitability score (P-PASS) was in-
troduced within Eurotransplant to predict suitability of pancreas donors. A P-PASS of 17 
or higher would have lower graft survival compared with pancreatic grafts from donors 
with a P-PASS lower than 17. In 2010, a continuous model, the pancreas donor risk index 
(PDRI), was designed. Before using this model in the European donor population, it has to 
be validated in the European setting.
Methods: In this study, P-PASS and PDRI were validated using the results of all pancreas 
transplants performed at our center. The P-PASS and PDRI were compared as both continu-
ous and dichotomous values. The original cutoff point of 17 divided P-PASS groups. Median 
PDRI (1.24) divided PDRI groups.
results: In total, 349 pancreas transplantations were performed. The P-PASS of 17 or higher 
was not associated with graft survival (p = 0.448). The PDRI of 1.24 or higher was associated 
with reduced graft survival in univariate analysis (p = 0.007) and multivariate analysis (p = 
0.002). The PDRI concordance index was 0.69.
Conclusions: The P-PASS has no predictive value for pancreas graft survival and should not 
be used in clinical decision making. The PDRI is a significant predictor of pancreas graft 
survival but should be used carefully, because good results can be achieved with grafts from 
high-PDRI donors.
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inTroduCTion
The well-known scarcity of suitable organ allografts available for transplantation and the 
increasing number of patients on the waiting list1 has stimulated the use of extended criteria 
donors. The difficulty with these extended criteria donors is the lack of a good definition. 
Several factors for pancreas donors are named as extended, such as high donor age, high 
body mass index (BMI), and pancreas allografts from donation after circulatory determina-
tion of death (DCDD) donors.2 However, there is no clear consensus on the extended criteria 
of pancreas donor and the question remains whether extended donor criteria donors should 
be used for pancreas donation at all.3
The preprocurement pancreas suitability score (P-PASS) was introduced within Eu-
rotransplant in 2008.4 This score, consisting of solely donor factors (age, BMI, intensive 
care unit [ICU] stay, asystole, sodium, amylase, lipase, and inotropic therapy), is primarily 
intended to identify a suitable pancreas donor, using a cutoff point of 17. The P-PASS is 
even believed to predict graft survival, where a pancreas from a donor with a P-PASS of 
17 or higher would have a lower graft survival as compared with a pancreas from a donor 
with a P-PASS lower than 17.5 Even though this is a continuous model, the disadvantage of 
this donor score is the fact that its current use is a black-and-white model approach and 
several single-center studies already demonstrated the lack of relation between P-PASS and 
(long-term) graft survival.6,7
In 2010, a risk index for predicting graft survival after pancreas transplantation was 
designed using data from the Organ Procurement and Transplantation Network (OPTN): 
the pancreas donor risk index (PDRI). This continuous model consists of 8 donor factors 
(age, sex, race, height, BMI, serum creatinine, cause of death [COD], and DCDD) and 2 
transplant factors (cold ischemia time [CIT] and type of transplant, meaning simultaneous 
pancreas kidney [SPK], pancreas after kidney [PAK], or pancreas transplant alone [PTA] 
transplantation).8
Because no valid predictive model currently exists for pancreas transplantation in the Eu-
ropean setting, it would be of additional value to investigate these 2 pancreatic graft donor 
models. Organ donors in the United Network for Organ Sharing and the Eurotransplant 
region are quite different,9 so the PDRI should ideally first be validated in a European set-
ting. Regarding the P-PASS, because it was designed more than 5 years ago and the donor 
population changed a lot since then, the question rises if this model is still up-to-date.
The objective of this single-center study was to compare P-PASS and PDRI in our own 
center in their ability to predict graft survival after pancreas transplantation, using univari-
ate and multivariate analysis.
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MATeriALs And MeTHods
data
This study is a retrospective database analysis of all pancreas transplantations performed 
in our center from the first pancreas transplantation in 1984 until January 1, 2013. Donor, 
transplant, and recipient characteristics are displayed in Tables 1 to 4.
Table 1. Donor and transplant demographics in both P-PASS groups
donor factor
Pass < 17 Pass ≥ 17
 Pan (%) n (%)
Age category <0.001
<30 107 (56) 12 (9.5)
30-39 40 (20.9) 30 (23.8)
40-50 42 (22) 80 (63.5)
>50 2 (1) 4 (3.2)
Sex
Male 98 (51.3) 58 (46) 0.358
Cause of death <0.001
Trauma 87 (45.5) 29 (23)
CVA 91 (47.6) 89 (70.6)
Anoxia 6 (3.1) 3 (2.4)
Other 7 (3.7) 5 (4)
Diabetes Mellitus 0 (n/a) 0 (n/a) n/a
Hypertension 11 (5.8) 11 (8.7) 0.308
Malignancy 0 (n/a) 1 (0.8) 0.397
Drug use 7 (3.7) 1 (0.8) 0.152
Alcohol use 2 (1) 5 (4) 0.119
HCVAb pos 0 (n/a) 0 (n/a) n/a
HBcAb pos 1 (0.8) 1 (0.8) 1
HIVAb pos 0 (n/a) 0 (n/a) n/a
Cardiac arrest 20 (10.5) 20 (15.9) 0.156
Hypotensive period 68 (35.6) 40 (31.7) 0.478
Use of vasopressors 137 (71.7) 115 (91.3) <0.001
DCDD (yes) 5 (2.6) 1 (0.8) 0.408
  Median (range) Median (range) Pb
Age, y 27 (10-52) 43 (16-54) <0.001
Height, cm 175 (130-196) 175 (155-200) 0.704
Weight, kg 65 (27-100) 77 (45-105) <0.001
BMI 22 (14-33) 25 (18-35) <0.001
Serum sodium, mmol/L 144 (123-175) 144 (128-167) 0.875
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Analysis
To compare both predictive models, pancreatic graft survival was used as endpoint. Graft 
survival was defined using uniform definition of graft function/failure for whole pancreas 
and islet transplant by the Pancreas Transplantation Committee as a guideline.10 Endocrine 
pancreatic function was subdivided in grades A to E using HbA1c and the use of exogenous 
insulin as markers for pancreatic graft function. Allografts classified as grades A and B were 
Table 1. Donor and transplant demographics in both P-PASS groups (continued)
donor factor
Pass < 17 Pass ≥ 17
 PaMedian (range) Median (range) 
Serum creatinine, umol/L 70 (8-1756) 68 (28-190) 0.762
Serum lipase, U/L 21 (9-332) 20 (7-169) 0.524
Serum amylase, U/L 77 (8-1756) 92 (7-1057) 0.726
ICU stay, d 2 (1-33) 2 (1-24) 0.001
Transplant factor n (%) n (%) Pa
Allocation 0.725
Local 23 (12) 17 (13.5)
Regional 128 (67) 87 (69)
Extra-regional 40 (20.9) 22 (17.5)
Procurement team 0.219
Local 32 (16.8) 27 (21.4)
Non-local 135 (70.7) 90 (71.4)
Unknown 24 (12.6) 9 (7.1)
Transplantation type 0.131
SPK 181 (94.8) 114 (90.5)
PAK 10 (5.2) 10 (7.9)
PTA 0 (n/a) 2 (1.6)
Donor kidney 0.144
No kidney 10 (5.2) 12 (9.5)
Left 154 (80.6) 103 (81.7)
Right 27 (14.1) 11 (8.7)
Perfusion fluid 0.564
UW 176 (92.1) 113 (89.7)
HTK 14 (7.3) 11 (8.7)
Other 1 (0.5) 2 (1.6)  
  Median (range) Median (range) Pb
Cold ischemia time, h 12 (5-20) 11 (4-19) 0.397
PDRI 1.03 (0.68-2.21) 1.61 (0.76-2.31) <0.001
P-PASS 15 (9-16) 18 (17-22) <0.001
a Pearson X2
b Independent Samples Median Test
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considered functioning grafts and grafts with grades C to E were considered failed allografts. 
According to this definition, persistent HbA1c more than 6.3% and/or exogenous insulin 
use was classified as grade C (insulin use <50% of pretransplant dose) or grade D (insulin 
use >50% of pretransplant dose) and persistent HbA1c of 7.0% or higher was classified as 
grade E. A full breakdown of categories A to E at different follow-up points is shown online 
(SDC Figure 1, http://links.lww.com/MPA/A417).
Table 2. Recipient demographics in both P-PASS groups
recipient factor
Pass < 17 Pass ≥ 17
Pan (%) n (%)
Age category 0.182
<40 85 (44.5) 49 (38.9)
40-49 82 (42.9) 53 (42.1)
50-59 24 (12.6) 22 (17.5)
≥60 0 (n/a) 2 (1.6)
Sex 0.444
Male 110 (57.6) 78 (61.9)
Type of dialysis 0.988
No dialysis (pre-emptive transplant) 82 (42.9) 53 (42.1)
Hemodialysis 51 (26.7) 34 (27)
Peritoneal dialysis 58 (30.4) 39 (31)
Repeated transplantation 9 (4.7) 9 (7.1) 0.36
CMV mismatch 40 (21.1) 29 (23.2) 0.652
Modern induction therapy 65 (34) 107 (84.9) <0.001
Primary drainage 0.02
Bowel 45 (23.6) 45 (35.7)
Bladder 145 (75.9) 81 (64.3)
Coronary artery disease 31 (16.2) 17 (13.5) 0.499
Cerebrovascular disease 12 (6.3) 8 (6.3) 0.986
Thromboembolic event 3 (1.6) 1 (0.8) 1.000
  Median (range) Median (range) Pb
Age, y 42 (23-57) 43 (25-64) 0.136
BMI 23 (17-33) 24 (18-33) 0.081
Time on waiting list, y 1 (0-6) 1 (0-10) 0.047
Time since DM I, y 27 (14-48) 29 (12-45) 0.177
Time since first dialysis treatment, y 0.7 (0-6.8) 0.6 (0-8.3) 0.945
Total HLA mismatches 4 (0-6) 4 (1-6) 0.845
a Pearson X2
b Independent Samples Median Test
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Table 3. Donor and transplant demographics in both PDRI groups
donor factor
Pdri < 1.24 Pdri ≥ 1.24
Pa n (%) n (%)
Age category <0.001
<30 130 (76.9) 2 (1.1)
30-39 35 (20.7) 43 (24.6)
40-50 4 (2.4) 123 (70.3)
>50 0 (n/a) 7 (4)
Sex
Male 106 (62.7) 64 (36.6) <0.001
Cause of death <0.001
Trauma 105 (62.1) 21 (12)
CVA 47 (27.8) 150 (85.7)
Anoxia 8 (4.7) 1 (0.6)
Other 9 (5.3) 3 (1.7)
Diabetes Mellitus 0 (n/a) 0 (n/a) n/a
Hypertension 0 (n/a) 25 (14.3) <0.001
Malignancy 1 (0.6) 0 (n/a) 0.308
Drug use 4 (2.4) 4 (2.3) 0.96
Alcohol use 2 (1.2) 5 (2.9) 0.272
HCVAb pos 0 (n/a) 0 (n/a) n/a
HBcAb pos 2 (1.2) 0 (n/a) 0.149
HIVAb pos 0 (n/a) 0 (n/a) n/a
Cardiac arrest 29 (17.2) 11 (6.3) 0.002
Hypotensive period 68 (40.2) 54 (30.9) 0.069
Use of vasopressors 133 (78.7) 141 (80.6) 0.666
DCDD (yes) 5 (3) 1 (0.6) 0.091
  Median (range) Median (range) Pb
Age, y 21 (10-42) 44 (24-54) <0.001
Height, cm 178 (130-197) 170 (155-200) <0.001
Weight, kg 70 (27-105) 70 (45-100) 0.77
BMI 23 (14-33) 23 (18-35) 0.031
Serum sodium, mmol/L 145 (128-175) 144 (123-167) 0.487
Serum creatinine, umol/L 71 (31-138) 64 (25-190) 0.052
Serum lipase, U/L 29 (7-332) 19 (9-140) 0.188
Serum amylase, U/L 97 (7-1756) 62 (11-846) 0.001
ICU stay, d 2 (1-33) 2 (1-24) 0.36
46 Chapter 3
Graft survival was death censored and patient death with functioning graft was not 
considered graft failure. Graft survival was defined as time from the date of transplantation 
until the date of graft failure.
For the statistical survival analysis, Kaplan-Meier method for categorical variables and 
Cox proportional hazards regression model for continuous variables were used, with SPSS 
Version 22.0. Because the P-PASS was originally constructed using a cutoff of 17, this cutoff 
point separated groups. The P-PASS was also analyzed as a continuous model. Because the 
PDRI was developed as a continuous risk model, it was analyzed accordingly. In addition, 
the median PDRI was used as a cutoff point, to compare groups on the basis of low or high 
PDRI. Donor race was not included in the analysis, because this is not registered in the Eu-
Table 3. Donor and transplant demographics in both PDRI groups (continued)
Transplant factor
Pdri < 1.24 Pdri ≥ 1.24
Pa n (%) n (%)
Allocation 0.058
Local 23 (13.6) 24 (13.7)
Regional 105 (62.1) 126 (72)
Extra-regional 41 (24.3) 25 (14.3)
Procurement team 0.572
Local 26 (15.4) 34 (19.4)
Non-local 121 (71.6) 117 (66.9)
Unknown 22 (13) 24 (13.7)
Transplantation type 0.108
SPK 153 (90.5) 168 (96)
PAK 15 (8.9) 6 (3.4)
PTA 1 (0.6) 1 (0.6)
Donor kidney 0.125
No kidney 16 (9.5) 7 (4)
Left 130 (76.9) 144 (82.3)
Right 23 (13.6) 24 (13.7)
Perfusion fluid 0.313
UW 150 (88.8) 161 (92)
HTK 13 (7.7) 12 (6.9)
Other 6 (3.6) 2 (1.1)  
  Median (range) Median (range) Pb
Cold ischemia time, h 12 (4-20) 12 (4-19) 0.829
PDRI 0.91 (0.68-1.23) 1.65 (1.24-2.31) <0.001
P-PASS 14 (9-20) 17 (13-22) <0.001
a Pearson X2
b Independent Samples Median Test
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rotransplant database. All donors were set to reference (caucasian). For group analysis (both 
P-PASS and PDRI), risk factors were considered in a forward selection-based model, if a 
factor is unequally distributed across both groups (χ2 p < 0.1) and that factor is considered 
to influence graft survival in univariate or multivariate graft survival analysis (p < 0.1).11 
In multivariate analysis, logPDRI was used. For both univariate and multivariate analyses, a 
p-value of less than 0.05 was considered significant.
Table 4. Recipient demographics in both DPRI groups
 
recipient factor
Pdri < 1.24 Pdri ≥ 1.24
Pan (%) n (%)
Age category 0.149
<40 85 (50.3) 67 (38.3)
40-49 60 (35.5) 81 (46.3)
50-59 23 (13.6) 26 (14.9)
≥60 1 (0.6) 1 (0.6)
Sex 0.477
Male 110 (57.9) 78 (61.9)
Type of dialysis 0.654
No dialysis (pre-emptive transplant) 73 (43.2) 68 (38.9)
Hemodialysis 42 (24.9) 50 (28.6)
Peritoneal dialysis 54 (32) 57 (32.6)
Repeated transplantation 9 (4.7) 9 (7.1) 0.366
CMV mismatch 27 (16.4) 45 (26) 0.030
Modern induction therapy 109 (64.5) 128 (73.1) 0.083
Primary drainage 0.701
Bowel 43 (25.6) 48 (27.4)
Bladder 125 (74.4) 127 (72.6)
Coronary artery disease 31 (16.5) 17 (13.6) 0.487
Cerebrovascular disease 12 (6.4) 8 (6.4) 0.995
Thromboembolic event 3 (1.6) 1 (0.8) 0.539
  Median (range) Median (range) Pb
Age, y 40 (23-64) 43 (23-64) 0.009
BMI 23 (17-33) 24 (18-33) 0.156
Time on waiting list, y 1 (0-10) 1 (0-6) 0.783
Time since DM I, y 26 (14-44) 29 (12-48) 0.030
Time since first dialysis treatment, y 0.7 (0-8) 0.7 (0-7) 1.000
Total HLA mismatches 4 (1-6) 4 (0-6) 0.254
a Pearson Chi-Square
b Independent Samples Median Test
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resuLTs
A total of 349 pancreas transplantations were performed at the Leiden University Medical 
Center from January 1, 1984 to January 1, 2013. For all 349 transplantations, follow-up was 
conducted until October 31, 2013.
Analysis of P-PAss
The cohort was divided into 2 groups, using the original cut-off point of P-PASS lower than 
17 (n = 191) and P-PASS of 17 or higher (n = 126). From 32 donors, the P-PASS could not 
be calculated. Demographic donor, recipient, and transplantation factors of both P-PASS 
lower than 17 and P-PASS of 17 or higher related transplantations are shown in Tables 1 
and 2. Groups were different on the following P-PASS–associated risk factors: donor age 
(p < 0.001), use of vasopressors (p < 0.001), BMI (p < 0.001), and duration of ICU stay (p< 
0.001). Mean duration of ICU stay was 2.7 days in P-PASS lower than 17 and 3.7 days in 
P-PASS of 17 or higher (p = 0.01). Other factors that were also significantly different among 
groups were weight (p < 0.001), COD (p < 0.001), PDRI (p < 0.001), modern induction 
therapy (p < 0.001), and primary enteric or bladder drainage (p = 0.02). Induction therapy 
and primary enteric or bladder drainage had little influence on graft survival (p < 0.1).
The P-PASS with the cutoff point of P-PASS lower than 17 was not associated with graft 
survival (p = 0.504). Graft survival at 1-year, 5-year, and 10-year follow-up for P-PASS lower 
than 17 was 87.8%, 81%, and 72.7% and for P-PASS of 17 or higher was 83.3%, 76.0%, and 
71.4%, respectively (Fig. 1A). After changing the cutoff to P-PASS lower than 20 (n = 299) 
and P-PASS of 20 or higher (n = 18), we still did not find a relation with outcome after 
transplantation (p = 0.402). Graft survival at 1-year follow-up for these 2 groups was 86% 
and 83%, respectively (Fig. 1B). These groups were different on the following graft survival 
predictors: local or nonlocal origin of procurement center and induction therapy (p < 0.1).
As a continuous model, P-PASS was not associated with graft survival (p = 0.738). When 
analyzing the P-PASS in a multivariate analysis using the original cutoff of 17, there was 
no significant relation with outcome: hazard ratio (HR), 1.19 (0.76–1.85, p = 0.448). When 
the cutoff P-PASS of 20 or higher was used in the multivariate analysis, the association was 
stronger, however, still not significant: HR, 2.21 (0.95–5.16, p = 0.067). With P-PASS evalu-
ated as a continuous model, multivariate analysis still revealed no relation with outcome: 
HR, 1.03 (0.93–1.14, p = 0.574).
Analysis of Pdri
The median PDRI was 1.24. The PDRI was analyzed both as a continuous model and using 
a cutoff of PDRI of 1.24. The 2 groups were PDRI lower than 1.24 (n = 169) and PDRI of 
1.24 or higher (n = 175). The PDRI of 5 donors could not be calculated. Demographics 
of donor, recipient, and transplantation factors of both PDRI lower than 1.24 and PDRI 
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Figure 1.  
A Comparison of P-PASS categories: P-PASS < 17 versus P-PASS ≥ 17.  
B Comparison of P-PASS categories: P-PASS < 20 versus P-PASS ≥ 20. 
 
   
figure 1. A Comparison of P-PASS categories: P-PASS < 17 versus P-PASS ≥ 17.
 B Comparison of P-PASS categories: P-PASS < 20 versus P-PASS ≥ 20.
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of 1.24 or higher related transplantations are shown in Tables 3 and 4. The groups were 
different on the following PDRI-associated risk factors: donor age (p < 0.001), donor sex (p 
< 0.001), donor height (p < 0.001), donor BMI (p = 0.031), and COD (p < 0.001). Factors not 
included in PDRI that were different among groups were donor hypertension (p < 0.001), 
donor cardiac arrest (p = 0.002), serum amylase (p = 0.001), P-PASS (p < 0.001), recipient 
age (p = 0.009), donor-recipient cytomegalovirus mismatch (p = 0.03), and time since onset 
of DM1 (p = 0.03). Donor cardiac arrest, serum amylase, and induction therapy had little 
influence on graft survival (p < 0.1).
Graft survival at 1-year, 5-year, and 10-year follow-up was 90.4%, 83.8%, and 77% in the 
low-PDRI group and 78.3%, 71.2%, and 66.7% in the high-PDRI group, respectively. In the 
univariate analysis, PDRI was significantly associated with graft survival using the cutoff 
point of PRDI of 1.24 (p = 0.007, Fig. 2). As a continuous model, PDRI did not influence 
graft survival (p = 0.254).
In the multivariate analysis, PDRI higher than 1.24 was associated with decreased graft 
survival: HR, 2.02 (1.29–3.16, p = 0.002). As a continuous model, PDRI was associated with 
graft survival, however, not significantly: HR, 1.85 (0.87–3.91, p = 0.110). The concordance 
index (c-index) for the PDRI was 0.69 (standard error, 0.045).
 
Figure 2.  
Comparison of PDRI categories: low PDRI < 1.24 versus high PDRI ≥ 1.24. 
 
   
figure 2. Comparison of PDRI categories: low PDRI < 1.24 versus high PDRI ≥ 1.24.
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disCussion
This study evaluates the following 2 current models for graft failure risk calculation of 
pancreas allograft donors: the PDRI and P-PASS. At first, the P-PASS was re-evaluated for 
its ability to predict outcome after pancreas transplantation. The P-PASS is currently used by 
Eurotransplant and pancreas transplant centers as categorical variable to identify a suitable 
pancreas donor, which is why it was analyzed as a categorical variable. Second, the PDRI 
was evaluated in our center (one of the larger European pancreas transplantation centers). 
To our knowledge, this is the first and largest study to evaluate the PDRI in the European 
region. A small study was conducted by Mittal et al12 investigating the relationship between 
1-year graft survival and PDRI for both SPK and PTA transplantations using the PDRI 
smartphone application. They confirm the relationship between graft survival and PDRI, 
however, only for SPK transplantations. In our study, the median PDRI was 1.24, which 
indicates the difference in donor quality between our center and the OPTN region, where 
median donor quality was in concordance with PDRI of 1.0. This is in line with other data 
used for validation of the DRI and construction of the Eurotransplant donor risk index in 
liver transplantation, showing higher risk donors in the European (Eurotransplant) region.9
For the analyses of both models (PDRI/P-PASS), we defined graft survival using the 
OPTN definition as a guideline. The authors feel that this is a uniform definition of graft 
survival and graft survival was analyzed accordingly. The main reason for this definition 
was its objectivity with regard to graft failure, because the moment of restart of exogenous 
insulin therapy as the moment of graft failure is a subjective way of defining graft failure. 
Worldwide, not all physicians are evenly aggressive in treating hyperglycemia and the restart 
of insulin therapy might differ between transplant centers.
The absent relationship between the P-PASS and outcome after pancreas transplantation 
has been demonstrated previously. Two studies from different Eurotransplant pancreas 
transplantation centers showed that there was no correlation between long-term pancreas 
graft survival and the P-PASS.6,7 Furthermore, it was concluded that pancreas allografts 
should not be rejected purely on the basis of high P-PASS values. The results of our study 
are in concordance with these previous studies. Regardless of the P-PASS, no significant 
difference was found between pancreas allograft survival with a P-PASS lower than 17 or 
17 or higher. Even after altering the cutoff point to a P-PASS of 20, there was no significant 
difference in outcome. The choice to select a P-PASS of 20 as another cutoff point was 
arbitrary; however, the absent relationship, even with this higher cutoff, confirms that the 
P-PASS should not be used to decline pancreas allografts beforehand nor predict pancreas 
graft failure and it even raises the question whether it should be used to identify a suitable 
pancreas before allocation to any recipient, for which it was initially developed. In this study, 
it was not possible to examine the influence of P-PASS on graft acceptance practice, because 
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only accepted and actually transplanted organs were included in the analysis. In the original 
P-PASS study, a relationship between this model and organ acceptance was demonstrated.5
The PDRI was significantly associated with graft survival in univariate and multivariate 
analysis when using a cutoff of a PDRI of 1.24. It was not possible to establish a relation-
ship between graft survival and the groups originally formulated by Axelrod et al.8 The 
authors believe that this is mainly due to the smaller numbers per group when breaking up 
in more groups. As a continuous model, the PDRI was not associated with graft survival, 
which might also be explained by too low numbers in the analysis. However, the association 
was stronger in the multivariate analyses. On the other hand, the index of concordance (c-
index) indicates that PDRI might be a valid predictor of graft survival and demonstrates the 
potential for clinical decision making in the future. The PDRI could potentially be used for 
risk stratification and also to compare studies and give an indication of the pancreas graft 
quality used within a center/region. The c-index was in accordance with the one reported 
in the original study by Axelrod et al.8 It might be interesting to adjust the PDRI to the 
European donor population and validate the model in a multicentered European cohort, 
before implementing the model in clinical practice, as was done for the DRI and Eurotrans-
plant donor risk index in liver transplantation,13 because this might lead to a more optimal 
model with adjusted weighing of risk factors or additional factors. Even with PDRI of 1.24 
or higher, long-term graft survival was relatively good (67% vs 77% at 10 years), indicating 
that pancreas allografts should not be declined only on the basis of a higher PDRI. The good 
results with high-PDRI donor grafts could (partially) be explained by the long experience 
in pancreas transplantation in our center and proper recipient selection. Furthermore, the 
scarcity of optimal pancreas donors has pushed us to be more liberal in accepting grafts.
The difference in significance between both models might be explained by the fact that 
P-PASS was originally designed as a suitable donor identifier based on a “soft” criterium as 
expert opinion, whereas the PDRI was initially intended to predict graft survival in trans-
planted grafts. To have a good, describing donor risk model in pancreas transplantation 
would be of great additional value. Within the field of pancreas transplantation, there are 
currently a lot of different opinions with regard to organ donor quality, as was recently de-
scribed by Loss et al in a survey among German pancreas transplant surgeons.14 Obviously, 
there are certain risk factors that are commonly accepted (e.g. age, ICU stay, macroscopy of 
the organ), but it would be of additional value to get a clear risk indication at the moment 
of an organ offer. The PDRI would be ideal for this, even though it was not analyzed for its 
ability to predict graft acceptance in this study. The authors feel that unknown factors at 
time of organ offering (CIT and transplant type) could be estimated or imputed on the basis 
of historical data.
One of the potential limitations of our study was the fact that we only analyzed pancreas 
allografts that were actually transplanted and the fact that this was conducted in a single-
center database. At our center, the Leiden University Medical Center, we have 30 years of 
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experience in pancreas transplantation and currently we are one of the largest pancreas 
transplantation centers in the Eurotransplant region.11 Another limitation was the absence 
of donor parameters, such as serum lipase, serum amylase, and admission at ICU, because 
these were not available in the Eurotransplant database. Therefore, it was not possible to 
calculate the P-PASS in 32 cases. On account of missing values for donor height, BMI, and 
serum creatinine, we were not able to calculate the PDRI in 5 cases. We are aware that the 
evaluation period is almost 30 years, with major changes concerning immunosuppression, 
donor and recipient management, and clinical experience. These factors might all have con-
tributed to outcome; however, the aim of this study was only to analyze both donor quality 
models in their ability to predict graft survival. In multivariate analyses of both prediction 
models, introduction of modern induction therapy (1999) was used as a surrogate marker 
to correct for major improvement in outcome in terms of graft survival. The validation of 
a donor risk index is the first step toward donor to recipient matching in pancreas trans-
plantation, in which both donors as well as recipient risk indices are to be incorporated. 
However, in The Netherlands allocation is currently purely based on waiting time.
ConCLusions
The P-PASS has no prognostic value for outcome after pancreas transplantation and the use 
of this model as a criterion for the evaluation of pancreas donors and prediction of graft 
survival is highly questionable. The PDRI is the more favorable model, because this study 
shows its ability to predict graft survival and it could therefore be helpful for clinical deci-
sion making. Although high-PDRI donors have a strong association with decreased graft 
survival, they should never be declined solely on the basis of their score, because these high 
risk grafts (PDRI ≥ 1.24) still have a good outcome. Further development of a European 
PDRI is warranted and should be performed in a multicenter collaboration.
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introduction: Pancreas donor selection and recognition are important to cope with in-
creasing organ shortage. We aim to show that the PDRI is more useful than the P-PASS to 
predict acceptance and should thus be preferred over P-PASS.
Methods: Eurotransplant donors from 2004 until 2014 were included in this study. PDRI 
logistical factors were set to reference to purely reflect donor quality (PDRI donor). PDRI 
and P-PASS association with allocation outcome was studied using area under the receiver 
operating characteristic curve (AUROC). Regional differences in donor quality were also 
investigated.
results: Of the 10 444 pancreata that were reported, 6090 (58.3%) were accepted and 2947 
(28.2%) were transplanted. We found that P-PASS was inferior to PDRIdonor in its ability to 
predict organ reporting, acceptance, and transplantation: AUC 0.63, 0.67 and 0.73 for P-
PASS vs. 0.78, 0.79 and 0.84 for PDRIdonor, respectively. Furthermore, there were significant 
differences in donor quality among different Eurotransplant countries, both in reported 
donors and in transplanted organs.
Conclusions: PDRI is a powerful predictor of allocation outcome and should be preferred 
over P-PASS. Proper donor selection and recognition, and possibly a more liberal approach 
toward inferior quality donors, may increase donation and transplant rates.
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inTroduCTion
Pancreas (and combined kidney) transplantation is the definitive treatment for patients with 
type 1 diabetes mellitus and end-stage renal disease.1-4 With increasing scarcity of suitable 
organ donors, the Eurotransplant Pancreas Advisory Committee is continuously working 
to improve pancreas transplantation outcomes, in part by improving the organ allocation 
process. Especially in pancreas transplantation, where discard rates are among the highest 
of all organs, proper donor recognition and selection is paramount.5,6
In 2008, the Eurotransplant International Foundation introduced the preprocurement 
pancreas allocation suitability score (P-PASS) was introduced.7 This donor scoring system, 
which was one of the first quantitative donor scoring systems, consists solely of donor fac-
tors (age, body mass index (BMI), duration of intensive care unit (ICU) stay, duration of 
asystole, sodium, amylase, lipase and inotropic therapy). The system identifies a suitable 
pancreas donor, using a cut-off value of 17 (range 9–27). Its intention was to educate and 
inform transplant professionals, such as ICU clinicians referring potential donors, as well 
as transplant coordinators reporting donors to Eurotransplant. Side by side with this educa-
tion, the donation rates were thought to increase, which appeared to be the case since 2009.8
The disadvantage of the P-PASS is that it was initially developed based on acceptance rate, 
without data on patient and graft survival. While the same authors went on to identify a 
relationship with graft survival in a later study9, studies by other researchers could not find 
any correlation between P-PASS and graft survival.10-12
Seven years after its introduction, the original P-PASS thresholds have shifted along with 
increasing donor age and numbers of donation after circulatory death (DCD) pancreas 
transplantations.13,14 Some factors are less relevant than previously believed or caused by 
other mechanisms, for example brain dead donors with high serum amylase due to man-
dibular trauma. This elevated amylase does not affect the outcome following pancreas trans-
plantation.15 Eurotransplant professionals still use the P-PASS to make decisions about the 
allocation process (e.g. whether to continue with whole-organ allocation, to proceed to islet 
allocation or to evaluate changes in guidelines), despite the above-mentioned shortcomings. 
Also, data on lipase and amylase might not always be available, which makes calculation of 
the P-PASS impossible in the current Eurotransplant algorithm. Therefore, a more recent 
and precise tool is needed.
In 2010, a risk index for predicting graft survival after pancreas transplantation was 
designed using data from the Organ Procurement and Transplantation Network (OPTN): 
the pancreas donor risk index (PDRI).16 This model consists of eight donor factors (age, 
sex, race, height, BMI, serum creatinine, cause of death (COD), and DCD) along with two 
transplant/logistical factors (cold ischemia time (CIT) and type of transplant (simultaneous 
pancreas–kidney transplantation (SPK), pancreas after kidney transplantation (PAK) or 
pancreas transplant-alone (PTA) transplantation)). The advantage of this PDRI is that it was 
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derived from a large data set. This evidence-based approach provided an index (indicating 
that the standard donor has a score of 1.0), which allows for direct comparison of a potential 
donor with this standard donor. This risk index was recently validated as means for predict-
ing graft survival in the UK population17 and in The Netherlands.12 The concept of a donor 
risk index allows risk estimation prior to transplantation and might aid in decision-making 
whether to accept the offer as well as, perhaps even more important, comparison of results 
post-transplantation.
While CIT and type of transplant are unknown factors of the PDRI at the time of organ 
reporting, these factors could be estimated or imputed based on historical data. In this 
study, these factors were set to reference, so that the PDRI calculations would purely reflect 
donor quality (PDRIdonor) and the concept would be the same as that from the P-PASS.
The objective of this study was to compare the association of the P-PASS and PDRIdonor 
with organ acceptance and pancreas transplantation and to investigate whether the PDRI is 
a more useful tool for donor characterization. If PDRI is more useful tool at the time of or-
gan reporting or offering, it might replace P-PASS. Also, we reported PDRI for transplanted 
organs to provide insight regarding regional differences in donor quality.
MATeriALs And MeTHods
donor selection
All donors of whom one or more abdominal organs were reported to Eurotransplant from 
January 2004 until December 2014 were included in the study. The data that were collected 
are shown in Table 1.
Data that were stored incorrectly in the Eurotransplant database (wrong unit, wrong 
entry) were corrected as following: for creatinine data, any 0.5% lower and 0.5% upper 
outliers were cross-checked and corrected when necessary. All data were converted to mg/
dl. For BMI data, any values >60 and <10 were checked for feasibility and corrected when 
appropriate and possible. Anything below 17 was considered a low P-PASS value, whereas 
P-PASS equal to or above 17 was considered a high P-PASS value, as was originally defined 
by the P-PASS authors. Eurotransplant currently recommends considering pancreas dona-
tion in cases of a low P-PASS18 values.
Pancreas donor risk index (Pdri)
PDRI was calculated according to Axelrod et al.16 Race is not recorded in the Eurotransplant 
database and was excluded from PDRI calculations (i.e. all donors were considered as the 
PDRI reference Caucasian donor). For all transplanted whole pancreas, pancreas donor risk 
index (PDRI) was calculated. Pancreas after kidney (PAK) was coded only when solitary 
kidney transplantation was followed by solitary pancreas transplantation. Solitary pancreas 
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retransplantation after SPK was considered pancreas transplant alone (PTA). Cold ischemia 
time (CIT) was coded in hours and, when missing, was imputed using 20 multiple imputa-
tion rounds in SPSS. CIT was the single factor that was imputed. Donor center, donor age, 
donor gender, weight, height, BMI, cause of death, donor type (DBD versus DCD), liver 
donor (Y/N), transplant center, transplant type, and CIT were set as predictors for multiple 
imputation. Donor quality in different Eurotransplant countries was assessed using PDRI. 
Mean and standard deviations were displayed, and P-values were calculated using one-way 
analysis of variance methods.
Pancreas donor risk index (Pdridonor)
PDRIdonor was calculated for all reported pancreas donors, where CIT was set to 12 h and 
transplant type was set to SPK, as these were the reference values in the original equation. 
This PDRIdonor enabled the use of the PDRI at time of organ reporting and was analyzed for 
its association with pancreas acceptance and transplantation.
statistical methods
Statistical analyses were performed in SPSS version 22. P-value <0.05 was considered 
significant for all analyses. PDRIdonor and P-PASS were evaluated as continuous variables 
for their ability to predict allocation outcome (reported, accepted, procured, transplanted) 
using area under the receiver operating curve (AUROC) analysis. Odds ratios for high and 
low P-PASS were calculated for allocation outcome. Also, P-PASS was evaluated for its cor-
relation with PDRIdonor using Spearman’s rank correlation coefficients. Pancreas discard was 
defined as an organ being procured, but not transplanted.
results
In the study period (January 2004–December 2014), 23 851 abdominal organ donors were 
reported to Eurotransplant. Of these organ donors, 10 444 (43.8%) reported pancreas; 21 
063 (88.3%) reported liver; and 22 336 and 22 379 (93.6% and 93.8%) reported left and right 
kidney, respectively. More than half of the donors (53.8%) were reported from Germany. 
Other baseline demographics are shown in Table 1.
Allocation outcome
Of the 10 444 pancreas donors, 10 092 (96.6%) pancreases were offered. Offered pancreases 
were accepted from 6090 (58.3%) donors. Procurement of the pancreas took place in 4731 
(45.3%) procedures. In 2947 cases (28.2%), the pancreas donation procedure led to trans-
plantation. An overview of allocation outcome is shown in Fig. 1. Pancreas was discarded 
in 1784 cases (56.8%).
The majority of transplants were primary simultaneous pancreas and kidney (SPK) 
transplants (70.5%), followed by islet transplantations (14.1%). Retransplantations were 
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Table 1. Demographics of reported donors (minimum 1 abdominal organ) to Eurotransplant (January 2004 – 
December 2014)
  n (%)
donors 23851 (100)
Sex a/b
Male 13079 (54.8)   
Female 10772 (45.2)
Bloodtype
A 10198 (42.8)
B 1317 (5.5)
AB 2687 (11.3)
O 9649 (40.5)
Cause of death a
Stroke 14820 (62.1)
Trauma 5456 (22.9)
Circulatory 1264 (5.3)
Anoxia 1604 (6.7)
CNS tumor 147 (0.6)
Other 560 (2.3)
Donor type a
DBD 21639 (90.7)
DCD 2212 (9.3)
Reported organs
Liver 21063 (88.3)
Pancreas 10444 (43.8)
Left kidney 22336 (93.6)
Right kidney 22379 (93.8)
Inotropic support (Y)b 19139 (80.2)
Cardiac arrest b
Yes 3207 (13.4)
No 9888 (41.5)
Unknown 10756 (45.1)
Donor country
Austria 2263 (9.5)
Belgium 3319 (13.9)
Croatia 945 (4.0)
Germany 12811 (53.7)
Hungary 345 (1.4)
Luxembourg 48 (0.2)
Netherlands 3048 (12.8)
Slovenia 416 (1.7)
Outside ET 656 (2.8)
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performed in 206 patients (7.0%), and these were pancreas after SPK (5.0%) or SPK after 
SPK (2.0%) (Table 2).
P-PAss evaluation
P-PASS could be calculated in 19 767 cases (82.9% of all 23 851 organ donors). P-PASS could 
not be calculated in 4084 cases (17.1% of all 23 851 donors). This was mainly due to missing 
amylase and lipase values (n = 3253) or unknown ICU stay (n = 739). Median (25th–75th 
percentile) P-PASS was 19 (17–20). From all 10 444 pancreas donors, P-PASS could be cal-
culated in 9795 cases (93.7%). Of these donors, 3497 (35.7% of these 9795 donors) yielded 
a low P-PASS value. In 2516 cases (71.9% of those 3497 cases), the responsible transplant 
coordinator adhered to the Eurotransplant recommendation and reported the pancreas to 
Eurotransplant. In 745 cases (28.1%), despite a low P-PASS value, the pancreas was not 
reported to Eurotransplant due to other (unspecified) medical reasons. Of the 16 270 high 
P-PASS-value- donors, 7279 of 16 270 (44.7%) pancreases were reported to Eurotransplant. 
Odds ratio of a pancreas being accepted with low versus high P-PASS was 2.21 (95% CI 
2.13–2.31) (Table 2). Pancreas reported, accepted, procured and transplanted versus not 
reported, not accepted, not procured and not transplanted, respectively, yielded the fol-
lowing AUROC’s (95% CI of AUROC): 0.63 (0.62–0.63), 0.67 (0.67–0.68), 0.68 (0.67–0.69) 
and 0.73 (0.72–0.74), respectively (Figure S1 a–d). AUROC’s (95% CI of AUROC): 0.78 
(0.77–0.78), 0.79 (0.78–0.80), 0.76 (0.75–0.77), and 0.84 (0.83–0.84), respectively (Figure 
S2 a–d).
Pdridonor evaluation
After correction of the raw data, PDRIdonor was calculated (Table 1 for individual factors). 
There was a significant correlation between P-PASS and PDRIdonor for all donors (Spearman’s 
Table 1. Demographics of reported donors (minimum 1 abdominal organ) to Eurotransplant (January 2004 – 
December 2014) (continued)
   n  Missing (%) Median (25th – 75th pct)
Age, y a/b 23851 0 53 (41 - 64)
Weight, kg 23849 <0.1 75 (68 - 85)
Height, cm a 23851 0 172 (165 - 180)
BMI, kg/m2 a/b 23849 <0.1 25.2 (23.1 - 27.8)
Sodium, mmol/l b 23648 0.9 147 (142 - 152)
Creatinine, mg/dl a 23851 0 0.86 (0.64 – 1.17)
Amylase, U/lb 16378 31.3 73 (39 - 145)
Lipase, U/l b 16582 30.5 29 (17 - 68)
PPASS 19767 17.1 19 (17 - 20)
a PDRI factor
b P-PASS factor
64 Chapter 4
r = 0.343, p < 0.001). Correlations were stronger for different outcomes: reported (r = 0.479), 
accepted (r = 0.557), procured (r = 0.569), and transplanted (r = 0.615) (p < 0.001 for all). 
Pancreas reported, accepted, procured and transplanted versus not reported, not accepted, 
not procured and not transplanted, respectively, yielded the following AUROC’s (95% CI 
of AUROC): 0.78 (0.77–0.78), 0.79 (0.78–0.80), 0.76 (0.75–0.77), and 0.84 (0.83–0.84), 
respectively (Figure S2 a–d). Pooled sample PDRIdonor was 1.27 (0.42). Dutch donor centers 
reported the highest PDRIdonor values from donors, with a mean PDRIdonor value of 2.50 (SD 
1.08). Most pancreata (48.6%) were reported in German donor centers (mean PDRIdonor 
1.69, SD 0.66).
Pancreas donor risk index for transplanted organs
From 2408 transplanted pancreata, cold ischemia time was missing in 756 (31.3%) cases. 
Prior to imputation rounds, mean (SD) cold ischemia time was 10.7 (3.1) hours. Cold 
ischemia time could not be imputed in 67 cases due to missing predictors; this resulted 
in known cold ischemia time for 2341 transplanted grafts. Pooled sample mean CIT was 
10.7 h after 20 imputation rounds. Pancreas donor risk index (PDRI) was calculated for 
all transplanted pancreas grafts with known cold ischemia time. The pooled sample mean 
Table 2. Pancreas allocation outcome and transplant types
n (%)
odds ratio (95% Ci)
P-PASS<17 vs.
P-PASS≥17
Reported to Eurotransplant 10444 (100) 1.61 (1.57 – 1.65)
Accepted by transplant center 6090 (58.3) 2.21 (2.13 – 2.31)
Pancreas procured 4731 (45.3) 2.31 (2.21 – 2.43)
Pancreas transplanted 2947 (28.2) 3.43 (3.21 – 3.66)
 
Pancreas transplanted 2947 (100)
Primary transplantation
Simultaneous pancreas kidney (SPK) 2077 (70.5)
Pancreas transplant alone (PTA) 96 (3.3)
Pancreas after kidney (PAK) 29 (1)
Multi organ transplantation 62 (2.1)
Islets 417 (14.1)
Simultaneous islet kidney (SIK) 6 (0.2)
Islets after kidney (IAK) 35 (1.2)
Secondary transplantation
Pancreas after SPK 147 (5.0)
SPK after SPK 59 (2.0)
Islets after SPK 19 (0.6)
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(SD) PDRI was 1.24 (0.41). PDRI was significantly lower than PDRIdonor: 0.027 (95% CI of 
difference 0.023–0.030, p < 0.001). Slovenia transplanted the highest PDRI organs, although 
only 8 PDRI could be calculated due to many missing values, with a pooled sample mean of 
1.64 (SD 0.30). Dutch transplant centers transplanted the 2nd highest PDRI organs, with a 
pooled sample mean of 1.35 (SD 0.43). All other data are shown in Tables 3 and 4.
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disCussion
This study is an overview of the pancreas quality of donors in the Eurotransplant area. Cur-
rently available donor risk indices, both Preprocurement Pancreas Allocation Suitability 
Score (P-PASS) and the Pancreas Donor Risk Index (PDRI), were evaluated for their ability 
to predict allocation outcome in the study cohort. It has become clear from this study that 
Table 3. donor risk index per eurotransplant country by allocation outcome for whole organ
Pancreas reported a Accepted
Transplanted whole 
organ
Transplanted whole 
organ
PDRIdonor PDRIdonor PDRIdonor PDRI
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD c)
Austria 634 1.44 (0.57) 421 1.24 (0.42) 303 1.23 (0.42) 298 1.19 (0.40)
Belgium 2090 2.07 (1.03) 258 1.21 (0.38) 197 1.18 (0.36) 181 1.14 (0.36)
Croatia 261 1.48 (0.59) 85 1.05 (0.29) 68 1.04 (0.30) 68 1.00 (0.28)
Germany 5027 1.69 (0.66) 2766 1.39 (0.48) 1626 1.28 (0.42) 1588 1.24 (0.41)
Hungary 59 1.43 (0.47) 43 1.33 (0.39) 23 1.16 (0.34) 23 1.12 (0.33)
Luxembourg 29 1.67 (0.91) 0 0 0
Netherlands 2028 2.50 (1.08) 345 1.43 (0.49) 245 1.39 (0.45) 242 1.35 (0.43)
Slovenia 211 1.67 (0.63) 23 1.45 (0.43) 8 1.64 (0.42) 8 1.64 (0.30)
Total 10339 1.90 (0.90) 3941 1.36 (0.47) 2470 1.27 (0.42) 2408  1.24 (0.41)
p b   p<0.001   p<0.001   p<0.001   p<0.001
a By donorcountry, all others displayed by accepting/transplant country
b One way analysis of variance (ANOVA)
c Pseudo-SD for imputed data
Table 4. Donor risk index per Eurotransplant country by allocation outcome for islets
 
Pancreas reported a Accepted Transplanted islets
n PDRIdonor n PDRIdonor n PDRIdonor
Austria 634 1.44 (0.57) 37 2.07 (0.53) 5 1.94 (0.37)
Belgium 2090 2.07 (1.03) 1509 2.25 (0.93) 392 2.27 (0.87)
Croatia 261 1.48 (0.59) 0 0
Germany 5027 1.69 (0.66) 134 2.19 (0.61) 25 2.22 (0.56)
Hungary 59 1.43 (0.47) 0 0
Luxembourg 29 1.67 (0.91) 0 0
Netherlands 2028 2.50 (1.08) 469 2.55 (0.91) 55 2.24 (0.81)
Slovenia 211 1.67 (0.63) 0 0
Total 10339 1.90 (0.90) 2149 2.31 (0.91) 477 2.26 (0.85)
p b p<0.001 p<0.001 p=0.846
a By donorcountry, all others displayed by accepting/transplant country
b Mean (SD). One-way ANOVA
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many potential donors are not being utilized and discard rates are high. This study also 
shows that in pancreas transplantation there is not so much an absolute shortage of organs, 
but merely a shortage of organs that are presumed suitable. Therefore, proper donor selec-
tion within a broad cohort of potential pancreas donors is important. We therefore selected 
the widest possible range of donors, without limiting age or BMI. Currently, guidelines in 
The Netherlands consider whole-organ DBD pancreas donation up to 60 years appropriate, 
and up to 50 years for DCD donation. In the UK, the upper age limit is even higher.19 
Despite this wide range, 75% of the donor population in our study was below 64 years and 
might therefore possibly be considered for pancreas transplantation.
The P-PASS is a scoring tool that was developed at Eurotransplant in 2008. It is well 
known that increasing organ shortage has pushed transplant professionals to accepting 
more extended criteria donor organs. Therefore, we aimed to analyze whether the P-PASS 
in its current form still has any value in the allocation process, whether it is still of aid to 
transplant professionals, and whether it can and should be used in the future. Compared to 
the data provided by the original authors, who analyzed a cohort from 2002 until 20057, the 
median potential donor quality, as measured by P-PASS, has declined to a median of 19. This 
finding questions the applicability of the P-PASS in current allocation practices, considering 
the recommendation that is given by Eurotransplant that any donor with a P-PASS below 
17 should be considered as a potential donor. It is remarkable that the P-PASS could not be 
calculated in 17% of the cases. The fact that 28% of the potential donors were not reported 
due to medical reasons, despite a low P-PASS, questions the value of the current cut-off. 
Furthermore, some P-PASS factors have become more common today, so the question is 
whether the P-PASS scoring system is still up to date. Especially in countries with relatively 
high numbers of DCD donors, such as The Netherlands and, to a lesser extent, Belgium, 
P-PASS does not fully apply, as the factor DCD is not taken into account (although it is a 
known risk factor16). Also, in our cohort, median donor age was 53 years, which does not 
compare to the earlier reported median age of 34 years, for accepted donor grafts, nor to 
the median age of 40 years, for grafts that were not accepted. The odds ratio of pancreas 
acceptance with low versus high P-PASS was lower than reported by the original authors, 
which also indicates its decreased predictive value.7
The Pancreas Donor Risk Index, which was developed using OPTN data in 2010, was 
recently validated in a European setting to predict graft survival.12,17 Again, as the PDRIdonor 
only contains donor factors, similar to the P-PASS, it would be applicable at the time of 
organ allocation. We deliberately chose not to modify the intrinsic regression coefficients 
of the model, but decided to use the model with the logistical factors set to their reference 
values. In this model, cold ischemia time was set to 12h, race set to Caucasian, and trans-
plant type set to SPK. With this approach, we were able to establish excellent discriminatory 
properties of the model. The additional value of the full PDRI is that it has already been 
proven to be associated with graft survival.
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Even though the correlation between P-PASS and PDRIdonor was statistically significant, 
the correlation coefficient indicates that the actual correlation was not perfect. Both indices 
share risk factors and have different factors, which explains this partial correlation. For 
example, age and BMI are included in both indices. Both factors influence the final P-PASS 
score, as well as the PDRI and have also been identified as risk factors in other studies.20,21 
One of the strongest risk factors of the PDRI, DCD donation, is not included in the P-PASS. 
DCD pancreas transplantation has become a more accepted option in recent years.14,22,23 
With traumatic brain injuries, elevated amylase, as one of the P-PASS factors, does not 
have to be related to pancreas injury, but increases the P-PASS score.15 Duration of ICU 
stay and vasopressor use, P-PASS but not PDRI factors, are associated with pancreas being 
declined for transplantation.6,24 Because these donors are declined for transplantation, there 
is little evidence to support that finding. A small trial found no association with donor 
vasopressor use and short-term outcome.25 Electrolytes, such as the P-PASS factor sodium 
and the PDRI factor creatinine, do not necessarily influence pancreas graft survival, but 
they do provide insight in donor kidney function and general donor condition. Especially 
creatinine, the main indicator of kidney function, may reflect kidney damage (but also other 
organ damage) in an early stage. When taking those factors into account, it is obvious that 
the role of P-PASS in organ allocation should be reconsidered. Furthermore, from this study 
it becomes clear that the PDRIdonor is a more powerful tool to predict allocation outcome. All 
supplemental AUROC curves show that the PDRI is superior over the P-PASS. This implies 
that the PDRIdonor and PDRI are more valuable tools in donor selection and donor popula-
tion comparison and should be used instead of the P-PASS for aforementioned applications.
The difference in pancreas donor quality in different Eurotransplant countries is a re-
markable finding. Donation after cardiac death is believed to play a major role in the high 
PDRIdonor values in The Netherlands and Belgium. Even with these high-risk donors, good 
outcomes can be achieved, so organs and potential donors should never be turned down 
solely based on high PDRI; a high PDRI value should not be used as a single argument to 
turn down an organ offer. PDRI is merely a valid tool to estimate outcome. The authors think 
that this assessment is useful for physician-to-patient communication as well as retrospec-
tive reporting purposes. Other factors, such as recipient selection and center experience, 
should also be taken into account. Furthermore, countries with a lower mean PDRIdonor that 
also have increasing waiting lists and increased waiting time until transplantation26,27 might 
utilize a more aggressive approach by accepting higher risk donors. Therefore, to answer the 
question on the usefulness of these donor risk indices raised by Berney and Kandaswamy 
in a recent commentary in Transplant International, a donor risk index, such as the PDRI, 
can be helpful in proper donor selection, but also in describing a certain donor population 
to compare center or country specific outcome.28
The most important limitation of our study is that our data do not contain any outcome 
after transplantation. Eurotransplant depends on the willingness of its related transplant 
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centers for data entry and data on survival is not complete. The authors therefore chose to 
select allocation outcome as a surrogate marker for donor quality. The authors presume that 
once an organ is transplanted, outcome among centers is comparable, taking the differences 
in donor and recipient populations into account. Multiple studies from large Eurotransplant 
centers have shown excellent results in terms of graft and patient survival.1, 4, 29, 30 Ideally, we 
would have validated the PDRI for graft survival in the Eurotransplant region in this study. 
Unfortunately, due to above-mentioned reasons, this was not possible and requires further 
study.
ConCLusion
As the pancreas donor risk index (PDRI) has been shown to be associated with outcome 
in other studies and this study shows that the PDRIdonor has a stronger association with 
allocation outcome, the pancreas donor risk index (in both forms) should be used instead 
of the P-PASS in organ allocation practices, as well as to describe overall pancreas donor 
quality in a population. Adequate donor recognition in different Eurotransplant regions 
might lead to increased numbers of successful pancreas donation procedures. The authors 
believe that better tools to identify donors will eventually increase donation rates. The PDRI 
is such a tool.
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introduction: Outcome after surgery depends on several factors, among these, the annual 
volume-outcome relationship. This might also be the case in a highly complex field as pan-
creas transplantation. No study has investigated this relationship in a European setting.
Methods: All consecutive pancreas transplantations from January 2008 until December 
2013 were included. Donor-, recipient-, and transplant-related factors were analyzed for 
their association with patient and graft survivals. Centers were classified in equally sized 
groups as being low volume (<5 transplantations on average each year in the 5 preceding 
years), medium volume (5-13/year), or high volume (≥13/year). 
results: In the study period, 1276 pancreas transplantations were included. Unadjusted 
1-year patient survival was associated with center volume and was best in high volume 
centers, compared with medium and low volume: 96.5%, 94% and 92.3%, respectively (p = 
0.017). Pancreas donor risk index (PDRI) was highest in high volume centers: 1.38 versus 
1.21 in medium and 1.25 in low volume centers (p < 0.001). Pancreas graft survival at 1 year 
did not differ significantly between volume categories: 86%, 83.2%, and 81.6%, respectively 
(p = 0.114). After multivariate Cox-regression analysis, higher PDRI (hazard ratio [HR], 
1.60; p < 0.001), retransplantation (HR, 1.91; p = 0.002) and higher recipient body mass 
index (HR, 1.04; p = 0.024) were risk factors for pancreas graft failure. High center volume 
was protective for graft failure (HR, 0.70; p = 0.037) compared with low center volume.
Conclusions: Patient and graft survival after pancreas transplantation are superior in higher 
volume centers. High volume centers have good results, even though they transplant organs 
with the highest PDRI.
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inTroduCTion
Pancreas transplantation is the only definitive treatment for patients with type 1 diabetes 
mellitus. This can be as a simultaneous pancreas kidney transplantation (SPK) in case of 
end-stage renal disease (ESRD) or as a solitary pancreas transplant (pancreas after kidney 
[PAK], pancreas transplant alone [PTA]) in case of life-threatening hypoglycemic unaware-
ness.1-3 Even though the number of patients on the waiting list is relatively stable since 2009, 
optimal usage of scarce number of potential pancreas allografts is still highly important.4 
Apart from donor, recipient and transplant factors influencing outcome after transplanta-
tion,5,6 center factors may also play a significant role.
The Dutch Institute for Clinical Auditing has been working on valid outcome measures 
in 18 domains of health care, most of them in oncological surgery. Eurotransplant is a non-
profit organization that facilitates patient-oriented allocation and cross-border exchange 
of deceased donor organs. Active for transplant centers and their associated tissue typing 
laboratories and donor hospitals in 8 countries, Eurotransplant ensures an optimal use of 
donor organs. To be able to develop allocation policies based on state-of-the-art medical 
knowledge, Eurotransplant collects donor, recipient, and center data, as well as outcome 
data after transplantation. Information on center-related outcome, provided that they 
represent valid and useful outcome measures, should be publicly available: to centers, to 
improve their results; to patients, to make a well-founded decision on a preferred center; 
and to politicians, to design legitimate healthcare policies. This information can be derived 
from organizations, such as the Dutch Institute for Clinical Auditing or Eurotransplant or 
from single-center reports.
With this information, efforts are being put into concentrating “high complex, low vol-
ume” care in The Netherlands.7 Especially oncology care is subject of this ongoing change. 
Transplantation has been the subject of concentration of care by the government longer 
and especially pancreas transplantation, with currently only 2 of 8 transplant centers with 
an active pancreas transplantation program. The question rises whether this concentra-
tion is justified and if the volume outcome relationship also exists in the field of pancreas 
transplantation, as has been stated before.8,9 Recently, a German study advocated for an 
extensive analysis of volume-outcome after transplantation.10 In 2014, within Eurotrans-
plant there were 37 centers with an active pancreas transplant program, performing a total 
of 199 vascularized pancreas transplants, thus averaging an annual number of pancreas 
transplantations of a little over 5 each year.4
The aim of this study is to investigate the effect of center volume on outcome after pan-
creas transplantation in the Eurotransplant region.
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design
All consecutive vascularized pancreas transplantations that were performed in Eurotrans-
plant centers from January 1, 2008, until December 31, 2013, were analyzed. Donor, pro-
curement, recipient, and transplant data that were derived from the standard Eurotransplant 
database are shown in Table 1. Follow-up data were collected through the Eurotransplant 
registry. The Eurotransplant registry data were extracted at October 6, 2015. Graft survival 
was death censored. A frequently used definition of graft failure is that graft failure has 
occurred, when the recipient had returned to exogenous insulin therapy. This was the defi-
nition that the authors applied to all patients that were transplanted at the Leiden University 
Medical Center. For all other centers, it was unknown which definition was used, so the 
definition of pancreas graft failure was left up to the discretion of the transplant centers. 
When graft failure and death occurred at the same day or a graft had not been reported 
as failed before recipient death, this was not considered graft failure, and these cases were 
censored. The procurement surgeon determined organ quality (good, acceptable, poor) 
based on macroscopic evaluation; however, exact criteria were unknown.
Center volume for each year was defined as the total transplant volume of the 5 preceding 
years, based on standard Eurotransplant data reports (i.e., factor center volume for 2008 was 
based on average volume from 2003 to 2007, for 2009 based on 2004 to 2008, and so on).11 
Volume calculations were not performed for centers before their entry in the Eurotransplant 
collaboration. Croatia entered Eurotransplant in 2007, therefore, only transplants in 2013 
(volume based on 2008-2012) were included in the center volume-survival analysis. Hungary 
entered in 2013, so was excluded from the center volume-survival analysis. Three equally 
sized groups were determined (low, medium, and high volume), based on the total volume 
in the 5 preceding years. Multiorgan transplants were only used to compute the total volume 
and were excluded from further analysis. Data in all 3 categories were pooled in order not 
to compromise recipient privacy and in order to not be able to identify individual centers.
statistical Analysis
Differences between different volume categories were displayed using pooled sample mean 
and SE. P-values were calculated using 1-way analysis of variance. Missing values were im-
puted using 20 imputation rounds. Missing survival data were not imputed. Survival analysis 
for categorical variables was done using Kaplan-Meier estimates and groups were compared 
using Log-rank tests. Continuous variables were analyzed using Cox proportional hazard 
models after testing of the proportional hazards assumption.12 P-values less than 0.05 were 
considered statistically significant. All significant factors from univariate survival analysis, 
as well as factors that were different among volume groups were entered in multivariate 
Cox proportional hazards model. To account for clustering of the data, robust sandwich 
estimates of the standard errors were used in multivariate analysis.13 Only complete cases 
after multiple imputations were analyzed.
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Table 1. Demographics, univariate analysis of association with pancreas graft survival a
  n (%) P X2
donors 1276 (100)
Sex b (male) 0.150 2.070
Male 678 (53.1)
Female 598 (46.9)
Cause of death b 0.076 8.460
Cerebrovascular accident 624 (48.9)
Trauma 497 (38.9)
Circulational/Anoxia 115 (9.0)
CNS tumor 7 (0.5)
Other 33 (2.6)
Donor type b 0.387 0.749
DBD 1268 (99.4)
DCD 8 (0.6)
  Mean (sd) P Hr
Age, y b 32 (12) 0.006 1.014
Weight, kg 71 (14) 0.218 1.006
Height, cm b 173 (12) 0.884 1.001
BMI, kg/m2 b 23 (3) 0.036 1.045
Sodium, mmol/l 147 (9) 0.611 1.004
Creatinine, mg/dl b 0.87 (0.58) 0.358 1.089
Amylase, U/l 125 (281) 0.114 1.000
PDRI 1.27 c 0.006 1.466
  n (%) P X2
Transplant
Perfusion solution 0.036 6.658
UW d 339 (26.6)
HTK 906 (71)
Other 13 (1.0)
Unknown 18 (1.4)
Transplant type b <0.001 61.191
SPK d 1148 (90.0)
PAK 84 (6.6)
PTA 44 (3.4)
Retransplantation (yes) 118 (9.2) <0.001 13.036
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Missing data imputation
Recipient weight (6.2%), recipient height (6.2%), and pancreas cold ischemia (25.4%) had 
missing values. Variables that were included in the imputation model were: donor age, 
sex, weight, height, body mass index (BMI), cause of death, creatinine, DBD versus DCD, 
pancreas donor risk index (PDRI), and donor country; recipient age, sex, weight, height, 
dialysis type, waiting time; pancreas cold ischemia time in minutes and hours, total pan-
creas cold ischemia time (hours), transplant type (SPK, PAK, PTA), center volume, warm 
ischemic period, transplant center, transplant year, organ quality, perfusion solution. Warm 
ischemic time, PDRI, creatinine, amylase, lipase, sodium, transplant center, donor country, 
perfusion solution, and organ quality were used as indicators only. Imputation method 
Table 1. Demographics, univariate analysis of association with pancreas graft survival a (continued)
Transplant year 0.691 3.060
2008 199 (16.4)
2009 172 (14.2)
2010 228 (18.8)
2011 220 (18.1)
2012 211 (17.4)
2013 184 (15.2)
  Mean P Hr
Pancreas cold ischemia, h b 10.4** 0.610 1.012
  n (%) P X2
recipient
Gender 0.577 0.312
Male 785 (61.5)
Female 491 (38.5)
End stage renal disease
No end stage renal disease (PAK/PTA) 128 (10.0)
End stage renal disease (SPK) 0.140 0.140
Pre-emptive 218 (19.0)
Hemodialysis 736 (64.1)
Peritoneal dialysis 194 (16.9)
  Mean (sd) P Hr
Age, y 44 (9) 0.487 0.995
BMI, kg/m2 24 c 0.025 1.038
Waiting time, y 1.15 (1.3) 0.970 0.998
a Kaplan-Meier estimates (Log rank Mantel-Cox) for categorical variables. Cox proportional hazards for con-
tinuous variables.
b PDRI factor 
c based on imputed data
d favorable factor
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was automatically selected by SPSS (SPSS version 22, IBM, North Castle, NY) based on 
patterns of missing value analysis. To reduce sampling variability from the imputations, 20 
imputation rounds were performed.14 Results of multiple imputations are shown in Table 2. 
Recipient BMI and PDRI were calculated based on the imputed values.
resuLTs
In the study period (January 2008 to December 2013), 1276 pancreas transplantations were 
included in the study. There were 1148 (90%) SPK transplantations, 84 (6.6%) PAK trans-
plantation, and 44 (3.4%) PTA transplantations. During the study and follow-up period, 
122 (9.6%) patients were reported deceased and 256 (20.1%) grafts were reported as failed 
(death-censored). Mean duration of follow-up was 3.2 years. Mean pancreas donor risk 
index was 1.27. Demographics are shown in Table 1.
Patient and Pancreas Graft survival
Overall patient survival at 180 days, 1 year, and 3 years was 95.4%, 94.1%, and 91.2%, re-
spectively. Patient death was associated with higher recipient age (hazard ratio [HR], 1.03; p 
= 0.006). Pancreas graft survival (death-censored) at 180 days, 1 year, and 3 years was 85.3%, 
83.7%, and 78.8%, respectively. Pancreas graft failure was associated with higher donor age 
(p = 0.006), higher donor BMI (p = 0.036), higher PDRI (p = 0.007), and high recipient BMI 
(p = 0.027), retransplantation (p < 0.001) and the use of histidine tryptophan ketoglutarate 
(HTK) as perfusion solution (p = 0.036). Simultaneous pancreas kidney transplantation 
(p < 0.001) was protective in univariate analysis. Results of univariate analysis on factors 
associated with pancreas graft failure are shown in Table 1. Year of transplant was not as-
sociated with pancreas graft survival (p = 0.69).
In a separate subgroup analysis of recipients with ESRD (SPK recipients), the influence of 
dialysis modality (either pre-emptive transplantation, peritoneal dialysis or hemodialysis) 
was analyzed for the association with patient and graft survival. In this analysis, patient (p = 
0.235) and graft survivals (p = 0.140) were not associated with dialysis technique.
Table 2. Imputation of missing data
original data imputed data a
n % missing Mean (SEM) n % missing Mean (SEM)
Recipient height (cm) 1198 6.2 172 (0.26) 1276 0 172 (0.26)
Recipient weight (kg) 1198 6.2 72 (0.39) 1276 0 72 (0.40)
Pancreas CIT (hr) 952 25.4 10.4 (0.09) 1276 0 10.4 (0.08)
a 20 rounds of multiple imputations
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Analysis of Center Volume on outcome
For 1214 (95.1%) transplantations, center volume was calculated. Nine transplantations 
(0.7%) were from Hungary and 53 (4.2%) from Croatia, and these were excluded, because 
they had too few preceding years in Eurotransplant. Low volume centers (<25 transplanta-
tions/5 preceding years) performed 396 (32.6%) transplantations, 425 (35%) were performed 
in medium volume (25-64 transplantations/5 years) centers and 393 (32.4%) in high volume 
(≥65 transplantations/5 years) centers. An overview of number of transplantations in each 
year by center category is shown in Table S1 (SDC, http://links.lww. com/TP/B303). Center 
demographics are shown in Table 3. The pooled sample mean PDRI of donors transplanted 
in different categories differed significantly: 1.25 in low volume centers, 1.21 in medium 
volume centers, and 1.38 in high volume centers (p < 0.001). Post hoc testing (Bonferroni 
corrections) showed that PDRI only differed between high versus low (p < 0.001) and high 
versus medium (p < 0.001), not low versus medium (p = 0.316). High volume centers trans-
planted patients with ESRD more frequently in a preemptive setting, compared with low 
and medium volume (p < 0.001). Mean time from waiting list registration to transplantation 
Table 3. Demographics in center categories
  Low volume b Medium volume b High volume b p a
n 396 (32.6%) 425 (35%) 393 (32.4%)
PDRI 1.25 (0.41) 1.21 (0.41) 1.38 (0.46) <0.001
PDRI factors
Donor age, y 33 (11) 30 (12) 35 (13) <0.001
Donor BMI, kg/m2 23.6 (2.8) 22.9 (3.2) 23.3 (2.9) 0.005
Pancreas CIT, hr 9.7 (2.6) 10.4 (3.1) 11.2 (2.6) <0.001
SPK transplantation 361 (91.2%) 375 (88.2%) 353 (89.8%) 0.019
Cause of death (stroke) 196 (49.5%) 194 (45.6%) 210 (53.4%) 0.252
DCD 0 (0%) 0 (0%) 8 (2%) <0.001
Recipient age, y 44 (8.7) 44 (8.6) 44 (8.7) 0.660
Recipient BMI, kg/m2 24.2 (4.2) 24.1 (3.8) 24.2 (3.8) 0.593
Sensitized 0.177
6 – 80 % PRA 15 (4%) 28 (6.9%) 21 (5.5%)
>80% PRA 3 (0.8%) 0 (0%) 3 (0.8%)
Waiting time, d 586 (434) 649 (497) 583 (532) 0.087
Retransplantations 32 (8.1%) 46 (10.8%) 40 (10.2%) 0.387
End stage renal disease (SPK) <0.001
Pre-emptive 61 (16.9%) 54 (14.4%) 101 (28.6%)
Hemodialysis 243 (67.3%) 262 (69.9%) 192 (54.4%)
Peritoneal dialysis 57 (15.8%) 59 (15.7%) 60 (17.0%)
a One-way ANOVA for continuous variables (mean, SD), X2 for categorical variables (n, %)
b Low volume (<5 transplantations/year), medium volume (5-13/year) or high volume (≥ 13/year). 
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was not significantly different in 3 volume categories (Table 3). The proportional hazards 
assumption was not violated (p = 0.350).
Patients transplanted in high volume centers had longest patient survival (p = 0.017) 
(Figure 1A). Other than age and center volume, no factors were significantly associated 
with patient survival in univariate analysis. After correcting for recipient age (HR, 1.04; 
95% confidence interval [95% CI], 1.02-1.06; p = 0.001) in a multivariate Cox regression 
analysis, high volume (HR, 0.51; 95% CI, 0.32-0.81, p = 0.004) but not medium volume 
(HR, 0.65; 95% CI, 0.42-1.00; p = 0.052) was protective compared with low volume. One 
 
Figure 1a Kaplan-Meier estimates for p tient survival in different volume categories (p=0.017) 
  
 0 days 180 days 1 year 3 years Low volume     N at risk 382 353 332 216 Patient survival 100% 94.2% 92.3% 88.3% 
Medium volume     N at risk 399 353 329 170 Patient survival 100% 95.1% 94.0% 92.4% 
High volume     N at risk 382 360 346 236 Patient survival 100% 97.4% 96.5% 93.6% 
0 days 180 days 1 year 3 years
Low volume
N at risk 382 353 332 216
Patient survival 100% 94.2% 92.3% 88.3%
Medium volume
N at risk 399 353 329 170
Patient survival 100% 95.1% 94.0% 92.4%
High volume
N at risk 382 360 346 236
Patient survival 100% 97.4% 96.5% 93.6%
figure 1a Kaplan-Meier estimates for patient survival in different volume categories (p=0.017)
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hundred twelve cases (8.8%) were excluded due to missing follow-up data or because they 
were performed in the first years of Croatian or Hungarian membership of Eurotransplant.
In univariate analysis, graft survival was not significantly different among the 3 categories 
(p = 0.11) (Figure 1B). Higher PDRI (HR, 1.60; p<0.001), retransplantation (HR, 1.91; p = 
0.002), and higher recipient BMI (HR, 1.04; p = 0.024) were independent risk factors for 
pancreas graft failure after multivariate Cox regression analysis. Perfusion with University 
of Wisconsin (UW) solution was not protective after multivariate analysis, compared with 
 
 
Figure 1b Kaplan-Meie  estimates for pancreas graft survival in different volume categories (p=0.114) 
 
 
 
 
  
 0 days 180 days 1 year 3 years Low volume     N at risk 382 300 280 170 Graft survival 100% 83.3% 81.6% 75.2% 
Medium volume     N at risk 399 310 284 139 Graft survival 100% 84.3% 83.2% 78.2% 
High volume     N at risk 382 324 307 203 Graft survival 100% 88.2% 86.0% 82.1% 
0 days 180 days 1 year 3 years
Low volume
N at risk 382 300 280 170
Graft survival 100% 83.3% 81.6% 75.2%
Medium volume
N at risk 399 310 284 139
Graft survival 100% 84.3% 83.2% 78.2%
High volume
N at risk 382 324 307 203
Graft survival 100% 88.2% 86.0% 82.1%
figure 1b Kaplan-Meier estimates for pancreas graft survival in different volume categories (p=0.114)
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HTK (p = 0.111) or other solutions (p = 0.739). Higher center volume was associated with a 
lower risk of pancreas graft failure. This effect was statistically significant for low versus high 
volume (HR, 0.70; p = 0.037), but not for low versus medium volume (HR, 0.89; p = 0.562). 
Results of multivariate analyses are shown in Table 4a. One hundred thirty (10.2%) cases 
were excluded from multivariate analysis due to missing follow-up data or because they 
were performed in the first years of Croatian or Hungarian membership of Eurotransplant.
In a separate subgroup analysis (Table 4b) with only SPK transplants included, PDRI, 
volume category, and perfusion solution (significant factors from univariate analysis), 
Table 4.1. Multivariate analysis of association of risk factors with pancreas graft survival (all transplantations)
  Hr (95% Ci) P
PDRI 1.60 (1.23 - 2.07) <0.001
Perfusion solution
UW reference
HTK 1.28 (0.95 - 1.72) 0.111
Other 0.71 (0.09 – 5.40) 0.739
Retransplantation 1.91 (1.26 - 2.91) 0.002
Recipient BMI 1.04 (1.00 - 1.07) 0.024
Center volume
Low volume reference
Medium volume 0.89 (0.59 - 1.33) 0.562
High volume 0.70 (0.50 - 0.98) 0.037
Table 4.2. Multivariate analysis of association of risk factors with pancreas graft survival (SPK transplantations)
  Hr (95% Ci) P
PDRI 1.94 (1.45 – 2.60) <0.001
Perfusion solution
UW reference
HTK 1.56 (1.07 – 2.28) 0.021
Other 1.02 (0.13 – 7.93) 0.984
Retransplantation 1.33 (0.84 – 2.13) 0.227
End stage renal disease
Pre-emptive reference
Hemodialysis 0.97 (0.67 – 1.39) 0.85
Peritoneal dialysis 1.47 (0.96 – 2.24) 0.07
Recipient BMI 1.04 (1.00 – 1.07) 0.047
Center volume
Low volume reference
Medium volume 0.91 (0.58 – 1.44) 0.696
High volume 0.69 (0.49 – 0.97) 0.032
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recipient BMI, and dialysis category were included in multivariate analysis. In this mul-
tivariate analysis, high PDRI was associated with graft failure (HR, 1.94; p < 0.001). High 
volume, as compared to low volume, was protective for graft failure (HR, 0.69; p = 0.032), 
whereas medium volume was not (HR, 0.91; p = 0.696). The use of HTK was associated with 
a higher risk of graft failure compared with UW (HR, 1.56, p = 0.021). Whether a recipient 
was transplanted preemptively or while on dialysis was not associated with pancreas graft 
survival. Of all 1148 SPK transplantations, 119 (10.4%) were excluded from multivariate 
analysis due to missing follow-up data or because they were performed in the first years of 
Croatian or Hungarian membership of Eurotransplant.
disCussion
This study investigates the association of center volume with outcome after pancreas trans-
plantation. We have shown that there is a significant relationship between center volume 
(defined as volume in 5 preceding years) and outcome, measured both in patient survival 
years as in pancreas graft survival years.
In this study, center volume was calculated based on the total number of pancreas trans-
plantations in the previous 5 years. The authors have the opinion that 5 years is a reasonable 
timeframe to maintain an experienced program for pancreas transplantations. The calcula-
tions of volume were deliberately performed on data from preceding years, in order not to 
violate assumptions in analysis of longitudinal data.11 This allowed us to analyze the influ-
ence of volume on outcome, and we excluded the possibility that lower or higher volume was 
influenced by previous results. This is the preferred method to investigate volume-outcome 
in any specialty; however, results might have been clouded by the fact that centers were 
allowed to migrate between the categories. It could thus have been that a center was defined 
as medium volume in the first year, but was analyzed as being low volume in the following 
year. This might be considered as a limitation, but the authors consider this as a strength of 
the study, because this method allowed us to establish the existence of the volume-outcome 
relationship, without considering the individual center effect. We acknowledge the fact that 
center volume is a surrogate marker, because true quality depends on multiple factors, such 
as surgical experience, adequate recipient selection and screening, postoperative care, and 
long-term follow-up protocols.
Patient survival after transplantation was associated with recipient age, as well as cen-
ter volume. Higher recipient age was a risk factor for patient death, whereas high center 
volume was a protective factor. The better patient survival might be explained by a more 
rigorous pretransplant screening, especially regarding cardiovascular status of the intended 
recipients, and more optimal posttransplant management of cardiovascular complications 
in higher volume centers. A recent study from Scalea et al15 demonstrated comparable 
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patient survival in older recipients in a high volume center with very strict pretransplant 
cardiovascular workup.
In univariate analysis, we could not find a significant difference in graft survival and 
center volume. However, when correcting for relevant donor and recipient characteristics 
in multivariate analysis, the association with graft failure and center volume became clear. 
High volume centers have better results compared with low volume centers, even though 
they are more aggressive in their acceptance policy, indicated by higher PDRI. Furthermore, 
from our available recipient data, we did not establish a significant difference in transplant 
recipient demographics (age, BMI, waiting time, retransplantation) that could have ex-
plained these results.
Even though it is not the aim of our study, next to the volume-outcome relationship, 
several other factors that were significantly associated with pancreas graft survival were 
identified. The first is the pancreas donor risk index (PDRI), which was found to be associ-
ated with graft failure. This is in line with results from previous studies.16,17 Next to donor 
risk, 2 recipient factors were also found to be risk factors for inferior graft survival. Higher 
recipient BMI is considered a risk factor in many types of surgery, being associated with 
higher complication rate, and this relationship has recently been confirmed in 2 studies 
on pancreas transplantation.18,19 The results of our study confirm this increased risk for 
recipients with higher BMI. Also, retransplantation was a risk factor for graft failure (in fact, 
the strongest). The authors believe that this is independent of the transplant type, because 
we corrected for transplant type using the PDRI. Our results are in line with previously 
published results from a large registry analysis from the United States.20 For the subgroup 
of SPK transplantations, retransplantation was not a significant risk factor. This may be 
because of small numbers, because most retransplantations are performed in a PAK/PTA 
setting.
The protective effect of UW as perfusion solution in univariate analysis disappeared after 
multivariate analysis of all transplantations. Possible explanations could be that HTK was 
used in higher risk donors, retransplantations or that HTK was used more frequently in low 
volume centers. On the other hand, HTK was identified as an independent risk factor for 
graft failure in the subgroup analysis of SPK transplantations. The authors think that this 
study provides more evidence regarding the optimal cold storage solution for pancreata.21 
To identify an association was not within the scope of this study and to adequately investi-
gate the relationship between outcome and perfusion solution a randomized controlled trial 
would be preferred. No association with transplant year and graft survival was found in this 
study, indicating that in this cohort, the era effect was of minor importance. The relatively 
modern cohort (without major changes in surgical techniques, preservation methods and 
immunosuppression) may be the reason for this absent association.
This study had some limitations. Most important one is the definition of graft failure. 
Because there appears to be no consensus on the definition of pancreas graft failure, graft 
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failure was left up to the discretion of the centers. There may be significant differences in re-
ported survival rates, depending on the definitions. Furthermore, data on reported survival 
and exact numbers lost to follow-up may not be complete; this may have influenced the 
results. Also, Eurotransplant depends on data filled in by the donor and transplant centers. 
Some data were missing, however, multiple imputation has been shown to provide valid 
results and is an accepted technique to handle missing data.22,23 We believe that using this 
technique did not influence the results in any way and has provided valid estimations of the 
missing data. The authors realize that the volume cutoffs that were chosen are debatable, 
however, still feasible, when looking at centers privacy and current group sizes. It could be 
that, next to recipient age, patient survival was associated with factors, such as preexistent 
peripheral artery disease, coronary or cerebrovascular disease; however, these data were not 
available in this study.
In conclusion, it is a remarkable finding that almost one third of all pancreas transplanta-
tions in the Eurotransplant region are being performed in centers that had performed less 
than on average 5 transplantations each year in the 5 preceding years. Given the fact that 
the highest risk organs are transplanted in the high volume centers with good outcome, it 
is an interesting thought that improving experience in the pancreas transplant centers may 
facilitate acceptance and allow transplantation of higher risk organs and increase transplant 
numbers.
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introduction: Complete graft thrombosis is the leading cause of early graft loss follow-
ing pancreas transplantation. Partial thrombosis is usually subclinical and discovered on 
routine imaging. Treatment options may vary in such cases. We describe the incidence and 
relevance of partial graft thrombosis in a large transplant center.
Methods: All consecutive pancreas transplantation at our center (2004–2015) were included 
in this study. Radiological follow-up, type and quantity of thrombosis prophylaxis, compli-
cations and graft and patient survival were collected. Partial thrombosis and follow-up were 
also studied.
results: All 230 pancreas transplantations were included in the analysis. Computed to-
mography was performed in most cases (89.1%). Early graft failure occurred in 23 patients 
(13/23 due to graft thrombosis, 3/23 bleeding, 1/23 anastomotic leakage, 6/23 secondary to 
antibody mediated rejection). There was evidence of partial thrombosis in 59 cases (26%), 
of which, the majority was treated with heparin and a vitamin K antagonist with graft pres-
ervation in 57/59 patients (97%).
Conclusions: Thrombosis is the leading cause of early graft loss following pancreas trans-
plantation. Computed tomography allows for early detection of partial thrombosis, which is 
usually subclinical. Partial graft thrombosis occurs in about 25% of all cases. In this series, 
treatment with anticoagulant therapy (heparin and vitamin K antagonist) resulted in graft 
preservation in almost all cases.
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inTroduCTion
Graft thrombosis is still considered the Achilles’ heel of pancreas transplantation. Great 
successes have been achieved with this procedure in terms of curing patients from type 1 
diabetes mellitus over the last 40 years, but thrombosis remains a challenging problem with 
a reported incidence of 3–10%.1,2 Several risk factors are associated with complete graft 
thrombosis which usually leads to graft loss. A review on risk factors showed that donor 
age, cerebrovascular death, procurement related problems, type of preservation solution, 
and graft pancreatitis are risk factors.1 The Pancreas Donor Risk Index (PDRI), which was 
developed using data on 1 year graft survival, clearly shows that a higher donor risk leads to 
a higher risk of graft failure.3
Complete graft thrombosis, in most cases accompanied by marked hyperglycemia and/
or graft tenderness, is the most common cause of early pancreas graft loss.2,4 Little is known 
about the clinical significance of partial graft thrombosis. By some, this is believed to be 
a ‘physiological’ phenomenon caused by ligation of the mesenteric and splenic veins and 
their side branches.5 Especially in pancreas transplantation, this ligating of smaller ves-
sels contributes to Virchow’s triad (hypercoagulable state, venous stasis, and endothelial 
injury), which may be one of the contributors to the relatively high incidence of thrombosis 
in pancreas transplantation, as compared to other organs.6 However, sometimes partial 
thrombosis extends from the ligated venous ends to larger and more centrally located veins. 
Partial graft thrombosis is usually subclinical (i.e. without hyperglycaemia) and discovered 
on routine ultrasound or computed tomography (CT) imaging in the early postoperative 
phase.7 It is unclear whether this form of thrombosis should be considered a precursor for 
complete thrombosis. If this were so, it would be necessary to detect its presence as early 
as possible, so antithrombotic treatment may salvage the graft. One recent study, where 
only donors younger than 40 years of age without other risk factors for graft thrombosis, 
showed a partial thrombosis incidence of 27%. All of these partial thrombosis were safely 
managed with unfractionated intravenous heparin, without any negative consequences.8 
Another recent study proposed a CT-based grading scheme for graft thrombosis, stating 
that not all graft thrombosis requires treatment.9 It is our aim to evaluate these findings by 
describing our experience regarding partial thrombosis. We evaluated the clinical relevance 
of this partial thrombosis, the incidence, clinical outcome, and treatment.
study population and design
A retrospective analysis in which all consecutive pancreas transplantations [simultaneous 
pancreas kidney (SPK), pancreas after kidney (PAK), pancreas transplant alone (PTA)] 
from January 1st 2004 until December 31st 2015 performed at the Leiden University Medi-
cal Center were included. A minimum of 90 days follow-up was registered.
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recipient surgical technique
Standard SPK transplantations were performed using a midline incision, where the kidney 
was first transplanted in the left iliac fossa without direct ureteric anastomosis, allowing for 
hemodynamic stability and reduction of edema, followed by the pancreas on the right, anas-
tomosed on the common iliac artery and caval vein. Only then is the ureteric anastomosis 
completed. Since 2011, exocrine drainage is usually performed by duodeno-enterostomy. 
Prior to 2011, duodeno-cystostomy with secondary enteric conversion to duodeno-enter-
ostomy after 12 months was performed in most cases. For recipients with PRA≤6%, the 
transplantation commenced directly after blood type confirmation and crossmatch was 
performed retrospectively as soon as possible.10 Recipients received routine postoperative 
intravenous contrast enhanced CT imaging within the first week after transplantation to 
rule out any postoperative complications. This was performed sooner when indicated (e.g. 
two consecutive blood glucose levels above 10 mM) or later when impaired kidney function 
hindered early CT imaging. Indications for imaging (including per protocol imaging) and 
their respective outcome (whether thrombosis was diagnosed or not) are shown in Table 2. 
In most cases of complete thrombosis, our intention is to surgically salvage or remove the 
graft. In case of partial or peripheral thrombosis, patients are initially treated with therapeu-
tic intravenous heparin, followed by conversion to vitamin K antagonists (VKA) for at least 
3 months. At that moment follow-up CT imaging was performed. In our center, no routine 
screening for thrombophilia is performed.
Post-transplant medical therapy
Since 2008, recipient immunosuppressive therapy consists of alemtuzumab induction (15 
mg subcutaneous, 1st dose preoperative, 2nd dose postoperative day 1), rapidly tapered 
steroids (3 days, 500–250–125 mg intravenous), followed by tacrolimus (trough levels 
8–12 g/l) and mycophenolate mofetil maintenance immunosuppressive therapy. Previous 
protocols (regarding induction and maintenance) were described elsewhere.4 Standard 
anticoagulation therapy consisted of a twice daily, low dose low molecular weight heparin 
(LMWH), based on the recipients weight: nadroparin 2 dd 5700 IE for patients weighing 
over 100 kg and nadroparin 2dd 2850 IE for patients below 100 kg. This was a once daily 
regime prior to 2007, as is our standard protocol to prevent deep venous thrombosis and 
pulmonary embolism in all surgical patients. The first dose is administered at the recovery 
room and no other anticoagulants, especially platelet inhibitors, are prescribed. The clinical 
protocol was changed after the data collection and currently states that patients are pre-
scribed once daily 5700 IE LWMH, and adjusted in case of impaired kidney function. In all 
cases, LMWH was prescribed for duration of the hospital admission. No new anti-platelet 
therapy was prescribed in the postoperative period.
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data collection
Donor, recipient, and transplant related risk factors are shown in Table 1. Follow-up data 
include HbA1c levels, surgical interventions, imaging studies including the reason for 
imaging, as well as anticoagulation therapy during the first postoperative admission, date 
last seen, date of restart of exogenous insulin therapy. When thrombosis, either partial or 
complete, occurred, clinical outcomes were registered. Only graft thrombosis within the 
first 90 days (early graft loss) was analyzed. Very peripheral thrombosis in ligated ends of 
veins, was not considered graft thrombosis, this is considered grade 1 pancreas graft throm-
bosis according to the recent study from Cambridge.9 When thrombus was found in the 
parenchymal part of either superior mesenteric or splenic vein but there was still passage 
of contrast and perfusion of the graft, this was considered partial thrombosis. Absence of 
contrast due to thrombus was considered complete thrombosis. The actual involved vessel 
was not recorded in the database. Antibody mediated rejection (AMR) was defined as posi-
tive C4d staining and signs of rejection on histological examination of the graft following 
explantation and the presence of donor specific antibodies (DSA). Suspected AMR was 
defined as the presence of either positive C4d or the presence of DSA.11 Graft thrombosis 
was considered to be secondary to AMR when AMR was suspected. Consequently, graft 
thrombosis was only considered primarily when rejection was not suspected and data were 
reported separately.
statistical analysis
Risk factors associated with thrombosis were analyzed using Chi-square analyses for 
categorical variables and Analysis of Variance (ANOVA) tests for continuous variables. 
Whether partial thrombosis was associated with graft survival was analyzed using Cox-
regression analysis.
resuLTs
overall results
In the study period a total of 230 consecutive pancreas transplantations were performed, 
of which 203 (88%) were SPK, 25 (11%) were PAK, and two (0.9%) were PTA. Fifteen of 
230 (6.5%) were retransplantations. Donation after circulatory death (DCD) pancreata were 
used in 21 (9.1%) transplantations. Median cold ischemia time for pancreata was 10.7 h, for 
kidneys 10 h. Donor and recipient characteristics are shown in Table 1. Mean hospital stay 
after transplantation was 26 days (SD 16 days). Median follow-up was 4.5 years (0–12 years). 
Mean PDRI was 1.36 (SD 0.44). Early graft failure occurred in 23 (10%) cases (90 days graft 
survival 90.0%). Eighteen of these grafts were lost due to thrombosis (7.8%), three due to 
bleeding, one due to anastomotic leakage, and one due to T-cell mediated rejection.11 One 
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year graft survival was 87%, longer term results of our series have been published elsewhere 
recently.12 Follow-up was complete until June 2016.
Postoperative imaging
In 205 (89%) patients, computed tomography was the first postoperative radiological study. 
In 21 cases (9.1%) this was ultrasound. In one case MRI was used and in three cases no 
imaging was performed. Median interval from transplantation until the first (sequential 
CT imaging was performed during follow-up, but is not reported in this study) radiological 
investigation was 6 days (IQR 3–9 days). The reasons for imaging were as follows: majority 
per protocol (without (acute) clinical indication), 122/227 (54%), because of sudden pro-
gressive hyperglycemia in 52 cases (23%), because of persistent fever in 19 cases (8.4%) and 
because of abdominal tenderness in 12 cases (5.3%). Other indications included increase 
Table 1a. Demographics of donors
No 
thrombosis
Partial 
thrombosis
Complete 
thrombosis
n (%) n (%) n (%) n (%) p a
Gender 0.29
Male 100 (44) 69 (45) 26 (44) 5 (26)
Female 130 (56) 83 (55) 33 (56) 14 (74)
Cause of death 0.49
Stroke 131 (57) 84 (55) 32 (54) 15 (79)
Trauma 76 (33) 53 (35) 19 (32) 4 (21)
Anoxia 15 (6.5) 10 (7) 5 (9) 0 (0)
Other 8 (3.5) 5 (3) 3 (5) 0 (0)  
  Mean (SD) Mean (SD) Mean (SD) Mean (SD)  
Age, y 35 (13) 34 (13) 36 (13) 40 (11) 0.07
BMI, kg/m2 23 (3) 23 (3) 23 (2) 25 (3) 0.02
PDRI 1.36 (0.44) 1.34 (0.43) 1.40 (0.47) 1.48 (0.40) 0.32
Table 1b. Demographics of recipients
  n (%) n (%) n (%) n (%)  
Gender 0.05
Male 133 (58) 92 (61) 35 (59) 6 (32)
Female 97 (42) 60 (39) 24 (41) 13 (68)
Previous graft thrombosis 13 (6) 8 (5) 4 (7) 1 (5) 0.91
Sensitized (PRA>5%) b 19 (12) 14 (14) 3 (8) 2 (13) 0.66
  Mean (SD) Mean (SD) Mean (SD) Mean (SD)  
Age, y 43 (8) 43 (7) 43 (9) 43 (5) 0.95
BMI, kg/m2 25 (4) 25 (4) 25 (3) 25 (3) 0.84
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in serum amylase, hematuria in a bladder drained patient, or decreased hemoglobin levels. 
There was no statistical significant association between reason for imaging and whether 
thrombosis was diagnosed (p = 0.48) (Table 2). In 25% of the per protocol scans (in the 
absence of clinical symptoms), thrombosis was diagnosed. In 10–17% of the performed CT 
scans the radiologist did or could not diagnose or exclude thrombosis.
Table 1c. Demographics of transplantations
  n (%) n (%) n (%) n (%)  
Transplant type 0.18
SPK 203 (88) 137 (90) 51 (86) 15 (79)
PAK 25 (11) 14 (9) 8 (14) 3 (16)
PTA 2 (1) 1 (1) 0 (0) 1 (5)
Donation after circulatory death 21 (9) 14 (9) 7 (12) 0 (0) 0.30
Retransplant 15 (6.5) 9 (6) 4 (7) 2 (11) 0.74
Perfusion solution 0.43
UW 208 (90) 139 (91) 51 (86) 18 (95)
HTK/Other 22 (10) 13 (9) 8 (14) 1 (5)
Exocrine drainage 0.91
Duodenocystostomy 86 (37) 56 (37) 22 (37) 8 (42)
Duodeno-enterostomy 144 (63) 96 (63) 37 (63) 11 (58)
Anticoagulant therapy 0.87
Nadroparin 2850IE 71 (31) 43 (30) 21 (36) 7 (37)
Nadroparin 5700IE (2dd2850IE) 143 (62) 97 (66) 35 (60) 11 (58)
Nadroparin 11400IE (2dd5700IE) c 9 (4) 6 (4) 2 (2) 1 (5)  
a Chi-square for categorical variables, ANOVA for continuous variables
b PRA known 160/230
c Therapeutic dosage LMWH or iv heparin
Table 2. Indications for postoperative imaging associated with diagnosis of thrombosis
n Thrombosis
Imaging reason
  Yes No Uncertain
  n (%) n (%) n (%)
Protocol 122 30 (25) 80 (66) 12 (10)
Hyperglycemia 52 20 (39) 25 (48) 7 (14)
Fever 19 3 (16) 13 (68) 3 (16)
Abdominal tenderness 12 2 (17) 8 (67) 2 (17)
Other 20 6 (30) 11 (55) 3 (15)
Pearson X2 p=0.48
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Postoperative thrombosis
In 78/230 cases (34%) CT imaging showed signs of graft thrombosis (either complete 
occlusive graft thrombosis or non-occlusive peripheral thrombosis requiring treatment) 
within 90 days (Fig. 1). Higher recipient BMI was associated with a higher risk of complete 
thrombosis (p = 0.019). Although our center does not routinely screen for hypercoagulable 
states (e.g. protein S or C deficiency) there were two recipients (one protein C deficiency 
and protein S deficiency) with hypercoagulable syndromes, both did not develop throm-
bosis. Also, previous graft thrombosis was not associated with renewed graft thrombosis 
in this series. In 19/230 cases (8.2%) complete venous thrombosis was found. In 2/19 there 
also was arterial thrombosis. This arterial thrombosis was considered to be secondary to 
venous thrombosis, since, during transplantectomy of the pancreas, arterial anastomoses 
were patent. Thrombosis was secondary to confirmed AMR in 2/19 cases and to suspected 
AMR in 4/19 cases.11 In 17/19 cases the graft had to be removed. In one case with both 
splenic and superior mesenteric venous occlusion, the patient was put on therapeutic 
anticoagulation therapy with intravenous heparin and later switched to VKA resulting in 
preserved graft function. This strategy was chosen because blood glucose levels remained 
normal and contrast CT showed normal parenchymal perfusion of the graft. In one case 
partial thrombosis had progressed to complete venous thrombosis at the 3-month follow-up 
CT scan. This patient was insulin independent and kept on anticoagulation. In 11/17 after 
transplantectomy, patients were relisted on the waiting list: two for islet transplantation and 
nine for PAK transplantation.
In 59/230 (25.6%) there was evidence of partial thrombosis on CT imaging (Fig. 1). 
Follow-up data were available in 47 of 59 patients. All 59 patients were treated with intrave-
nous heparin, followed by VKA (one patient received acetylsalicylic acid (ASA) instead of 
VKA, the reason was unknown). In 36/47, there was no evidence of remaining thrombus on 
follow-up CT scan after a median of 94 days (4–284 days), VKA were ceased and patients 
were switched to ASA. Median duration of oral anticoagulant use was 122 days (6–1902 
days). In seven patients, thrombus was still present at the end of follow-up and patients were 
kept on OAC. In four cases, thrombus had progressed, with persistent functioning in two 
cases and graft failure in the other two. Figure S1 represents and an overview of patients and 
different forms/stages of thrombosis. Median duration of follow-up after discovery of partial 
thrombosis was 125 days (range 4–804 days). When complete graft thrombosis was not the 
cause of graft failure, early graft failure occurred in 3/59 (5%) following partial thrombosis 
versus 3/149 (2%) when there was no evidence of thrombosis at all (p = 0.35). Adjusting for 
PDRI, using Cox-regression analysis, partial thrombosis was not associated with pancreas 
graft survival (HR 0.89, 95% CI 0.36–2.24, p = 0.81), compared to no thrombosis.
Median interval between transplantation and diagnosis of complete graft thrombosis was 
3 days, 84% occurred within the first week. Complete thrombosis that was believed to have 
occurred secondary to AMR was diagnosed after a median of 2 days. All transplantations 
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Table 3. Indications for relaparotomy following transplantation
n (%)
Th rombosis 19 (8.3)
Bleeding 22 (9.6)
Infection 13 (5.7)
Bowel anastomosis leakage 3 (1.3)
Other 3 (1.3)
 
Figure 1  
Computed tomography image of partial thrombosis in head of the pancreas (arrow). 
  
figure 1. Computed tomography image of partial thrombosis in head of the pancreas (arrow).
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were performed with negative retrospective crossmatch and only 1/6 patients had PRA>6% 
(in this case 12% at time of transplantation, 55% highest). Donor specific antibodies were 
positive in 2/6. Median interval between transplantation and diagnosis of partial thrombosis 
was 6 days. The rate of thrombosis did not increase over the years (p = 0.77). Total reopera-
tion rate was 26% (59/ 230). In 22/230 cases (9.6%), surgical intervention was required for 
a bleeding complication (Table 3).
For seven recipients, the postoperative anticoagulation regime could not be identified 
from the patient records. Standard postoperative anticoagulation with LMWH in single 
dose (which was per protocol prior to 2007) was administered to 71 patients (31%) and 
143 patients (62%) received double dose from the 1st post-operative day until discharge. 
Nine patients (3.9%) were on therapeutic anticoagulation (intravenous heparin or high 
dose LMWH), since they required anticoagulation prior to the transplantation due to 
cardiac arrhythmias or peripheral vascular disease. Seventeen patients received platelet 
aggregation inhibition after transplantation, all because this was prescribed to them prior 
to transplantation. Different anticoagulation is prescribed throughout the field (Table 4). 
Standard anticoagulation protocol with single or double dose LMWH was not significantly 
associated with complete thrombosis risk, 7/71 (9.9%) vs. 11/143 (7.7%) (p = 0.59) or partial 
thrombosis risk, 21/71 (30%) vs. 35/143 (25%) (p = 0.42).
disCussion
This study is an overview of diagnosis and treatment of thrombosis following pancreas 
transplantation. As shown in previous literature, graft thrombosis is the leading cause of 
early graft failure.1,2 Our findings corroborate with those results. We also evaluated partial 
venous thrombosis, a complication following pancreas transplantation of which little is 
known.5,8
Table 4. Overview of reported anticoagulation (<1 week postoperative)
Leiden University Medical Center LMWH (nadroparin) 2850IE, twice daily
Madison, Wisconsin ASA
Oxford ASA, subcutaneous heparin. Tailor-made based on TEG
Bochum Unfractionated heparin iv
Pisa LMWH (nadoparin) 5700IE, once daily for SPK; unfractionated heparin iv for 
PTA/PAK
Minnesota Unfractionated heparin iv
Oslo, Norway LMWH (dalteparin) 5000IE, once daily. PO day 0+1, Dextran 500ml + ASA
San Fransisco Aspirin, dipyridamole and unfractionated heparin iv in non-uremic
Cambridge Epoprostenol, ASA
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Standard radiological follow-up in our center consists of contrast enhanced CT. This 
could be considered quite aggressive, especially since kidney function may still be impaired 
in the early postoperative phase. In our series, data on kidney DGF (hemodialysis within 
the first week) have been published elsewhere, and DGF is mostly related to DCD pancreas 
transplantation.12 In the case of DGF, CT imaging was usually postponed until kidney func-
tion was restored. Unfortunately, no data on acute kidney injury (25% increase in eGFR or 
44 uM increase in serum creatinine) were available in our database. However, CT imaging 
allows for early detection of sub-clinical partial thrombosis, which may be amenable for 
treatment.7,9 This is supported by the finding that in 25% of the CT scans that were performed 
per protocol, some form of thrombosis was discovered. Furthermore, especially fever and 
abdominal tenderness appear to be aspecific clinical features accompanying thrombosis. 
Obviously, these may indicate other complications, which may be the indication for imag-
ing. Some centers may prefer the use of ultrasound.13,14 A disadvantage of ultrasound may 
be that not all vessels are visualized properly by overlying bowel gas and that an experienced 
radiologist has to be available, making results observer dependent. The proposed grading 
system of thrombosis by the Cambridge group is supported. Unfortunately, due to the 
retrospective nature of our study, the grading system was not incorporated in our database.9 
Even though CT imaging in this study was inconclusive in 10–17% with regard to graft 
thrombosis, we do, however, believe that CT imaging should be part of routine follow-up, 
following pancreas transplantation. It has to be noted however, that in our study, we did 
not consider very peripheral thrombosis (grade 1) amongst the cases of thrombosis. These 
forms of thrombosis were considered not to be clinically relevant. Further studies will focus 
on quantifying the grade of thrombosis in our center and which forms are clinically relevant 
and require treatment.
Complete thrombosis leading to graft loss occurred in 17 patients. In all cases, this was 
with venous thrombosis. The two cases of arterial thrombosis are believed to be secondary 
to the venous thrombosis. The percentage of graft thrombosis in our series is similar to 
that reported in literature although some centers report even lower thrombosis rates.15 The 
thrombosis rate, however, is likely related to intrinsic risks of the pancreatic graft, reflecting, 
for example, in the PDRI. As published before, due to scarcity of donors, the pancreata 
reported and accepted in our country have a relatively higher PDRI as compared to other 
countries.16 Also, as is shown in this study, thrombosis may be secondary to (antibody medi-
ated) rejection, and thus, the incidence of ‘true’ thrombosis was lower (in fact 13/230, 5.7%). 
It is not always clear from previously published reports whether thrombosis was secondary 
to rejection. In this study, the relationship of peripancreatic infection or pancreatitis was 
not studied, however, one of our previous reports did not show an association between 
pancreatitis and thrombosis (2/30).12
In 59 patients (26%), there was evidence of partial thrombosis. This is in line with recent 
results published by Harbell.8 Most patients were treated with heparin and VKA. During 
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follow-up, the majority of thrombus resolved with this treatment and most recipients re-
mained insulin independent. In fact, only four progressed to complete thrombosis, of which 
only two required exogenous insulin. This data show that our current treatment of this partial 
thrombosis is effective and sufficient in preventing graft loss. However, we cannot predict 
outcome if no anticoagulants would have been given. Patients with partial thrombosis were 
treated with VKA after intravenous heparinization. Novel oral anticoagulants or directly 
acting oral anticoagulants (NOAC/DOAC) may also be used, however the experience with 
graft thrombosis is limited to our knowledge. Because of the risk of partial thrombosis, we 
suggest to include CT imaging in routine follow-up, to evaluate the presence (or absence) of 
thrombus. In our series, VKA were ceased only after CT imaging had confirmed resolution 
of thrombus, which was substantially longer than 3 months in some cases.
We currently prescribe once daily LWMH (5700 IE) to most of our patients as thrombosis 
prophylaxis. Whether this is the optimal treatment remains up for debate. Clearly, there are 
as many possibilities as there are pancreas transplant centers: intravenous heparin, LWMH, 
acetylsalicylic acid, and a combination of either of them.2,8,15,17-20 We did not find an associa-
tion between single or double dose LMWH prescription and thrombosis. It could however 
be that changes over time, especially in donor quality, may have masked such an associa-
tion. It may be that the double dose LWMH masked an increased thrombosis risk with the 
increased willingness to accept higher risk donor grafts in more recent years. As was shown 
in this study, the change in protocol to a double dose of LMWH did come at the cost of a 
slightly higher bleeding risk, which on the other hand, may also have been caused by higher 
donor risk. Being even more aggressive in terms of anticoagulation, either by prescribing 
higher dosage of LMWH or prescribing intravenous heparin to each patient, does not seem 
justified in our series and may only be necessary in case of certain risk factors in a setting of 
tailor-made anticoagulation, for example when using intra-operative thromboelastograms 
(TEG).6,17 Since adequate modification into Virchow’s triad is difficult in the setting of 
pancreas transplantation, optimal monitoring of the cascade of coagulation is paramount. 
A combination of intra-operative TEG and postoperative CT imaging, may lead to the most 
optimal protocol in preventing both complete, as well as partial thrombosis. Furthermore, 
almost 75% of the patients in our current series (those that did not develop any form of 
thrombosis) would be ‘over-treated’ and thus be exposed to a potential higher bleeding risk.
Several limitations apply to our study. Due to the retrospective design, it was not possible 
to retrieve all the data. Also, protocol adjustments, in particular from once to twice daily 
LMWH as thrombosis prophylaxis, may have obscured results. As was stated prior in the 
discussion, it remains unclear which form of partial thrombosis is clinically significant. 
Whether these patients require anticoagulation, possibly associated with higher bleeding 
risk, would optimally be investigated in a randomized trial, where patients with grade 2 
would be randomized to receive a particular dose of anticoagulation, or even none. The 
incorporation of CT imaging into clinical practice can’t be supported by data from this 
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study, but its usefulness has been studied and published in Transplant International 25 years 
ago, and has been part of our clinical protocol since then.21
ConCLusion
This study summarizes the single center outcome with regard to graft thrombosis follow-
ing pancreas transplantation. We have shown that our current protocol to prevent graft 
thrombosis with once or twice daily low dose LMWH results in a low thrombosis incidence 
of 5.7%, similar to that reported in literature. Partial thrombosis is frequently discovered on 
routine CT imaging following transplantation. It is usually without clinical symptoms and 
may be adequately treated with heparin and VKA, with preservation of adequate graft func-
tion. Both postoperative CT imaging, as well as treatment with VKA for partial thrombosis, 
remain standard treatment at our transplant center.
suPPorTinG inforMATion
Additional supporting information may be found online in the Supporting Information 
section at the end of the article.
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figure s1. Flowchart of patients and stages of thrombosis through follow-up.
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introduction: Donation after circulatory death (DCD) pancreas transplantation has been 
shown to be an additional way to deal with donor organ shortages. The results of 5-year 
DCD pancreas transplantation are presented.
Methods: A retrospective, single center analysis (2011 – 2015) was performed to compare 
the results of donation after brain death (DBD) to DCD pancreas transplantation.
results: During the study period, 104 pancreas transplantations (83 from DBD and 21 from 
DCD) were performed. Median pancreas donor risk index (PDRI) was 1.47, (DBD
1.61 vs. DCD 1.35 (p=0.144)). Without the factor DCD, PDRI from DCD donors was 
significantly lower (DBD 1.61 vs DCD 0.97 (p<0.001). Donor age was the only donor re-
lated risk factor associated with pancreas graft survival (HR 1.06, p=0.037). Postoperative 
bleeding and kidney DGF occurred more frequently in recipients from DCD (p=0.006). 
However, DCD pancreata had a lower incidence of thrombosis. Kidney and pancreas graft 
survival were equally good in both groups.
Conclusions: Pancreas transplantation from DCD donors yields comparable results to 
DBD donors when PDRI of DCD are relatively low. Most DCD donors are younger donors 
with trauma as cause of death. These DCD pancreas grafts may be a better option to cope 
with increasing organ shortages than exploring the limits with older (and higher PDRI) 
DBD donors.
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inTroduCTion
Pancreas transplantation from donation after brain death (DBD) has been steadily improv-
ing over the last decades with good long-term outcome in terms of patient and graft sur-
vival.1-3 Simultaneously, the number of patients and time on the waiting list increased in the 
Eurotransplant area.4,5 Unfortunately, suitable DBD organs matching this need remained 
stagnant.5 Pancreatic grafts from donation after circulatory death (DCD) have been shown 
to be suitable for transplantation and may provide an additional organ source.6-11
The first DCD pancreas transplantation in our center was performed in 2011.8 In 2015, 
52% of all donor procedures in The Netherlands were DCD, and 9/20 (45%) of pancreas 
transplantations at our institute were from DCD procedures.12
The warm ischemic period during graft procurement is generally believed to inflict 
more ischemia reperfusion injury and subsequently postreperfusion graft pancreatitis and 
thrombosis. This makes transplant professionals reluctant to accept DCD grafts for trans-
plantation. In general, peripancreatic infections occur in approximately 35% of all pancreas 
transplantations, but the question is whether these are all clinically significant.13,14 However, 
with careful DCD donor selection, the detrimental effects of warm ischemia on the allograft 
may be limited.
This study investigates whether the use of DCD pancreas donors is feasible when careful 
donor selection, indicated by the Pancreas Donor Risk Index (PDRI), is performed. More 
specifically, short term outcome (90 days patient and graft survival and complications, 
specifically post reperfusion graft pancreatitis, peripancreatic infection, bleeding, graft 
thrombosis) were investigated.
MATeriALs And MeTHods
All consecutive primary pancreas transplantations performed at Leiden University Medical 
Center from January 2011 until December 2015 were included in this study. Follow up was 
collected until May 1st 2016. Standard SPK transplantations were performed using a midline 
incision. The kidney was first transplanted in the left iliac fossa, followed by the pancreas on 
the right anastomosed on the iliac artery and caval vein. Exocrine drainage was performed 
by duodeno-enterostomy. All patients received alemtuzumab induction therapy (15 mg 
subcutaneous on both the day of the transplantation and first postoperative day). Standard 
maintenance immunosuppression consisted of tacrolimus (Prograft) (twice daily 5mg based 
on trough levels 8-12 ug/l until 6 weeks, from then trough levels 5-10 ug/l) or cyclosporine 
(trough levels 150-200 ug/l until 6 weeks, from then trough levels 100-150 ug/l) combined 
with mycophenolate mofetil (twice daily 500mg when tacrolimus was prescribed and twice 
daily 1000mg when cyclosporine was prescribed), with or without addition of steroids. 
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Standard anticoagulant therapy after pancreas transplantation consisted of subcutaneous 
low molecular weight heparin (nadroparin) 2850IE twice daily. If indicated prior to trans-
plantation, therapeutic doses were prescribed (eg, in case of atrial fibrillation or previous 
deep venous thrombosis or pulmonary embolisms).
data collection
Donor, recipient and transplant related risk factors are shown in Tables 1-3. Follow up data 
included: peak serum amylase and drain fluid amylase levels during the first 3 postopera-
tive days, surgical and percutaneous reinterventions, patient and pancreas and kidney graft 
survival (including causes of graft failure). Pancreas graft failure was death censored and 
defined as return to exogenous insulin therapy. Minimal follow up was 90 days, to allow for 
analysis of early pancreas graft failure (EGF).15 Kidney graft failure (death censored) was 
defined as need for renal replacement therapy or relisting on the kidney transplant waiting 
list.
Analysis
Donor warm ischemia time was calculated from the time of withdrawal of ventilatory sup-
port (WVS) until the start of organ cold perfusion. Functional warm ischemia time was 
considered to start when systolic blood pressure < 50 mmHg, in line with Eurotransplant 
and British Transplantation Society guidelines.16,17 Post reperfusion graft pancreatitis 
Table 1. Demographics of donors after brain death and donors after circulatory death.
DBD DCD
n % n % p-value
Gender 0.037
Male 27 32% 12 57%
Female 56 68% 9 43%
Cause of death <0.001
Stroke 54 65% 5 24%
Trauma 22 26% 7 33%
Anoxia 3 4% 7 33%
Other 4 5% 2 10%
Median Min - max Median Min - max
Age 43 10 - 60 27 11 - 47 0.003
BMI 23 17 - 29 22 18 - 29 0.329
ICU days 2 0 - 13 3 0 - 7 0.009
Creatinine (mg/dL) 0.64 0.35 - 4.65 0.67 0.43 - 1.13 0.523
PDRI 1.61 0.68 - 2.48 1.35 1.03 - 2.44 0.143
PDRI (donortype excluded) 1.61 0.68 - 2.48 0.97 0.74 - 1.75 <0.001
* Difference measured using Chi square for categorical and Mann-Whitney for continuous variables
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was defined as an increased serum amylase levels (> 250U/L) in combination with drain 
fluid amylase levels (>3000U/L), not requiring additional interventions.18 Peripancreatic 
infection was defined as any peripancreatic infection, including abscess, infected fluid col-
lection or hematoma, requiring surgical intervention or radiological, percutaneous drain-
age (Clavien-Dindo grade IIIa/b).14,18 All other surgical complications, such as bleeding, 
anastomotic leakage, graft thrombosis, graft loss, and Clavien-Dindo grade III or higher 
were analysed. Other complications, such as pneumonia, postoperative wound infection 
and urinary tract infection were not included in the database. Delayed kidney graft function 
(DGF) was defined as the need for renal replacement therapy within the first week after 
transplantation. Patient and graft survival were estimated using the Kaplan-Meier method.
organ procurement
Standard DCD organ procurement in The Netherlands starts with withdrawal of ventila-
tory support at the ICU. No ante-mortem interventions (heparin administration or femoral 
artery cannulation) are legally allowed in The Netherlands. Following cardiac arrest, 
a 5-minute ‘no touch’-period is mandatory and when auto resuscitation does not occur 
within this period, the declaration of death is issued. Upon arrival in the operating room, 
a rapid laparotomy is carried out. The aorta is cannulated, the inferior caval vein vented 
and pressurized infusion of ice-cold preservation solution is started. This marks the end 
of the first warm ischemic period WIT. The remaining procedure, as well as DBD organ 
procurement, is performed as described in the ESOT MOD learning course.19 Of note, in 
Table 2. Demographics of recipients of DBD or DCD organs.
 DBD DCD
n % n % p-value
Gender 0.526
Male 45 46% 13 62%  
Female 38 54% 8 38%
Coronary artery disease 11 13% 3 14% >0.999
Cerebrovascular disease 10 13% 1 5% 0.455
Peripheral vascular disease 29 35% 8 38% 0.816
Sensitized (PRA>5%) 17 21% 5 24% 0.771
End stage renal disease (SPK recipients) 0.609
Preemptive 36 47% 7 35%
Hemodialysis 24 32% 8 40%
Peritoneal dialysis 16 21% 5 25%
Median Min - max Median Min - max
Age 43 25 - 64 43 28 - 55 >0.999
BMI 25 17 - 35 26 17 - 34 0.625
* Difference measured using Chi square for categorical and Mann-Whitney for continuous variables
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both DCD and DBD procedures mobilization of the pancreas was performed only after cold 
perfusion. Procurements were carried out by independent procurement teams, sometimes 
consisting of a local team, as was described elsewhere.20 All organs were cold stored on 
ice in University of Wisconsin (UW) solution or histidine-tryptophan-ketoglutarate (HTK) 
solution.
Table 3. Demographics of transplantations of DBD or DCD organs.
DBD DCD
n % n % p-value
Transplant type >0.999
SPK 76 92% 20 95%
PAK 7 8% 1 5%
PTA 0 0% 0 0%
Perfusion solution 0.075
UW 74 89% 15 71%
HTK/Other 9 11% 6 29%
Anticoagulant therapy 0.180
Nadroparin 2850IE 8 9% 0 0%
Nadroparin 5700IE 71 86% 21 100%
Nadroparin 11400IE** 4 5% 0 0%
Immunosuppression 0.073
Cyclosporin + Mycophenolate 1 1% 0 0%
Cyclosporin + Mycophenolate +
Prednisone 2 2% 3 14%
Tacrolimus + Mycophenolate 74 89% 18 86%
Tacrolimus + Mycophenolate +
Prednisone 6 7% 0 0%
Median Min - max Median Min - max
Pancreas CIT (hr) 10 4 - 14 11 7 - 15 0.143
Pancreas donor functional WIT
(min) *** 27 12 – 42 n/a
Pancreas donor WIT (min)**** 31 15 - 45 n/a
Pancreas recipient WIT (min) 26 14 - 64 25 10 - 41 0.613
* Difference measured using Chi square for categorical and Mann-Whitney for continuous variables
** These patients were on anticoagulation prior to transplantation
*** Withdrawal of ventilatory support - systolic blood pressure < 50 mmHg
**** Withdrawal of ventilatory support - organ cold perfusion
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resuLTs
In the 5-year study period (2011 –2015), 83 DBD (76 SPK, 7 PAK) and 21 DCD (20 SPK, 1 
PAK) primary pancreas transplantations were performed. All DCD donors were Maastricht 
category III. From the 83 DBD grafts, 3 were from another country and all other grafts, 
including all 21 DCD grafts, were from The Netherlands. Our local team procured 31/104 
(30%). Of 21 DCD grafts, 8 (38%) were procured locally, compared to 23/83 (28%) DBD 
grafts (p=0.353). Four pancreatic grafts were initially bladder drained with conversion to 
enteric drainage in a second operation in 2 cases, as described before.(21) All other grafts 
were anastomosed to the terminal ileum. Donor, recipient and transplant demographics are 
shown in Table 1-3. There was no significant difference in steroid-free immunosuppression 
between both groups (90% in DBD vs. 86% in DCD, p=0.073). Mean duration of follow up 
was 2.6 years for DBD organ recipients and 2.2 years for DCD organ recipients (p=0.2).
Median PDRI of all pancreata was 1.47 (0.68 – 2.48). No statistical significant difference 
in PDRI of DBD grafts compared to DCD grafts (1.61 vs. 1.35, p=0.143) was observed. 
However, if donor type was excluded from the PDRI calculation, the difference between 
DBD and DCD was significant (1.61 vs 0.97 respectively, p<0.001). DCD donors were 
significantly younger than DBD donors:27 (11 – 47) years vs 43 (10 – 60) years (median 
(range), p=0.001). Stroke was the leading cause of death in DBD (65%), whereas DCD do-
nors died from trauma or anoxia in 66% of the cases (p=0.001). Median donor WIT of DCD 
grafts was 31 (15 – 45) minutes, median functional WIT was 27 (12 – 42) minutes. (Table 3)
Graft pancreatitis and peripancreatic infection
Postreperfusion graft pancreatitis occurred in 47 patients (45%), of which 27 resolved 
spontaneously without interventions. The remaining 20 recipients developed (infected) 
fluid collections that required intervention (either percutaneous or surgical drainage). Peri-
Table 4. Early (<90 days) postoperative complications after DBD and DCD transplantation.
DBD DCD p value
n % n %
Thrombosis 0.282
Complete 8 10% 0 0%
Partial 24 29% 7 33%
Bleeding 9 11% 8 38% 0.006
Post reperfusion graft pancreatitis 40 48% 7 33% 0.222
Peripancreatic infection 25 30% 5 24% 0.568
Pancreas graft loss 9 11% 0 0% 0.198
Kidney delayed graft function 10 13% 7 35% 0.041
Patient death 1 1% 0 0% >0.999
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pancreatic infection that was not preceded by postreperfusion graft pancreatitis occurred in 
10 patients (Table 4). There was no statistical difference in the incidence of graft pancreatitis 
between DBD and DCD graft recipients. Logistical regression analysis did not show an 
association between donor WIT with post reperfusion pancreatitis and peripancreatic 
infection. From 30 patients that suffered from peripancreatic infection, 2 lost their graft 
within 90 days due to thrombosis.
other early Postoperative outcome
Relaparotomy was required in 32/104 patients (31%). In 17 patients, a reoperation was re-
quired due to postoperative bleeding. This occurred significantly more frequent in recipient 
of DCD organs (11% vs. 38%, p=0.005). DBD organ recipients lost 9 grafts (7 due to throm-
bosis, 1 due to bleeding and 1 due to anastomotic leakage), versus none of the DCD organ 
recipients (p=0.198). Of all 96 SPK recipients, 17 (16%) suffered from kidney delayed graft 
function (DGF). Kidney DGF occurred significantly more frequently with kidneys from 
DCD donors (13% vs. 35%, p=0.043). There was a statistically significant association with 
kidney DGF and reinterventions for bleeding (6/17), compared to recipients with immedi-
ate kidney function who required fewer reinterventions (10/80, p=0.032). Prescription of 
steroids as part of initial immunosuppression was not associated with thrombosis (p=0.314) 
One recipient with a DBD SPK died during the initial hospital stay due to systemic inflam-
matory response syndrome following 2 exploratory laparotomies for anastomotic leakages.
Long Term outcome
Mean duration of follow up was 2.5 years (SD 1.3 years). Kaplan- Meier estimated patient 
survival after 90 days, 1 year and 2 years was 98.8%, 97.5% and 94.5% for DBD recipients 
versus 100% for DCD recipients after 2 years (p=0.268) (Figure 1). Kaplan-Meier estimated 
pancreas graft survival after 90 days, 1 year and 2 years was 89.2%, 85.5% and 85.5% for 
DBD organs and 100%, 100% and 93.3%, respectively, for DCD organs (p=0.428) (Figure 2). 
For recipients with functioning grafts (insulin independence) at 3 months (n=95), data on 
HbA1c levels were available in 81/95 (85%). Mean HbA1c was 33 mmol/mol (SD 4mmol/
mol) in the DBD group and 32 mmol/mol (SD 5 mmol/mol) in the DCD group (p=0.45). 
Kaplan Meier estimated kidney graft survival after 90 days, 1 year and 2 years was 98.7%, 
96.0% and 94.1% for DBD kidneys and 100%, 93.8% and 93.8% for DCD kidneys (p=0.342) 
(Figure 3).
In univariate survival analysis, analyzing the complete cohort, donor age was a significant 
risk factor for pancreas graft failure (HR 1.06, 95% CI 1.00 – 1.11, p=0.037). Also, PAK was 
a significant risk factor for pancreas graft failure compared to SPK (Chi2 11.80, p=0.001). 
DCD, as stated above, and donor cause of death (Chi2 3.51, p=0.320) were not associated 
with pancreas graft survival. Using a previously described PDRI cut-off of 1.2422, high 
PDRI was identified as a risk factor for pancreas graft failure (Chi2 4.61, p=0.032). Numbers 
Donation after circulatory (DCD) death pancreas transplantation 117
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 1. Kaplan-Meier estimated patient survival at 90 days, 1 year, and 2 years for DBD pancreas recipients 
versus DCD pancreas recipients.
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figure 2. Kaplan-Meier estimated pancreas graft survival at 90 days, 1 year, and 2 years for DBD pancreas grafts 
versus DCD pancreas grafts.
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were too small to analyse PDRI as a continuous variable and to perform multivariate Cox-
regression analysis.
disCussion
This study compares the outcome of DCD pancreas transplantation to DBD pancreas trans-
plantation in a recent cohort. This study shows that pancreas transplantation from young 
(mainly low PDRI) donors, either DCD or DBD, yields good results. Consequently, DCD 
grafts with low PDRI should certainly be considered for transplantation.
Multiple reports, as well as multiple recent meta-analyses, have shown that it is feasible to 
utilize DCD pancreata for vascularized pancreas transplantation.6,9-11,23 Our results corrobo-
rate with these results. Even more, this study demonstrates that with careful donor selec-
tion, especially in terms of donor age, but also transplant type (SPK vs. PAK), results from 
DCD pancreas transplantation are comparable to those of DBD pancreas transplantation. 
DBD donors had other risk factors and were on average from older donors and had more 
frequently stroke as a cause of death. All DCD grafts were from The Netherlands, mostly 
from the western region (17/21), to keep CIT as short as possible. Therefore, PDRI was not 
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 3. Kaplan-Meier estimated kidney graft survival at 90 days, 1 year and 2 years for DBD kidney grafts 
versus DCD kidney grafts.
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significantly different between DBD and DCD donors. But when the factor ‘donor type’ 
(DBD or DCD) was eliminated from the equation, the differences in PDRI were remarkable 
and showed that DCD donors with otherwise near-to-perfect characteristics were selected. 
These data indicate that DCD donors can be used for pancreas transplantation, especially 
with relatively low PDRI (in our study mean PDRI 1.35). The number of reinterventions 
(30.8%) is comparable to the number reported in most studies, which may be as high as 
35% in pancreas transplantation.24 In our opinion, and in accordance with the risk analysis 
in this study, DCD donors can be used in addition to DBD donors with more unfavorable 
donor characteristics.
Elaborating on individual risk factors such as age, this may be explained by the fact that 
young donors tend to have leaner pancreas grafts, with smooth intravascular lining. The 
absence of excessive peripancreatic fat may facilitate easier back table procedure (with 
construction of the Y-graft and trimming of excess fat). We hypothesize that these factors 
may prevent early fatty necrosis with subsequent peripancreatic infection and thrombosis. 
In terms of PDRI, a 28- year-old DCD donor bears a similar risk as a 41-year-old DBD 
donor.7,25
The donor WIT we report is like that described in the large study from the UK5, but 
longer than the 15 – 20 minutes that have previously been mentioned in studies from the 
United States.6,23,26 Again, the current study shows that, even with prolonged donor WITs, 
even up to 45 minutes (withdrawal of ventilatory support to cold perfusion) and, which may 
even be more important, prolonged periods of relative hypoperfusion (functional warm 
ischemia time up to 42 minutes) good results can be achieved. This has also been shown by 
another single center report in 2012, which reported donor WITs up to 110 minutes, albeit 
with very long agonal phase in at least 1 case.9 Nevertheless, WIT should still be considered 
an important risk factor associated with postoperative complications such as kidney DGF.
An interesting observation was the higher risk of bleeding in DCD. It could be that 
the higher bleeding percentage in DCD recipients may be related to the higher percent-
age of kidney DGF in this group and subsequently antifactor Xa accumulation or uremia 
associated thrombopathy. In this study, no anti-factor Xa was determined as a measure 
of nadroparin accumulation, nor were blood urea levels post transplantation registered. 
Therefore, it was not possible to proof these interactions. The clinical data show a higher 
percentage of bleeding in the kidney DGF group. The same mechanism may explain the 
difference in graft thrombosis, although this difference was not statistically significant. In 
those cases, following DCD pancreas transplantation, delayed or slower kidney graft func-
tion may have caused factor Xa accumulation and subsequently, may have played a role 
in the prevention of pancreas graft thrombosis. We realize that the 10% risk of complete 
pancreas graft thrombosis in the DBD group seems rather high. However, 1 of cases with 
thrombosis did not lead to graft loss and was preserved with function with anticoagulant 
treatment. Another explanation might be the relative high risk pancreas grafts that are be-
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ing used in The Netherlands (medium PDRI 1.61 in this study).27 We do not believe that 
procurement, back table preparation or transplantation caused the difference, since all are 
done the same for DBD and DCD.
The percentage of postreperfusion graft pancreatitis in this study is 45%. In a review 
by Nadalin et al, postreperfusion graft pancreatitis is thought to occur in up to 100% of 
pancreas transplantation and is usually self-limiting.13 However, this difference could be 
explained by the definition. We arbitrarily defined postreperfusion graft pancreatitis as el-
evated drain amylase levels in combination with elevated serum amylase. Neither DCD nor 
the duration of donor WIT were found to be a risk factor for postreperfusion pancreatitis 
or peripancreatic infection. In our series, of 48 patients that suffered from post reperfusion 
graft pancreatitis, only 20 (42%) also suffered from peripancreatic infection. This is 19% of 
our total population, which is like data reported in 2013.14 Furthermore, 10/30 peripancre-
atic infections weren’t preceded by any biochemical abnormalities. The clinical relevance of 
postreperfusion graft pancreatitis is not entirely clear.13,18 Interestingly, there were slightly 
more peripancreatic infections in DBD. Possibly, this is caused by the higher donor age in 
DBD.
Mid to long-term kidney, pancreas and patient survival were generally good. Although 
DCD organ recipients suffered from more postoperative bleeding and endured more kidney 
delayed graft function, this did not reflect in inferior long term outcome. All patients with 
functioning pancreas grafts at 90 days had good glycemic control and kidney function. Pan-
creas graft survival (insulin independence) was excellent, especially for the DCD recipients, 
even up to 2 years after transplantation. Kidney graft survival was also good in both groups.
Several limitations apply to this study. This is a retrospective database analysis with pos-
sible drawbacks that are characteristic of such studies. In addition, the data concern a single 
center and there was a relatively small number of patients in the study. This limited our 
ability to perform a multivariate risk factor analysis. Nevertheless, this is still 1 of largest 
single center reports on DCD pancreas transplantation that included all consecutive DCD 
pancreas transplantations in our center.23 There is an ongoing discussion in the pancreas 
transplant community concerning the definition of pancreas graft failure. In this study, 
failure was defined as insulin independence (death censored). We appreciate that this is a 
subjective definition, which makes comparison difficult. However, this definition reflects the 
clinical situation of this patient, which is evaluated by a clinician. HbA1c levels, both at any 
time during follow and at start of exogenous insulin levels, facilitate comparison between 
different reports. We did not report HbA1c at the start of exogenous insulin therapy, since 
almost all had failed within 90 days (and HbA1c would thus reflect glycemic control from 
prior to the transplantation). Unpublished data from our center indicates that graft survival 
depends partially on the definition of failure. The protocol of immunosuppression changed 
over the course of the study. We now aim to transplant our patients in a steroid free regime, 
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with only tacrolimus and mycophenolate mofetil. There is no evidence that this change in 
protocol influenced our results with regards to graft survival.
We did not experience a high rate of complications leading to graft loss in the DCD 
donors. These data indicate that that DCD donors can be considered for pancreas donation 
with all parameters and possible risk factors taken into account. A pancreas graft from 
a young, lean, DCD donor after trauma, with short cold ischemia time may in fact yield 
better results than pancreas grafts from older DBD donors. All those parameters combined, 
that are reflected in a low PDRI, may be a better predictor than just DBD or DCD. In our 
opinion, such low PDRI DCD donors should not be precluded from vascularized pancreas 
donation beforehand.
ConCLusion
Pancreas transplantation from carefully chosen DCD donors yields good results. Other 
factors than merely DCD are important in predicting outcome. We advocate that DCD 
pancreata, especially those with lower PDRI (younger donors and trauma as cause of death) 
should be considered for transplantation. This study shows that, although DCD recipients 
have more postoperative bleeding and kidney DGF, pancreas and kidney graft survival are at 
least equal to that of DBD recipients. Hopefully, these results will convince other transplant 
centers to utilize pancreata from DCD donors.
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suMMAry of CHAPTers
The aim of this thesis was to evaluate and investigate factors that are associated with the 
outcome following clinical pancreas transplantation. Although still considered an experi-
mental procedure by some, over the past 50 years pancreas transplantation has proven to 
be a lifesaving treatment for patients with diabetes mellitus and in fact the only curative 
option. The procedure itself comes at certain risks, which as this thesis argues, may lead to 
loss of a valuable graft and, even more dramatically, loss of life. Therefore donor, recipient 
and treatment selections are to be optimized. This thesis answers questions and addresses 
problems and challenges associated with pancreas transplantation. It is a product of the 
close collaboration of the transplantation division of the Leiden University Medical Center 
and the Eurotransplant International Foundation.
Chapter 2 provides an overview of the first 30 years of pancreas transplantation at Leiden 
University Medical Center. In those 30 years and through the effort of dedicated profession-
als, LUMC has become one of the largest pancreas transplant centers in Europe. The chapter 
describes a single-center study and is one of the few studies to evaluate long-term outcome 
following pancreas transplantation in the era of modern induction therapies.
Comparing the results from chapter 2 to results published in literature, it became clear 
that outcome, amongst other factors, largely depends on donor related risk factors and that 
adequate prediction models would be needed to compare outcome data. Those prediction 
models are frequently used in organ transplantation.1-7 In pancreas transplantation spe-
cifically, two prediction models exist: Preprocurement Pancreas Allocation Suitability Score 
(P-PASS)5 and Pancreas Donor Risk Index (PDRI).4 In chapter 3, outcome data from LUMC 
were analyzed to validate both models in a single center. It showed that P-PASS was inferior 
to PDRI and the recommendation was that P-PASS should not be used in clinical decision 
making.
Chapter 4 evaluates the predictive capacity of both models in the Eurotransplant database. 
Similar to the original P-PASS article, allocation outcome was used as primary endpoint 
instead of transplantation outcome as used in the original PDRI article. Interestingly, even 
in this study, PDRI outperformed P-PASS. Another interesting finding was that large differ-
ences in donor quality and donor acceptance policies exist, even within the Eurotransplant 
region.
Chapter 5 describes outcome data of almost 1300 pancreas transplantations within the Eu-
rotransplant region. This study was the first to show that pancreas transplantation outcome 
is associated with center volume. Even though the higher volume centers accepted higher 
risk donor graft, outcome in terms of graft and patient survival were superior compared to 
low volume centers. This study advocates centralization of this highly complex procedure.
In chapter 6, pancreas graft thrombosis was studied. This feared complication and leading 
cause of graft failure is still a very challenging problem. Many strategies have been under-
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taken to detect and prevent thrombosis.8-14 In this chapter, in particular, detection using CT 
imaging and treatment of (usually subclinical) partial graft thrombosis was analyzed. Using 
the current protocol, with heparin and vitamin K antagonists, partial graft thrombosis 
rarely progressed to full, occlusive thrombosis and graft function was preserved. However, 
it remains unclear whether such anticoagulation therapy is warranted for all kinds of partial 
thrombosis.
Chapter 7, describes another risk factor related to the pancreas donor. Donation after 
determination of circulatory death (DCD) remains a controversial topic in pancreas 
transplantation. This study showed that, with strict donor selection, excellent results can be 
achieved with DCD pancreas donors and that these results are similar to those of donation 
after determination of brain death (DBD) pancreas donors.
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GenerAL disCussion
Pancreas transplantation is to date the only definitive treatment for patients with type 1 
diabetes mellitus. Other types of diabetes, such as type 2 diabetes mellitus or mature-onset- 
diabetes of the young (MODY) in different forms may also be treated with transplantation. 
The former being an accepted treatment, the latter is not being performed as often and 
was not studied in this thesis. For patients with concomitant end stage renal disease, pan-
creas transplantation combined with kidney transplantation (either in a simultaneous or by 
consecutive procedures) does not only improve quality of life by rendering the patient off 
exogenous insulin and dialysis, but also by reversing secondary diabetic complications and 
protecting the kidney graft.15-17 With this in mind, a successful procedure may be considered 
life-saving, even though the absence of endogenous insulin may not be life-threatening per 
se.18,19 In the case of absence of endogenous insulin and when life-threatening hypoglycemic 
unawareness occurs, solitary or pancreas transplant alone (PTA) may be a feasible and life- 
saving option.20,21
This thesis focusses on a variety of risk factors that may play an important role in the 
outcome following pancreas transplantation. As was stated in the introduction, the equation 
predicting outcome contains the following factors: donor risk factors, recipient risk factors, 
center related factors and procurement related factors. Some of those factors were studied 
in this thesis, others were also studied, but are not a part of this thesis and will only be 
mentioned briefly in this discussion.
Prior to discussing outcome related data that was studied in this thesis, one important 
remark has to be made: pancreas transplantation research is lacking one uniform definition 
of pancreas graft failure. This makes comparison of outcome in different studies and centers 
difficult. Also, organ transplant registries, such as the Eurotransplant registry, encounter 
problems with the lack of adequate definitions. Sub-analyses on the definition of graft 
survival were performed using the data described in the first chapter.22 This was the first 
study to evaluate the difference. It showed that the difference especially becomes relevant 
at a longer time after transplant, up to 28% after ten years, when exogenous insulin therapy 
use was used as definition (76% graft survival) compared to when the definition of DM, as 
defined by the American Diabetes Association (ADA) was used (48% graft survival).23 The 
need for a uniform definition of graft failure does not necessarily apply to early graft failure. 
Graft failure early after transplantation is generally caused by surgical complications (such 
as thrombosis, bleeding or pancreatitis) which usually warrants direct organ removal and 
subsequent return to exogenous insulin therapy.24 The definition of early graft failure (EGF) 
is clear and insulin has to be administered to keep the patient alive and euglycemic. In such 
cases, measuring HbA1c values, which may be of interest for long-term graft failure, will 
partly represent pre-transplantation values and would thus be futile. On the mid- and lon-
ger term, the difference in reported graft survival increases with the duration of follow up.22 
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Although one perfect definition of pancreas graft failure does not exist, there are definitions 
that have advantages over others. A definition that is based on regularly available data, should 
form the basis of a uniform definition. This allows for easy implementation in databases and 
registries. During the development of this thesis, it became clear that definitions that are 
constructed of multiple endpoints, such as the OPTN definition in chapter 1, are difficult to 
use for research purposes, since many clinical parameters (HbA1c, C- peptide, exogenous 
insulin use) would have to be entered in the database. Also, using a definition that is based 
on lab values only, is a snapshot analysis and does not allow individual assessment of the 
patient, which can only be done by a physician. For example: a definition states that a graft 
had failed in case of HbA1c > 48 mmol/mol and low c-peptide.
Given patient A, who has low c-peptide, has low bodyweight and is not-dependent on 
exogenous insulin, but suffers from in infection or rejection and has high HbA1c at time of 
measurement. This graft should be considered a failed graft based on the definition, even 
though, when evaluated by both physician and patient, the transplant might still be function-
ing. Furthermore, not every clinic does routine c-peptide measurements on their patients. 
Despite the limitations that are mentioned above, a workgroup consisting of members of 
both European Pancreas and Islet Transplantation Association (EPITA) and International 
Pancreas and Islet Transplantation Association (IPITA) elaborately evaluated all pros and 
cons and reached consensus on the definition of B-cell replacement therapy success and 
failure; the Igls definition of functional and clinical outcomes for ß-cell replacement therapy 
or ‘Igls criteria’ on pancreas graft failure (Table 1).25 In this definition, which is based on lab 
values (HbA1c, C-peptide) and medical records (hypoglycemia due to exogenous insulin 
overdose, exogenous insulin requirement), ß -cell replacement is considered successful 
with good to optimal ß -cell graft function and considered failed with marginal or failed 
ß -cell graft function. This is the definition that is recommended when reporting pancreas 
transplantation results.
ß-cell graft 
functional status
HbA1c, %
(mmol/mol)
severe hypoglycemia, 
events per yr
insulin requirements, 
u/kg/day
C-peptide Treatment
success
Optimal ≤ 6.5(48) None None >Baseline Yes
Good < 7.0 (53) None <50% baseline >Baseline Yes
Marginal Baseline < Baseline ≥50% baseline >Baseline No
Failure Baseline Baseline Baseline Baseline No
Table 1. Igls definition of functional and clinical outcomes for ß-cell replacement therapy (25)
Prediction models have become increasingly more important in transplantation. Such 
models, and in particular donor risk indices (DRI), were initially developed to predict 
outcome following transplantation.1-4 This was thought to be helpful in clinical decision 
making, as well as physician-to-patient communication. In pancreas transplantation, the 
General discussion 135
first prediction model was described by Vinkers et al.5 Using routine data on organ ac-
ceptance, the preprocurement pancreas allocation suitability score (P-PASS) was developed. 
This score was implemented in Eurotransplant in 2010, assisting transplant coordinators 
and other professionals to estimate whether it would be suitable to report the pancreas for 
transplantation. Also, it has been validated to predict survival.26 It has been widely used 
since then and is still being used in some countries. Data in this thesis, amongst other re-
ports, have repeatedly shown the limited value of P-PASS.27,28 One recent study from Poland 
reported that PDRI was not related to outcome, however even with low risk donors (PDRI 
< 1.0), 1 year death-uncensored graft survival was only 66% and therefore their results seem 
incomparable to other reports.29 Even more, 8 years after its introduction, the PDRI is con-
sidered superior, as is shown in this thesis.30,31 More recently, another study from Germany 
also reported that PDRI but not P-PASS is associated with pancreas graft survival.32
The first step was to validate the newly constructed PDRI by Axelrod in the contemporary 
database that was described in chapter 233 Also, the P-PASS was evaluated in this cohort to 
predict graft survival. This was the first time that the PDRI would be validated in another 
cohort. The results are described in chapter 3. Following the first study on DRI, our aim 
was to re-evaluate and basically re- do the study that was performed by Vinkers.5 In close 
collaboration with Eurotransplant a similar, but larger database was constructed to repeat 
the experiment Vinkers carried out. This database contained 10 444 pancreas donors. The 
P-PASS that was constructed by Vinkers was compared to the PDRI constructed by Axelrod, 
but modified to contain only donor factors.
The modified PDRI, contained only donor factors and was, in that regard, in line with 
the concept of Vinkers’ P-PASS. This study clearly revealed the limitations of the P-PASS. 
The P-PASS does not include all factors that are believed relevant in pancreas transplanta-
tion, because it was designed based on a historic database with strict age and BMI limits. 
Another important factor here is DCD, which nowadays contributes to a large proportion of 
all donors in the Netherlands. Only donors below 50 years old were included, with a mean 
of 35 years old. This study shows, that this in no way represents the current donor popula-
tion and recently the German EXPAND trial advocated that older and higher BMI donors 
should be used for pancreas transplantation.34 When comparing both models side by side 
in their ability to predict allocation outcome (that is, the organ being accepted), it appeared 
that the PDRI was superior over the P-PASS. Unfortunately, this database did not include 
the most clinically relevant endpoint, namely pancreas graft survival, since outcome after 
transplantation is not routinely recorded in the Eurotransplant database. Nevertheless, since 
the PDRI had been validated to graft survival in the above mentioned study by Axelrod4, the 
study advised to use PDRI for donor selection instead of P-PASS. Unfortunately, the P-PASS 
is still a tool that is used in the Eurotransplant community, despite its limitations.
In general, there is a lot of discussion about the clinical usefulness of prediction models, 
such as the PDRI. Advocates of these models claim that they might be used in clinical deci-
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sion making, for example to accept or decline a graft that is offered for transplantation. It is 
stated that, by using the PDRI, a structured and evidence based decision can be achieved. 
Opponents on the other hand, claim that the data included in a model is too scarce to 
draw any solid conclusions and that there are many more factors that need to be taken into 
account when making this decision. Based on the data in this thesis, especially in chapter 3 
and 4, arguments for both statements can be found. Clearly, the PDRI performs better than 
the P-PASS in predicting outcome. The poor performers should not be used in a clinical 
setting.
Furthermore, only a small percentage of the variation in graft survival is explained by 
DRIs, even when correcting for other factors that may play a role (recipient factors, center 
factors). In conclusion, using DRIs for clinical decision making has to be done with great 
caution. The greatest advantage of the PDRI, or any validated risk index for that matter, is 
that it allows comparison of large groups of donors in a standardized way. Chapter 3 and 4 
of this thesis provide such examples. By providing these insights, we may be able to better 
communicate with each other about how to improve the transplantation community and 
thereby improving transplantation numbers and outcome.
Chapter 5 shows that there is a clear relationship with the annual number of transplanta-
tions performed in a center and outcome. Striking is the fact that not only is the proce-
dure  more successful in higher volume centers, but also that patients survive longer after 
transplantation when they are transplanted in a high volume center. This study shows that 
higher volume centers are more willing to accept higher risk organs for transplantation 
and still have better results as compared to low volume centers. This is a vicious circle that 
will be even more pronounced in the future since centers will be forced to accept higher 
risk donors due to organ shortage. Therefore smaller centers are less likely to accept organs 
for transplantation and subsequently will become smaller and smaller. This will lead to a 
loss of expertise and even more reluctance to accept higher risk organs. This is the first 
study to actually show such a relationship, one which obviously was thought to exist by 
many professionals, because such relationships had been published for other fields of organ 
transplantation.35,36 Similar studies on both pancreas, but also liver transplantation have 
been published afterwards and have shown similar results.37,38 Because of the perceived rela-
tionship with volume and outcome, collecting data for such a study is problematic, because 
lower volume centers may feel reluctant to provide data. Unfortunately, in Europe, or in the 
Eurotransplant area, there are no mandatory registries.
Another problem in transplantation and especially in pancreas transplantation is pro-
curement related injury. A study has shown that procurement related pancreas injury may 
occur in up to 50% of the cases, and this is often the most important reason of the organ 
being declined for transplantation.39 At Leiden University, in close collaboration with the 
‘Nederlandse Transplantatie Stichting’ (Dutch Transplantation Foundation, NTS), a novel 
method was developed to assess procurement related injury and it was used to analyze 
General discussion 137
procurement quality in a prospective nationwide study.40 Quality forms had to be completed 
by both the procurement and the accepting surgeon (which is usually not the same surgeon 
because in The Netherlands separate teams perform the donor procedure). In this study, a 
new method to describe similarities and discrepancies between both forms was introduced. 
It appeared that in 23% of the cases there was a discrepancy between both surgeons. It could 
be that accepting surgeons are either more critical in their appraisal of an organ, that they 
are more experienced in evaluating this particular organ or that circumstances to evaluate 
are simply more optimal (better lighting, back table procedure). Regardless, this system 
allows evaluation of the procurement quality in The Netherlands in a prospective study. 
Especially in pancreas procurement, there was an association between procurement related 
injury and the number of organs procured, where lower procurement volume was a risk 
factor for injury.
These data are in line with the data that was used in chapter 5, which show a similar 
relationship in outcome after pancreas transplantation and clearly both studies provide 
arguments for (further) centralization of pancreas transplantation and procurement.
Whether centralization will lead to higher outcome remains to be seen, however high 
volume centers might be more willing to accept donors with certain risk factors. Risk factors 
that are related to poor outcome, are usually attributed to the donor. Factors such as donor 
age, BMI, cause of death and impaired kidney function are related to early graft failure due 
to technical failure, caused by graft thrombosis, bleeding or pancreatitis.24 It is acknowl-
edged that still, after many years of pancreas transplantation, graft thrombosis remains the 
Achilles’ Heel of pancreas transplantation. Usually, complete graft thrombosis occurs within 
the first 2 weeks after transplantation and may be secondary to rejection or surgical com-
plications. The Virchow triad of endothelial injury, venous stasis and hypercoagulability is 
believed to also play a role in the development of thrombosis.10,41 Venous stasis is caused 
by changes in splanchnic blood flow (from high flow in de the donor to low flow in the 
recipient due to exclusion of splenic and intestinal blood flow). Hemodynamic instability 
in the peri-operative period, sudden changes in extent of uremia following kidney trans-
plantation or calcineurin inhibitor use may also be associated with thrombosis. Complete 
thrombosis is extensively studied and multiple strategies have been proposed to prevent and 
treat this complication. For example, the positioning of the graft and type of enteric drain-
age of the pancreas graft, may be associated with graft thrombosis.42,43 Currently, in most 
centers, the pancreas is anastomosed ‘head up’ to either part of the small intestine from 
duodenum to terminal ileum, to prevent the graft from kinking due to gravitational forces 
or to allow duodeno-duodenal anastomosis (expert opinion). Complete thrombosis usually 
leads to immediate graft failure, although endovascular or surgical salvage procedures and 
even conservative treatment have been reported with varying rates of success.44-46 These 
studies state that salvage procedures in case of complete thrombosis should be considered. 
Partial graft thrombosis remains a far less studied entity. Questions still remain whether 
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this entity requires treatment, for example whether patients with partial graft thrombosis 
require anticoagulation with heparin. LUMC results, as presented in chapter 6 clearly show 
that using heparin and vitamin K antagonists leads to excellent outcome, however, it is not 
known what the outcome would have been if patients would not have been treated. Perhaps, 
outcome would have been similar. Using, by some considered as controversial, CT imaging 
allows visualization of partial thrombosis that may be amenable to treatment. Using color 
enhanced doppler ultrasound may also be an option to investigate thrombosis, but can only 
be used in experienced hands.47 This requires either training of transplant surgeons in the 
use of doppler or intensive collaboration with radiologists. The former may be preferable, 
because ultrasound analysis may then be done daily and/or instantly upon indication. Also, 
another advantage lies in the omission of intravenous contrast, which may damage the 
newly transplanted kidney. Evaluating recent data, contrast induced acute kidney injury 
(CI-AKI) due to iodine based contrast media occurs in about 2.5% of patients with chronic 
kidney disease undergoing contrast based CT, although kidney transplant recipients are 
excluded from those studies.48
Future studies should focus on identifying and investigating factors that may be associated 
with thrombosis. Also, intra-operative measurements may be investigated. For example, 
ROTEM or thromboelastrography11,49 analysis during and after transplantation may provide 
more insight. Also maintaining hemodynamic stability throughout the transplantation may 
influence the risk of thrombosis. Whether this is achieved by transplanting the kidney first, 
as is done in our center, or whether the use of catecholamines should be limited or used 
liberally, remains unclear.
In the 7th chapter, another recent cohort of pancreas transplantations in our center was 
analyzed. The main goal of the study was to compare the results of DCD pancreas transplan-
tation, which is generally considered to be a high risk pancreas transplantation, to standard 
DBD pancreas transplantation. By analyzing the specific outcome of DBD to DCD pancreas 
transplantation and showing good results for the DCD group, we aimed to increase the 
potential donor pool. It became clear from this study that results following DCD pancreas 
transplantation were at least equal to those of DBD pancreas transplantation. This however, 
has to be interpreted with caution due to multiple issues raised in the study. The first issue 
is donor selection: DCD donors were generally younger and had considerably fewer risk 
factors. This reflected in a relatively low PDRI in the DCD group and when DCD was not 
taken into account, these donors could otherwise be considered low risk. The relatively 
higher risk of graft loss could be largely attributed to the numbers of early graft loss in the 
DBD group, mainly due to thrombosis. Simultaneously, the risk of bleeding was lower in 
the DBD group. Obviously, this suggests some form of yin and yang analogy. The sugges-
tion of factor Xa accumulation was raised in the study. This would be caused by impaired 
kidney function following DCD transplantation, due to the higher incidence of DGF. In 
this retrospective study, factor Xa was not measured, therefore the relationship could not 
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be proven. In any case, the study shows that simply declining DCD donors for vascularized 
pancreas transplantation seems unjustified and not based on data. Especially, with younger 
and donors with less other risk factors, excellent results can be achieved following DCD 
pancreas transplantation.
ConCLusion
Beta-cell replacement therapy, and in particular pancreas transplantation is the only cura-
tive treatment for patients with complicated type 1 diabetes mellitus. Due to organ shortage, 
transplantation professionals are forced to accept higher risk organ donors to meet the 
increasing demand. This thesis investigates these risks and shows that it is justified to accept 
a certain risk, for example by transplanting grafts from DCD donors. Graft thrombosis is 
still the main cause of early graft failure, but in the light of long term outcome, the risk is ac-
ceptable and the majority can be treated with good outcome. Preferably performed in high 
volume centers with good outcomes, pancreas transplantation is life-saving for patients 
with type 1 diabetes mellitus, especially when combined with kidney transplantation in 
case of concomitant end stage renal disease.
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fuTure PersPeCTiVes
In the nearby future, pancreas transplantation will remain the only definitive option for 
patients with type 1 diabetes mellitus. Although promising, pre-clinical results on the treat-
ment of diabetes mellitus, have, so far, not been translated into clinical practice. Islet trans-
plantation currently exists complementary to vascularized pancreas transplantation and 
results are improving, however, rendering patients of exogenous insulin in the long term, 
is still difficult.50,51 In the future, using stem-cell based cells or even xenotransplantation, 
diabetes may be treated or cured, however, current progress is still on the experimental, 
laboratory and pre-clinical level.52,53
Multinational collaborations in organ sharing
Implementation of new evidence into the allocation algorithms in a multi-national col-
laboration such as Eurotransplant will remain a challenge in the future. Understandably, 
national legislation, as well as nationalistic feelings, may delay implementation of science- 
based organ allocation. Efforts to maintain multinational collaborations are paramount, 
especially for those highly vulnerable recipients that benefit most from larger donor 
populations, such as highly immunized recipients and small children. Another advantage of 
large collaborations is the availability of large amounts of data. The Eurotransplant database 
contains donor, recipient and transplant data. The Eurotransplant Registry is a voluntary 
registry where centers can enter their outcome data. High levels of data completeness, as 
is achieved in UK Transplant Registry, is lacking in the Eurotransplant registry. Currently, 
Eurotransplant depends on both synchronization with national registries, as well as the 
willingness of the centers to deliver outcome data, mostly encouraged by the hard work 
of the registry coworkers. A (semi-)mandatory Eurotransplant, or even European registry 
would allow for multinational studies in the field of organ transplantation.
Legislation to increase the donor pool
Increasing the donor pool may be done in several ways. First, and this is beyond the scope 
of this thesis, legislation may be used to increase the number of potential donors. In a 
presumed consent or opt-out system, where all adults are considered to be an organ donor 
unless they object, the number of donors per million inhabitants will very likely increase, 
as is the case in Belgium, Spain and Croatia. Fortunately, such a bill was recently accepted 
in The Netherlands and will be written into law soon. Despite its good intentions, the law 
caused an increase in people registering ‘decline’ in the national registry. So, whether this 
law will lead to higher donation rates remains to be seen, but it will encourage people to 
consider their decision and discuss it with their peers. By raising awareness for organ dona-
tion, which is partially done by this law, organ donation following brain death or controlled 
DCD may become standard practice and the public may become more liberal and hopefully 
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more accepting towards the subject. Although this law attempts to solve organ shortage, this 
will probably be insufficient and therefore, extending donor criteria and novel preservation 
techniques are required.
Centralization
As was stated earlier in this discussion, centers should strive to centralize and concentrate 
their programs, perhaps even across borders (e.g. The Netherlands and Belgium), although 
national or regional centralization would be a big step forward. This will inevitably lead to 
loss of transplant programs in some centers and increase in numbers in others. This is in 
line with regular healthcare reforms, at least in The Netherlands, where high complex – low 
volume care has been centralized for a long time.54 Communicating the reason for those 
reforms is crucial in physician to patient communication. The data in this thesis, together 
with other recently published studies, may support those reforms. Also, improving pancreas 
procurement quality, by centralizing procurement teams, preferably using procurement 
surgeons that are based in pancreas centers. This is largely done in The Netherlands already 
with independent procurement teams (so-called “Zelfstandig Uitname Teams”), but a similar 
system has to be extended to other countries. By centralizing both procurement and trans-
plantation, procurement injuries can be minimized and even the highest risk organs, which 
will be become the standard in the future, may yield higher numbers of transplantation, 
with excellent results. Unfortunately, despite centralization and certification, procurement 
related injury is still a problem, especially in pancreas procurement.39,40,55 Centralization is 
not a decision that is made by clinicians, but by politicians and other policymakers, also 
because, as stated above, some centers may lose their transplant program.
Machine perfusion
Novel preservation methods are being studied all around the world, with a special interest 
towards machine perfusion.56 This may be done intracorporal in the donor or extracorporal 
after procurement and may also be combined with the traditional static cold storage. It may 
be done using special preservation solutions or blood and using different temperatures, 
ranging from ice-cold to near physiological. Especially normothermic machine perfusion 
may be promising due to the possibility to provide near-physiological circulation providing 
oxygen and nutrients, elimination of waste products and toxins, endothelial protection and 
viability assessment.57 To date, machine perfusion for vascularized pancreas transplantation 
has been tested in pre-clinical studies and appears to be difficult due to the delicate structure 
of the organ. Promising results may be translated into clinical practice in the nearby future. 
(57-59) Machine perfusion of pancreata for clinical islet transplantation appears to be feasible 
and might improve islet viability.60-61 The only clinical application of machine based perfu-
sion of pancreata is being performed using normothermic regional perfusion (NRP) in a 
controlled DCD setting. In these cases following circulatory arrest, organs are preserved 
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in-situ at physiologic temperatures, allowing for reversal of deleterious ischemia related 
to the DCD procedure, as well as in-situ graft viability assessment. This may lead to the 
acceptance and transplantation of grafts that may have otherwise been discarded.62,63
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nederLAndse sAMenVATTinG
Dit proefschrift gaat over de gevolgen en een mogelijke behandeling voor suikerziekte, met 
name de vorm die op jonge leeftijd voorkomt: type 1 diabetes mellitus. Deze vorm van 
suikerziekte wordt gekenmerkt door een tekort aan insuline, een stof die een belangrijke rol 
speelt in de energiehuishouding en glucosebalans van het menselijk lichaam. Insuline wordt 
geproduceerd door de alvleesklier, ook het pancreas genoemd. Het pancreas is een orgaan 
dat in de buik bij de twaalfvingerige darm ligt en is onderdeel van ons spijsverteringsstel-
sel. Het geeft naast insuline aan het bloed, ook nog spijsverteringsenzymen aan de darm 
af. Type 1 diabetes wordt veroorzaakt doordat het eigen afweersysteem van de patiënt de 
insuline producerende cellen in de alvleesklier afbreekt, een auto-immuunziekte. Er bestaat 
ook nog een andere vorm van suikerziekte, type 2 diabetes. Deze vorm komt vaker op latere 
leeftijd voor en heeft met name te maken met leefstijl.
Bij type 1 diabetes is een patiënt altijd afhankelijk van insuline injecties of insulinepom-
pen. Soms zijn deze methoden niet voldoende en zorgt een continue disbalans in glucose 
en insuline voor schade aan bloedvaten en zenuwen, waardoor patiënten problemen krijgen 
met onder andere hun nieren en ogen. In enkele gevallen is de schade zelfs zo groot dat pa-
tiënten afhankelijk worden van nierdialyse. Omdat de levensverwachting van patiënten die 
afhankelijk zijn van dialyse slecht is, is dit het moment dat patiënten in aanmerking komen 
voor een niertransplantatie. Om te voorkomen dat de suikerziekte ook de getransplanteerde 
nier aantast, kan simultaan een alvleesklier worden getransplanteerd: een gecombineerde 
nier-pancreastransplantatie. Een pancreastransplantatie alleen is ook mogelijk. Deze pan-
creata voor transplantatie zijn afkomstig van overleden donoren. Het overgrote deel wordt 
gedoneerd door hersendode patiënten. Hierbij klopt het hart nog, is de bloedcirculatie van 
een patiënt op de intensive care nog intact en wordt de patiënt kunstmatig beademd. De 
hersenen zijn zodanig beschadigd dat bewustzijn, pijngevoel of reflexen afwezig zijn en dat 
herstel onmogelijk is.
In dit proefschrift worden de risico’s onderzocht en resultaten beschreven van deze ge-
combineerde nier-pancreastransplantatie, maar ook van pancreastransplantatie alleen. Het 
laat zien dat er risico’s zijn en dat het daarom niet voor iedere patiënt de beste optie is, maar 
dat bij goede uitkomsten de procedure levensreddend is.
In dit proefschrift zijn risicofactoren onderzocht en hun relatie met de uitkomsten van 
klinische gevasculariseerde pancreastransplantatie. De eerste pancreastransplantatie werd 
door Kelly en Lillehei uitgevoerd in University of Minnesota Hospital in 1966. Sindsdien 
zijn wereldwijd meer dan 50.000 pancreastransplantaties uitgevoerd. De meest gebruikelijke 
procedure is een gecombineerde nier-pancreastransplantatie. Echter een solitaire pancre-
astransplantatie is ook een optie, eventueel voor of na een niertransplantatie. Het orgaan is 
meestal afkomstig van een hersendode donor met intacte circulatie: heartbeating donatie 
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(HB) of donation after brain death (DBD). Donatie na gecontroleerde circulatiestilstand op 
een intensive care, genaamd non-heartbeating donatie (NHB) of donation after circulatory 
death (DCD), is ook mogelijk. De eerste pancreastransplantatie in Nederland werd in 1984 
in het Academisch Ziekenhuis in Leiden uitgevoerd, zoals te lezen in hoofdstuk twee.
Achtergrond
Pancreastransplantatie is tot op heden de enige curatieve behandeling voor patiënten met 
diabetes mellitus type 1. Bij type 2 diabetes of MODY (maturity onset diabetes of the young), 
kan pancreastransplantatie een optie zijn, dit is echter minder gebruikelijk. Met name pa-
tiënten met diabetes gerelateerd nierfalen komen in aanmerking voor een (gecombineerd) 
nier-pancreastransplantaat. Dit kan zowel gebeuren in één procedure of als opeenvolgende 
procedures waarbij eerst een nier wordt getransplanteerd (van een levende of overleden do-
nor) en daarna een pancreas (pancreas after kidney, PAK) of andersom (pancreas transplant 
alone, PTA). PTA kan ook gedaan worden bij patiënten met niet in te stellen diabetes met 
levensbedreigende hypoglycemieen, zonder nierfalen. 
Door een gecombineerde transplantatie, wordt niet alleen de kwaliteit van leven verbeterd 
(de patiënt is immers vrij van insuline toedieningen), maar ook wordt het niertransplantaat 
beschermd tegen nieuwe schade door diabetes, waardoor de patiënt niet meer afhankelijk is 
van dialyse. Dit in ogenschouw nemende, kan worden gesteld dat een succesvolle behande-
ling levensreddend is. De uitkomsten na pancreas transplantatie worden meestal beschreven 
aan de hand van insuline onafhankelijkheid na transplantatie en patiënt overleving. 
Niet iedere patiënt met type 1 diabetes komt in aanmerking voor een pancreastransplan-
tatie. De lasten van levenslange immunosuppressiva en de risico’s van een grote operatie 
wegen niet op tegen de baten, indien de patiënt adequaat is ingesteld op insuline therapie 
en nog geen secundaire complicaties heeft. Pancreastransplantatie voor maligniteiten wordt 
in Nederland niet gedaan.
Naast gevasculariseerde pancreastransplantatie is het ook mogelijk om insuline pro-
ducerende b-cellen te isoleren uit de eilandjes van Langerhans. Preparaten van enkele 
donoren worden meestal gecombineerd tot één preparaat en getransplanteerd. Hoewel het 
voor patiënten, die slecht in te stellen zijn op insuline, in de meeste gevallen nog niet goed 
mogelijk is om hiermee insuline onafhankelijk te worden, is het wel goed mogelijk om de 
ziekte en secundaire complicaties te stabiliseren. Op deze manier kan dus ook een eventueel 
niertransplantaat beter beschermd worden. Eilandjestransplantatie wordt in dit proefschrift 
buiten beschouwing gelaten.
Pancreastransplantatie is al jaren geen experimentele behandeling meer. Door groeiende 
ervaring en sterk verbeterde resultaten is men in toenemende mate bereid om meer patiën-
ten te transplanteren. Dit leidt tot een stijging van het aantal patiënten op de wachtlijst. Dit 
fenomeen wordt frequent beschreven als de transplantatie paradox: door een meer liberale 
selectie van ontvangers, stijgt de vraag harder dan het aanbod van donororganen, waardoor 
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de wachtlijst exponentieel groeit. Om de vraag bij te benen, zijn behandelaars genoodzaakt 
om risico’s te accepteren als het gaat om donorkarakteristieken. Dit proefschrift beschrijft 
enkele van deze risico’s en de resultaten wanneer deze risico’s worden geaccepteerd.
Door deze groeiende expertise en ervaring zijn de uitkomsten van pancreastransplantatie 
anno 2019 uitstekend. Gemiddeld heeft 80% van de ontvangers vijf jaar na transplantatie 
nog een werkend transplantaat en is dus niet afhankelijk van insuline. 90% van de mensen 
zijn vijf jaar na de transplantatie nog in leven. Helaas gaat nog altijd een aantal van de ge-
transplanteerde organen verloren. Het grootste risico op transplantaatverlies is in de vroege 
postoperatieve fase, met name door transplantaat trombose. Dit proefschrift richt zich dan 
ook met name op uitkomsten in deze vroege fase.
donor-risicofactoren en predictiemodellen in pancreastransplantatie
Aangezien het ontbrak aan objectieve maten om deze risicofactoren te kwantificeren zijn 
in 2008 en 2010 twee modellen ontwikkeld om deze factoren uit te drukken in maat en 
getal, respectievelijk de Preprocurement Pancreas Allocation Suitability Score (P-PASS) en 
de Pancreas Donor Risk Index (PDRI). Beide modellen incorporeren verschillende donor 
gerelateerde risicofactoren, zoals leeftijd, body mass index (BMI), intensive care opname, 
nierfunctie, ischemie tijd en trachten op basis van historische data een gewogen inschatting 
te maken van hun invloed op de uitkomst. 
Om te beginnen, zijn beide modellen gevalideerd op onze eigen dataset. In deze dataset 
blijkt de P-PASS geen goede voorspeller te zijn van uitkomst na transplantatie. Uit hoofd-
stuk drie blijkt dat de PDRI in onze dataset een significante voorspeller is van de uitkomst 
na transplantatie en dus valide instrument om de uitkomst na transplantatie te voorspel-
len. Desondanks blijft er veel (terechte) kritiek op deze modellen: ze zouden onvoldoende 
rekening houden met overige factoren en de klinische blik van de professional zal toch altijd 
prevaleren boven een statistisch model. Het belangrijkste voordeel van deze gevalideerde 
modellen is wel, dat het ons in staat stelt om donorpopulaties op een objectieve manier te 
vergelijken, zoals duidelijk wordt in hoofdstukken vier en vijf.
In hoofdstuk vier is onderzocht of de bestaande predictiemodellen gebruikt zouden kun-
nen worden in het proces van orgaan allocatie. De eerdergenoemde P-PASS was oorspron-
kelijk ontwikkeld om een voorspelling te doen over de geschiktheid van een pancreas voor 
donatie. In de ontwikkeling van de P-PASS zijn geen data over uitkomsten na transplantatie 
verwerkt. Daarentegen is de PDRI juist gebaseerd op data na transplantatie. De data in 
hoofdstuk drie laten zien dat de PDRI, zoals verwacht, beter in staat is om de uitkomst 
na transplantatie te voorspellen in vergelijking met de P-PASS. Uit hoofdstuk vier blijkt 
bovendien dat de PDRI een betere voorspeller is van de uitkomst van allocatie en dus in 
beide gevallen superieur is aan de P-PASS. 
Daarnaast is een opvallende uitkomst in dit hoofdstuk dat grote verschillen bestaan 
in geaccepteerde donorrisico’s ondanks de nauwe samenwerking binnen Eurotransplant. 
158 Chapter 11
Goede uitkomsten met relatief hoge donorrisico’s (zoals in Nederland), zouden andere 
landen (zoals België) kunnen stimuleren liberaler te zijn in hun aannamebeleid, en organen 
met een verhoogd risico op falen te transplanteren of buiten de eigen regio aan te bieden. 
Uiteindelijk wordt het voordeel van een transplantatie bepaald door het verschil tussen uit-
komst zonder transplantatie en de risico’s van transplantatie van dat specifieke orgaan. Dat 
betekent dat in een regio met een laag aantal orgaandonoren, een orgaan met een verhoogd 
risicoprofiel eerder geaccepteerd zou moeten worden voor transplantatie.  Deze resultaten 
zouden dus een stimulans kunnen zijn om een nog intensievere internationale uitwisseling 
van organen te bewerkstelligen, waardoor kostbare organen niet verloren gaan.
Hoofdstuk vijf gaat nader in op het centrum effect bij pancreas transplantatie. Het 
centrum effect beschrijft de relatie tussen de uitkomsten na transplantatie en het aantal 
procedures dat jaarlijks wordt uitgevoerd. Binnen de Eurotransplant regio (Nederland, 
België, Luxemburg, Duitsland, Oostenrijk, Slovenië, Kroatië en Hongarije) zijn meerdere 
centra die minder dan vijf transplantaties per jaar uitvoeren. Deze studie laat duidelijk zien 
dat bij vier of minder transplantaties per jaar het risico op overlijden van de ontvanger of 
falen van het transplantaat aanzienlijk en significant stijgt ten opzichte van centra waar 13 
of meer transplantaties worden uitgevoerd. Daarnaast blijkt dat de hoog volume centra (13 
of meer) bereid zijn om een hoger donor risico te accepteren en te transplanteren, zonder 
dat dit de resultaten negatief beïnvloed. Vergelijkbare verschillen, weliswaar kleiner, zijn 
ook te zien bij de centra die tussen vijf en 13 transplantaties per jaar uitvoeren met respec-
tievelijk de kleinere groep van vier of minder transplantaties en met de grootste groep van 
13 transplantaties of meer.
de Achilles hiel
Zoals eerder beschreven in deze samenvatting en te lezen in hoofdstuk zes, is de belangrijk-
ste oorzaak van transplantaat falen na pancreas transplantatie, de vorming van bloedstolsels 
in het transplantaat: transplantaat trombose. Ondanks alle vooruitgang in medicatie, 
monitoring en chirurgische techniek, blijft transplantaat trombose de Achilles hiel van de 
gehele procedure. De reden is niet compleet duidelijk en waarschijnlijk is sprake van een 
combinatie van afstoting, orgaanschade tijdens de uitname, back-table procedure of trans-
plantatie en ischemie. Daarnaast is het zeker dat er sprake is van meerdere risicofactoren 
voor trombose, ook wel beschreven in de trias van Virchow: verandering van doorbloeding 
(door het verwijderen van de milt), schade aan bloedvaten (door de chirurgische procedure 
zelf), verhoogde bloedstollingsneiging (doordat stollingsremmende eiwitten (ureum) door 
de nieuwe getransplanteerde nier worden uitgescheiden). Verscheidene behandelingen en 
strategieën ter voorkoming en behandeling van transplantaat trombose zijn voorgesteld, 
allen met verschillende mate van succes. Complete trombose van het getransplanteerde 
orgaan leidt vrijwel altijd tot orgaanverlies, terwijl gedeeltelijke trombose in de meeste 
gevallen goed behandeld kan worden met bloedverdunners.
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donatie na circulatiestilstand
Donatie van organen, in dit specifieke geval pancreata, na een gecontroleerde circulatiestil-
stand op een intensive care (non-heartbeating of donation after circulatory death) wordt 
in toenemende mate gedaan omdat het aanbod heartbeating donoren niet toereikend is. 
Ondanks het mogelijk schadelijke effect van zuurstoftekort (ischemie) tijdens de hartstil-
stand blijkt toch dat ook met deze groep donoren goede resultaten bereikt kunnen worden. 
De resultaten in hoofdstuk zeven laten zien dat bij de meeste DCD donoren de overige 
karakteristieken (met name leeftijd en doodsoorzaak) gunstiger zijn dan van DBD donoren 
en dat de uitkomsten tenminste vergelijkbaar zijn met die van DBD transplantatie. DCD 
pancreas transplantatie is dus een goede manier om een deel van schaarste aan donoren op 
te vullen.
Conclusie
Pancreas transplantatie is in meer dan 50 jaar uitgegroeid van een experimentele naar een 
levensreddende procedure voor een geselecteerde groep patiënten met type 1 diabetes mel-
litus. Door een tekort aan geschikte donororganen worden behandelaars gedwongen om 
meer risico’s te nemen in het accepteren van organen. Het blijkt dat hoog-volume centra 
goede resultaten behalen met betrekking tot insuline onafhankelijkheid en patiënt overle-
ving, juist ook met deze hogere donorrisico’s. Dit proefschrift onderzoekt deze risico’s en 
laat zien dat sommige risico’s, zoals het transplanteren van DCD organen, acceptabel zijn 
met goede uitkomsten.

Appendices
Abbreviations and defi nition
List of publications
Acknowledgement (Dankwoord)

163Abbreviations
AbbreViATions
ADA  American Diabetes Association
AMR  Antibody mediated rejection
ANOVA  Analysis of variance
ASA  Acetylsalicylic acid
ATG  Antithymocyte globulin
BMI  Body mass index
CIT  Cold ischemia time
COD  Cause of death
CT  Computed tomography
DBD  Donation after brain death
DCD  Donation after circulatory death
DCDD  Donation after circulatory determination of death
DGF  Delayed graft function
DOAC  Directly acting oral anticoagulants
DRI  Donor risk index
DSA  Donor specific antibodies
EGF  Early graft failure
EPAC  Eurotransplant pancreas advisory committee
EPITA  European pancreas and islet transplantation association
ESOT  European society for organ transplantation
ESRD  End stage renal disease
HR  Hazard ratio
HTK  Histidine tryptophan ketoglutarate
ICU   Intensive care unit
IL  Interleukin
IPITA  International pancreas and islet transplantation association
LMWH  Low molecular weight heparin
LUMC  Leiden University Medical Center
MOD  Multi organ donation
MODY  Maturity onset diabetes of the young
MRI  Magnetic resonance imaging
NOAC  Novel oral anticoagulants
NRP  Normothermic regional perfusion
NTS  Nederlands transplantatie stichting
OAC  Oral anticoagulation
OGTT  Oral glucose tolerance test
OPTN  Organ procurement transplantation network
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PAK  Pancreas after kidney
PDRI  Pancreas donor risk index
P-PASS  Preprocurement pancreas allocation suitability score
PRA  Panel reactive antibodies
PTA  Pancreas transplantation alone
PTC  Pancreas transplant committee
RRT  Renal replacement therapy
SD  Standard deviation
SE  Standard exception
SPK  Simultaneous pancreas kidney
T1DM  Type 1 diabetes mellitus
T2DM  Type 2 diabetes mellitus
TEG  Thromboelastography
TF  Technical failure
UNOS  United network for organ sharing
UW  University of Wisconsin
VKA  Vitamin K antagonist
WIT  Warm ischemia time
WVS  Withdrawal of ventilatory support
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dAnKWoord
Dat het schrijven van een proefschrift een werk van de lange adem is, ondervindt men pas 
als het ook echt gedaan is. Het was voor mij onmogelijk geweest dit te bereiken zonder de 
hulpen van velen.
Geachte Prof. dr. Hamming, Beste Jaap, ondanks dat je niet vanaf het begin bij dit 
proefschrift betrokken was, ben je voor mij op exact het juiste moment ingestapt. Na een 
onrustige tijd maakte jij direct duidelijk dat ik me alleen nog maar diende bezig te houden 
met het schrijven van een proefschrift en de randzaken moest laten varen. Hartelijk dank.
Beste Dries, onze niet aflatende discussies en momenten van tegenstrijdige inzichten 
vormen de basis van dit proefschrift. Jouw persoonlijke en eigenzinnige manier van bege-
leiding is zeer stimulerend en dat blijkt uit de aanwas van nieuwe onderzoekers. Dat ik ook 
de veranderingen in jouw privéleven van dichtbij mocht meemaken, beschouw ik als een 
bonus.
Alle mensen bij Eurotransplant, jullie hebben ervoor gezorgd dat bijna tweeëneenhalf 
jaar voorbij vlogen. De medische staf en in het bijzonder Axel, Undine en Serge, die de kans 
zagen om een vruchtbare samenwerking tussen het LUMC en Eurotransplant op te bouwen 
en deze op een zeer goede manier in te vullen. Joris, in jouw voetsporen treden was niet 
makkelijk, maar de trein reed op volle snelheid. Erwin, zonder jouw databases, zou mijn 
werk niet mogelijk zijn geweest. Je zult voor altijd gemist worden.
Alle chirurgen van de maatschap Haagse Chirurgen en alle assistenten van het HMC. 
Terugkomen in de kliniek voelde dankzij jullie als een warm bad. Dat ik nu opgeleid mag 
worden tot chirurg op deze plek is ook één van de redenen dat dit boekje er nu is.
Sandro, Andre, Jeroen, Volkert en Jan en alle transplantatiechirurgen van het LUMC. 
Zonder jullie energie en betrokkenheid was het nooit mogelijk geweest zo’n programma op 
te bouwen. Caroline, Marije, Josephine, bedankt dat jullie 2 jaar lang iedere dinsdag tegen 
mij aan wilden kijken.
Max en Arty, dankzij jullie ideeën en contacten en waanzinnige gastvrijheid, inmiddels 10 
jaar geleden is het onderzoekers vlammetje gaan branden. Dank voor de mooie tijd bij jullie 
in Arlington. Arty, hartelijk dank voor het lezen van het proefschrift.
Mannen van de Papengracht, Skander, Danny, Hilten, Erik, Tis en de rest waarmee ik heb 
gewoond, dank dat jullie ook voor een deel aan mijn ‘opvoeding’ hebben bijgedragen.
Clubgenoten, dank dat jullie iedere keer naar al ons geneeskundig gezever willen luiste-
ren. Ik ga er van uit dat dit nog vele jaren zal doorgaan, zeker nu het academisch gehalte 
steeds verder omhoog gaat.
Maarten, Maarten en Bas, ik zal de officiële namen die ons binden op deze plek niet 
noemen. Wat mij betreft een vriendschap gesmeed voor het leven. Dat jullie mij alleen in 
Den Haag achterlieten, vergeef ik jullie.
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Kees, avonden bij jou thuis, met een inmiddels goed rokend groen eitje, waren vaak een 
welkome afleiding. Dat het allemaal gelukt is, is ook aan jou te danken. 
Bou en Ro, van ‘vijanden’ vroeger naar beste maten nu. Ik ben ongelofelijk trots op jullie 
en vind het waanzinnig om te zien hoe jullie je eigen leven opbouwen.
Pap en mam, zonder jullie was ik nooit gekomen op de plek waar ik nu sta. Jullie nooit-
aflatende support hebben mij hier gebracht. Jullie trots en onvoorwaardelijke liefde vervult 
me altijd met een groot gevoel van dank. Ik hoop dat jullie samen nog vele jaren in goede 
gezondheid van deze nieuwe periode in jullie leven mogen genieten.
Lieve Liz, ondanks dat je me nooit als fulltime onderzoeker hebt meegemaakt, mag jij 
niet ontbreken in dit dankwoord. Je zorgt ervoor dat ik een betere versie van mezelf word. 
Daarom ben ik intens gelukkig dat ik jou heb weten over te halen jouw leven met mij te 
delen, ook al duurde dat bijna net zo lang als het voltooien van dit proefschrift.
